

### CLINICAL STUDY PROTOCOL


**Protocol Title:** A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or *Nab*-Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-Small Cell Lung Cancer


**Protocol Identifier:** BGB-A317-307

**Phase:** 3

**Investigational Product:** Tislelizumab (BGB-A317) Injection

**Indication:** Stage IIIB or IV Squamous Non-Small Cell Lung Cancer

**Sponsor:** 

**Sponsor Medical Monitor:** 

**Original Protocol:** 09 February 2018

## FINAL PROTOCOL APPROVAL SHEET

**Protocol Title:** A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or *Nab*-Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-Small Cell Lung Cancer

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

---

**INVESTIGATOR SIGNATURE PAGE**

**Protocol Title:** A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or *Nab*-Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-Small Cell Lung Cancer

**Protocol Identifier:** BGB-A317-307

<p><b>Instructions for Investigator:</b> Please SIGN and DATE this signature page. PRINT your name, title, and the name and address of the center in which the study will be conducted. Return the signed copy to BeiGene or its designee.</p>
--

I have read this protocol in its entirety and agree to conduct the study accordingly:

Signature of Investigator: \_\_\_\_\_ Date: \_\_\_\_\_

Printed Name: \_\_\_\_\_

Investigator Title: \_\_\_\_\_

Name/Address of Center: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

**TABLE OF CONTENTS**

<b>CLINICAL STUDY PROTOCOL .....</b>	<b>1</b>
<b>FINAL PROTOCOL APPROVAL SHEET.....</b>	<b>2</b>
<b>INVESTIGATOR SIGNATURE PAGE.....</b>	<b>3</b>
<b>TABLE OF CONTENTS .....</b>	<b>4</b>
<b>LIST OF TABLES .....</b>	<b>10</b>
<b>LIST OF FIGURES .....</b>	<b>10</b>
<b>SYNOPSIS.....</b>	<b>11</b>
<b>LIST OF ABBREVIATIONS AND TERMS .....</b>	<b>20</b>
<b>1 INTRODUCTION.....</b>	<b>22</b>
1.1 Background Information on Non-Small Cell Lung Cancer .....	22
1.2 Current First-Line Treatment of Advanced NSCLC .....	22
1.3 Current Treatment for Advanced Squamous NSCLC .....	27
1.4 Unmet Medical Needs for Advanced Squamous NSCLC .....	29
1.5 Background Information on Tislelizumab .....	30
1.5.1 Pharmacology .....	30
1.5.2 Toxicology .....	30
1.5.3 Clinical Pharmacology.....	31
1.5.4 Prior Clinical Experience of Tislelizumab.....	31
1.6 Study Rationales .....	33
1.6.1 Rationale for the Chemotherapy Regimens Administered With Tislelizumab in the Treatment of Advanced Squamous NSCLC .....	33
1.6.2 Rationale for Selection of Tislelizumab Dose in Combination With Chemotherapy .....	33
1.6.3 Rationale for Selection of Nab-Paclitaxel Dose and Schedule.....	34
1.6.4 Rationale for Carboplatin Doublet Chemotherapy as the Comparator .....	35
1.6.5 Rationale for Primary Endpoint of PFS as Assessed by the Independent Review Committee.....	35
1.6.6 Rationale for Requiring PD-L1 Testing.....	35
1.6.7 Rationale for Allowing Crossover to Tislelizumab .....	36
1.6.8 Rationale for Allowing Patients to Continue Tislelizumab Until Loss of Clinical Benefit.....	36

---

1.6.9	Rationale for Patient-Reported Outcome Assessments .....	37
1.7	Benefit-Risk Assessment .....	37
<b>2</b>	<b>STUDY OBJECTIVES AND ENDPOINTS.....</b>	<b>38</b>
2.1	Study Objectives .....	38
2.1.1	Primary Objective .....	38
2.1.2	Secondary Objectives.....	38
2.1.3	Exploratory Objectives .....	39
2.2	Study Endpoints .....	39
2.2.1	Primary Endpoint .....	39
2.2.2	Secondary Endpoints .....	39
2.2.3	Exploratory Endpoints .....	40
<b>3</b>	<b>STUDY DESIGN.....</b>	<b>40</b>
3.1	Summary of Study Design .....	40
3.2	Screening Period .....	43
3.3	Treatment Period.....	43
3.4	Safety Follow-up.....	44
3.5	Survival Follow-up .....	45
3.6	Patient, Treatment, Study, and Site Discontinuation .....	45
3.6.1	Discontinuation from Study Treatment .....	45
3.6.2	End of Study .....	46
<b>4</b>	<b>STUDY POPULATION .....</b>	<b>47</b>
4.1	Inclusion Criteria .....	47
4.2	Exclusion Criteria .....	48
<b>5</b>	<b>STUDY TREATMENT .....</b>	<b>50</b>
5.1	Formulation, Packaging, and Handling .....	50
5.1.1	Tislelizumab.....	50
5.1.2	Chemotherapy Agents.....	51
5.2	Dosage, Administration, and Compliance .....	51
5.2.1	Tislelizumab.....	52
5.2.2	Chemotherapy .....	52
5.3	Overdose .....	53
5.4	Investigational Medicinal Product Accountability .....	53

---

5.5	Dose Delay and Modification .....	53
5.5.1	General Guidance Regarding Dose Modifications .....	53
5.5.2	Dose Interruption for Tislelizumab.....	54
5.5.3	Dose Modifications of Chemotherapy Treatment.....	55
5.6	Criteria for Discontinuing Chemotherapy Regimens .....	55
<b>6</b>	<b>PRIOR AND CONCOMITANT THERAPY .....</b>	<b>56</b>
6.1	Prior Therapy .....	56
6.2	Concomitant Therapy.....	56
6.2.1	Permitted Concomitant Medications.....	56
6.2.2	Prohibited or Restricted Concomitant Medications .....	57
6.3	Potential Interactions Between the Study Drugs and Concomitant Medications .....	58
<b>7</b>	<b>STUDY ASSESSMENTS AND PROCEDURES .....</b>	<b>58</b>
7.1	Screening.....	58
7.1.1	Demographic Data and Medical History .....	59
7.1.2	Females of Childbearing Potential and Contraception .....	59
7.1.3	Informed Consent and Screening Log .....	59
7.1.4	Pulmonary Function Tests .....	59
7.2	Enrollment.....	60
7.2.1	Confirmation of Eligibility .....	60
7.2.2	Patient Numbering .....	60
7.2.3	Randomization .....	60
7.3	Tislelizumab and Chemotherapy Dispensation .....	60
7.4	Crossover .....	60
7.4.1	Crossover for Patients in Chemotherapy in Arm C With Documented and IRC Confirmed Disease Progression .....	60
7.4.2	Crossover Assessments and Procedures .....	61
7.5	Safety Assessments.....	61
7.5.1	Vital Signs.....	61
7.5.2	Physical Examinations .....	62
7.5.3	Eastern Cooperative Oncology Group Performance Status.....	62
7.5.4	Laboratory Safety Tests .....	62
7.5.5	Electrocardiograms .....	63

---

7.5.6	Adverse Events .....	63
7.5.7	Hepatitis B and C Testing .....	63
7.6	Tumor and Response Evaluations.....	63
7.7	Pharmacokinetic and Antidrug Antibody Testing .....	65
7.8	Biomarkers.....	66
7.9	Patient-Reported Outcomes .....	66
7.10	Visit Windows .....	66
7.11	Unscheduled Visits .....	67
<b>8</b>	<b>SAFETY MONITORING AND REPORTING .....</b>	<b>67</b>
8.1	Risks Associated With Tislelizumab .....	67
8.2	Risks Associated With Carboplatin and Paclitaxel or Nab-Paclitaxel.....	67
8.3	General Plan to Manage Safety Concerns .....	68
8.3.1	Eligibility Criteria .....	68
8.3.2	Safety Monitoring Plan .....	68
8.4	Adverse Events .....	69
8.4.1	Definitions and Reporting.....	69
8.4.2	Assessment of Severity .....	69
8.4.3	Assessment of Causality .....	70
8.4.4	Following Adverse Events.....	71
8.4.5	Laboratory Test Abnormalities .....	71
8.5	Definition of a Serious Adverse Event .....	72
8.6	Suspected Unexpected Serious Adverse Reaction.....	72
8.7	Timing, Frequency, and Method of Capturing Adverse Events and Serious Adverse Events .....	73
8.7.1	Adverse Event Reporting Period .....	73
8.7.2	Reporting Serious Adverse Events .....	73
8.7.3	Eliciting Adverse Events.....	74
8.7.4	Recording Disease Progression.....	74
8.7.5	Recording Deaths.....	74
8.7.6	Recording Pregnancies.....	75
8.7.7	Recording Poststudy Adverse Events .....	75
8.7.8	Expedited Reporting to Health Authorities, Investigators, Institutional Review Boards, and Independent Ethics Committees .....	75

---

8.7.9	Assessing and Recording Immune-Related Adverse Events .....	75
8.8	Management of Adverse Events of Special Interest .....	76
8.8.1	Infusion-Related Reactions .....	76
8.8.2	Severe Hypersensitivity Reactions and Flu-Like Symptoms.....	78
8.8.3	Immune-Related Adverse Events .....	78
<b>9</b>	<b>STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION.....</b>	<b>79</b>
9.1	Statistical Analysis.....	79
9.1.1	Randomization Methods .....	79
9.1.2	Analysis Populations.....	80
9.1.3	Patient Disposition .....	80
9.1.4	Demographic and Other Baseline Characteristics .....	80
9.1.5	Prior and Concomitant Medications .....	80
9.2	Efficacy Analyses .....	80
9.2.1	Primary Efficacy Analysis .....	80
9.2.2	Secondary Efficacy Analysis .....	82
9.2.3	Exploratory Efficacy Analysis.....	84
9.3	Safety Analyses.....	84
9.3.1	Extent of Exposure.....	84
9.3.2	Adverse Events .....	84
9.3.3	Laboratory Analyses .....	85
9.3.4	Vital Signs.....	85
9.4	Pharmacokinetic Analysis.....	85
9.5	Immunogenicity Analyses .....	86
9.6	Sample Size Consideration .....	86
9.7	Interim Analyses .....	86
<b>10</b>	<b>STUDY COMMITTEES AND COMMUNICATION .....</b>	<b>87</b>
10.1	Blinded Independent Central Review .....	87
10.2	Independent Data Monitoring Committee .....	87
<b>11</b>	<b>SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS</b>	<b>88</b>
11.1	Access to Information for Monitoring .....	88
11.2	Access to Information for Auditing or Inspections.....	88
<b>12</b>	<b>QUALITY ASSURANCE AND QUALITY CONTROL.....</b>	<b>89</b>



---

12.1	Regulatory Authority Approval .....	89
12.2	Quality Assurance .....	89
12.3	Study Site Inspections.....	89
12.4	Drug Accountability.....	89
<b>13</b>	<b>ETHICS/PROTECTION OF HUMAN PATIENTS .....</b>	<b>90</b>
13.1	Ethical Standard .....	90
13.2	Institutional Review Board/Independent Ethics Committee.....	90
13.2.1	Protocol Amendments.....	90
13.3	Informed Consent.....	91
13.4	Patient and Data Confidentiality .....	91
13.5	Financial Disclosure.....	92
<b>14</b>	<b>DATA HANDLING AND RECORD KEEPING.....</b>	<b>92</b>
14.1	Data Collection and Management Responsibilities .....	92
14.1.1	Data Collection .....	92
14.1.2	Data Management/Coding .....	92
14.2	Data Integrity and In-house Blinding .....	93
14.3	Study Records Retention.....	93
14.4	Protocol Deviations.....	94
14.5	Publication and Data-Sharing Policy .....	94
14.6	Study and Study Center Closure .....	95
14.7	Information Disclosure and Inventions.....	96
<b>15</b>	<b>REFERENCES.....</b>	<b>97</b>
	<b>APPENDIX 1. SCHEDULE OF ASSESSMENTS.....</b>	<b>105</b>
	<b>APPENDIX 2. ECOG PERFORMANCE STATUS.....</b>	<b>110</b>
	<b>APPENDIX 3. THE RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST) GUIDELINES, VERSION 1.1.....</b>	<b>111</b>
	<b>APPENDIX 4. PRE-EXISTING IMMUNE DEFICIENCIES OR AUTOIMMUNE DISEASES .....</b>	<b>121</b>
	<b>APPENDIX 5. NEW YORK HEART ASSOCIATION FUNCTIONAL CLASSIFICATION .....</b>	<b>122</b>
	<b>APPENDIX 6. IMMUNE-RELATED ADVERSE EVENT EVALUATION AND MANAGEMENT .....</b>	<b>123</b>

---

<b>APPENDIX 7. CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION (CKD-EPI) EQUATION .....</b>	<b>132</b>
<b>APPENDIX 8. CONTRACEPTION GUIDELINES AND DEFINITIONS OF “WOMEN OF CHILDBEARING POTENTIAL,” “NO CHILDBEARING POTENTIAL” .....</b>	<b>133</b>
<b>APPENDIX 9. DOSE MODIFICATION GUIDELINES FOR CHEMOTHERAPY ...</b>	<b>135</b>

## **LIST OF TABLES**

Table 1. Approved Anti-PD-1 or Anti-PD-L1 Inhibitors for the Treatment of Advanced or Metastatic NSCLC .....	25
Table 2. Clinical Data of Nab-Paclitaxel + Carboplatin versus Solvent-Based Paclitaxel + Carboplatin.....	28
Table 3. Selection and Timing of Dose for Each Patient.....	52
Table 4. Commonly and Specific Reported Toxicity of the Chemotherapeutic Agents .....	68
Table 5. Timeframes and Documentation Methods for Reporting Serious Adverse Events to the Sponsor or Designee .....	73
Table 6. Treatment Modification for Symptoms of Infusion-Related Reactions Due to Study Drug(s) .....	77
Table 7. Immune-Related Adverse Events .....	79
Table 8 Analysis Timing and Stopping Boundaries for PFS in Each of the Primary Testing at One-Sided $\alpha=0.0125$ (Initial $\alpha$ Assignment).....	87
Table 9. Analysis Timing and Stopping Boundaries for PFS in Each of the Primary Testing at One-Sided $\alpha=0.025$ ( $\alpha$ recycled at interim) .....	87
Table 10. Dose Reduction for Paclitaxel and Carboplatin.....	135
Table 11. Dose Reductions for Nab-paclitaxel and Carbopaltin .....	136

## **LIST OF FIGURES**

Figure 1. Study Schema .....	42
Figure 2. Type-I-Error Control Scheme.....	82

## SYNOPSIS

<b>Name of sponsor/Company:</b> BeiGene (Shanghai) Co., Ltd.
<b>Investigational Product:</b> Tislelizumab (BGB-A317) Injection
<b>Title of Study:</b> A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab-Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-Small Cell Lung Cancer
<b>Protocol Identifier:</b> BGB-A317-307
<b>Phase of Development:</b> 3
<b>Number of Patients:</b> 342
<b>Study Centers:</b> Approximately 45 centers
<b>Study Objectives:</b> <b>Primary:</b> <ul style="list-style-type: none"><li>To compare the progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) per response evaluation criteria in solid tumors (RECIST) v1.1 in an Intent-to-Treat (ITT) Population between tislelizumab either combined with paclitaxel + carboplatin (Arm A) or combined with <i>nab</i>-paclitaxel + carboplatin (Arm B) and paclitaxel + carboplatin alone (Arm C) in patients with untreated Stage IIIB or IV squamous non-small cell lung cancer (NSCLC).</li></ul> <b>Secondary:</b> <ul style="list-style-type: none"><li>To compare objective response rate (ORR) as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or <i>nab</i>-paclitaxel + carboplatin and paclitaxel + carboplatin alone.</li><li>To compare duration of response (DOR) as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or <i>nab</i>-paclitaxel + carboplatin and paclitaxel + carboplatin alone.</li><li>To compare overall survival (OS) between tislelizumab combined with paclitaxel + carboplatin or <i>nab</i>-paclitaxel + carboplatin and paclitaxel + carboplatin alone in an ITT Population.</li><li>To compare PFS as assessed by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or <i>nab</i>-paclitaxel + carboplatin and paclitaxel + carboplatin alone in an ITT Population.</li><li>To compare health-related quality of life (HRQoL) between tislelizumab combined with paclitaxel + carboplatin or <i>nab</i>-paclitaxel + carboplatin and paclitaxel + carboplatin alone.</li><li>To evaluate the safety and tolerability of tislelizumab combined with paclitaxel + carboplatin or <i>nab</i>-paclitaxel + carboplatin compared with paclitaxel + carboplatin alone.</li><li>To evaluate the correlation between programmed death ligand 1 (PD-L1) expression levels by immunohistochemistry (IHC) and antitumor activity of tislelizumab combined with paclitaxel + carboplatin or <i>nab</i>-paclitaxel + carboplatin.</li></ul>

**Exploratory:**

- To compare tumor assessment outcomes (eg, disease control rate [DCR], time to response [TTR]) between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone assessed by the investigator per RECIST v1.1.
- To assess tumor and blood-based biomarkers of tislelizumab response, resistance and patient prognosis.
- To characterize the pharmacokinetics (PK) of tislelizumab when given in combination with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin.
- To assess host immunogenicity to tislelizumab

**Study Endpoints:**

**Primary:**

- PFS as assessed by the IRC—the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the IRC per RECIST v1.1 in an ITT Population.

**Secondary:**

- ORR as assessed by the IRC and investigator—the proportion of patients who had complete response (CR) or partial response (PR) as assessed by the IRC and investigator per RECIST v1.1 in all randomized patients with measurable disease at baseline.
- DOR as assessed by the IRC and investigator—the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as assessed by the IRC and investigator per RECIST v1.1 in all randomized patients with documented objective responses.
- OS—the time from the date of randomization to the date of death due to any cause in an ITT Population.
- PFS as assessed by the investigator—the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1 in an ITT Population.
- HRQoL—measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) and Core 30 (EORTC QLQ-C30) as presented in patient-reported outcomes.
- Incidence and severity of treatment-emergent adverse events (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03.
- PD-L1 expression by IHC as a predictive biomarker for response.

**Exploratory:**

- DCR—the proportion of patients who had CR, PR, or stable disease (SD) as assessed by the investigator per RECIST v1.1.
- TTR—the time from randomization to the first occurrence of a documented objective response as

assessed by the investigator per RECIST v1.1.

- Status of exploratory biomarkers including but not limited to: PD-L1, tumor mutation burden (TMB), and immune-related gene expression profiling (GEP) in archival and/or freshly obtained tumor tissues and blood (or blood derivatives) obtained before, during, or after treatment with tislelizumab or at progression, and the association with disease status and/or response to tislelizumab in combination with chemotherapy.
- Summary of serum concentrations of tislelizumab.
- Assessments of immunogenicity of tislelizumab by determining the incidence of antidrug antibodies (ADAs).

### Study Design:

This is an open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with carboplatin and either paclitaxel (Arm A) or *nab*-paclitaxel (Arm B) versus paclitaxel + carboplatin alone (Arm C) as first-line treatment in approximately 342 patients who have Stage IIIB or IV squamous NSCLC.

The study design schema is in [Section 3, Figure 1](#).

The primary endpoint of the study is measured by PFS as assessed by the IRC in ITT Population.

Patients who have histologically confirmed and are untreated for their locally advanced or metastatic (Stage IIIB or IV) squamous NSCLC are eligible. Histology of squamous NSCLC will be confirmed at the investigator's site. Patients with known epidermal growth factor (*EGFR*) mutation or anaplastic lymphoma kinase (*ALK*) rearrangement are ineligible for the study but testing is not required if not known. Archival tumor specimens will be prospectively tested for PD-L1 expression by a central laboratory, and only patients who have evaluable PD-L1 results are eligible. If archived formalin-fixed paraffin-embedded (FFPE) tissue is not sufficient for PD-L1 analysis, a fresh biopsy sample will need to be obtained. PD-L1 status will be characterized as PD-L1 membrane staining on tumor cells (TC) via the Ventana SP263 assay.

Eligible patients will be stratified by tumor staging (IIIB versus IV), and PD-L1 expression (3 levels: < 1% TC versus 1% to 49% TC versus  $\geq$  50% TC) and randomized by a 1:1:1 to receive one of the following treatment regimens:

- Arm A: tislelizumab + paclitaxel + carboplatin
- Arm B: tislelizumab + *nab*-paclitaxel + carboplatin
- Arm C: paclitaxel + carboplatin

Administration of 4 to 6 cycles will be at the investigator's discretion. Chemotherapy will be administered on a 3-week cycle, until one of the following occurs (whichever occurs first): 1) completed administration of 4 to 6 cycles; 2) unacceptable toxicity; or 3) documented disease progression per RECIST v1.1.

For all patients in Arms A, B, C, if progression of disease is unconfirmed and the patient is clinically stable, it is at the discretion of the investigator to continue treating the patient with the assigned treatment per protocol until progression of disease is confirmed at least 28 days (or at the next scheduled tumor assessment) from the date of the scan suggesting progression of disease. If a patient has confirmed progression of disease by RECIST v1.1, the patient should not receive further chemotherapy treatment on study, and should follow the following guidance.

**For Arm A and Arm B (Experimental arms):**

Patients whose tumors show progressive disease per RECIST v1.1 during chemotherapy combination phase or thereafter while receiving tislelizumab monotherapy will be permitted to continue tislelizumab monotherapy provided they meet all the following additional criteria:

1. Evidence of clinical benefit as assessed by the investigator
2. Absence of symptoms and signs (including clinically significant worsening of laboratory values [eg, new, or worsening hypercalcemia]) indicating unequivocal progression of disease
3. No decline in ECOG PS that can be attributed to disease progression
4. Absence of tumor progression at critical anatomical sites (eg, CNS disease) that cannot be managed by protocol-allowed medical interventions
5. Patients must provide written consent to acknowledge deferring other treatment options in favor of continuing study treatment at the time of initial progression

**For Arm C (Control arm):**

Patients who develop radiographic disease progression per RECIST v1.1 at an initial or, if continued treatment, at the time of repeat CT scan, will be given the option to cross over to receive tislelizumab monotherapy (Section 7.4), provided disease progression has been confirmed by the IRC and as long as the following criteria are met:

1. ECOG PS  $\leq$  1
2. Absence of rapid progression of disease or of progressive tumor at critical anatomical sites (eg, CNS disease) that cannot be managed by protocol-allowed medical interventions
3. Patient provided written consent to acknowledge that tislelizumab is an experimental treatment used after failure of prior first-line platinum-containing regimen

Crossover is optional and is at the discretion of the investigator and with the sponsor's agreement.

**For All Arms:**

Once patients are receiving tislelizumab monotherapy, the investigator may consider continuing tislelizumab monotherapy beyond investigator-assessed progression, provided that patients meet the above outlined criteria, and upon discussion with the medical monitor.

The decision to continue tislelizumab beyond investigator-assessed progression must be documented in the study records.

Patients may continue tislelizumab until loss of clinical benefit as assessed by the investigator, withdrawal of consent, study termination by the sponsor, start a new anticancer therapy, or death, whichever occurs first.

A Steering Committee consisting of qualified investigators will be implemented to support the study and structure the scientific input.

Safety monitoring and interim efficacy data review will be performed by an Independent Data Monitoring Committee (IDMC). The first safety monitoring and review will occur after the first 30 patients recruited have been on treatment for  $\geq$  1 month or completed at least 1 cycle of study treatment. Thereafter, IDMC will review data approximately every 4 months, or more frequently if indicated or requested by the medical monitor based on ongoing safety monitoring of patients on study. The IDMC may recommend study modification including early termination of the study due to safety concerns, or for evidence of compelling efficacy at a preplanned interim analysis. A formal interim analysis for PFS in an ITT is planned after 67% of the targeted events in the ITT Population have been observed. The early stopping

rule for the interim analysis will be set for superiority. The function and membership of the IDMC will be described in the IDMC charter.

The study is an open-label, randomized, and multicenter study. The results of PD-L1 expression will be blinded to patients, investigators, study site personnel, sponsor staff, and representatives of the sponsor.

**Study Assessments:**

Patients will undergo tumor assessments at baseline and every 6 weeks for the first 52 weeks following Cycle 1, Day 1, regardless of dose delays to manage toxicities. After completion of the Week 52 tumor assessment, tumor assessment will continue every 12 weeks. Patients will undergo tumor assessments until radiographic disease progression per RECIST v1.1 or loss of clinical benefit (for tislelizumab-only patients who continue treatment after radiographic disease progression according to RECIST v1.1), withdrawal of consent, study termination by sponsor, start a new anticancer therapy, or death, whichever occurs first.

Patients who discontinue treatment for reasons other than radiographic disease progression (eg, toxicity) will continue scheduled tumor assessments until radiographic disease progression per RECIST v1.1, withdrawal of consent, loss to follow-up, study termination by sponsor, start a new anticancer therapy, or death, whichever occurs first.

To determine the PK properties of tislelizumab and host immunogenic response to tislelizumab, blood samples will be collected at various timepoints as outlined in [Appendix 1](#).

Patients will be evaluated for AEs and immune-related adverse events (irAEs) (all grades according to NCI-CTCAE v4.03). Serious adverse events (SAEs) and any AE that leads to treatment discontinuation will be followed and documented until the event resolves, the investigators assess the event as stable, or the patient is lost to follow-up, whichever occurs first.

After initiation of study drug, all AEs and SAEs, regardless of relationship to study drug, will be reported until either 30 days after last dose of study treatment (including chemotherapy) or initiation of new anticancer therapy, whichever occurs first. All irAEs (serious or nonserious) should be reported for 90 days after the last dose of tislelizumab, regardless of whether the patient starts a new anticancer therapy. The investigator should report any SAEs that are believed to be related to tislelizumab treatment at any time after treatment discontinuation.

**Duration of Patient Participation:**

The duration of the study from first enrolled patient to final analysis for PFS is estimated to be approximately 19 months.

**Study Population:**

The study will enroll approximately 342 patients who meet the following inclusion/exclusion criteria, with approximately 114 patients each in Arms A (tislelizumab combined with paclitaxel + carboplatin), B (tislelizumab combined with *Nab*-paclitaxel+ carboplatin), and C (paclitaxel + carboplatin chemotherapy alone), at a 1:1:1 randomization ratio.

**Key Eligibility Criteria:**

The population under study is adult patients (18 to 75 years old on the day the patient voluntarily agrees to participate in the study) with histologically confirmed locally advanced (Stage IIIB) not amenable to curative surgery or radiotherapy, or metastatic (Stage IV) squamous NSCLC. Patients with tumors of mixed non-small cell histology (squamous and nonsquamous) are eligible if the major histological component is confirmed to be squamous. Patients must be able to provide fresh or archival tumor tissues (FFPE blocks or approximately 15  $\geq$  6 freshly cut unstained FFPE slides) with an associated pathological report. In the absence of sufficient archival tumor tissues, a fresh biopsy of a tumor lesion at baseline is mandatory. Patients with NSCLC tumors that have known *EGFR*-sensitizing mutation or *ALK*



gene translocation are excluded but testing is not required if not performed previously. Patients must have an ECOG PS of  $\leq 1$ . Patients must have  $\geq 1$  measurable lesion as defined per RECIST v1.1 and must be treatment-naïve for locally advanced or metastatic NSCLC. Patients who have received prior neoadjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for nonmetastatic disease must have experienced a disease-free interval of  $\geq 6$  months from randomization since the last dose of chemotherapy and/or radiotherapy. Patients who have received prior treatment with *EGFR* inhibitors or *ALK* inhibitors or therapies targeting PD-1 or PD-L1 are excluded. Patients must have a life expectancy of  $\geq 12$  weeks. Patients must have adequate organ function as indicated by the screening laboratory values (obtained within 7 days prior to randomization) described in [Section 4.1](#).

**Test Product, Dose, and Mode of Administration:**

Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W.

[REDACTED]

**Statistical Methods:**

**Analysis Populations:**

The ITT Population includes all randomized patients. Patients will be analyzed according to their randomized treatment arms. This will be the primary analysis population for all efficacy analysis, including analyses of PFS and OS endpoints

The Safety Population includes all randomized patients who received  $\geq 1$  dose of any component of study drug; it will be the population for the safety analyses.

The PK Population includes all patients who receive  $\geq 1$  dose of tislelizumab per the protocol, for whom any postdose PK data are available.

**Primary Efficacy Endpoint Analysis:**

**PFS as assessed by the IRC:**

PFS per the IRC is defined as the time from randomization to the first documented disease progression as assessed by the IRC with the use of RECIST v1.1, or death from any cause, whichever occurs first. PFS will be analyzed in the ITT Population. Actual tumor assessment visit date will be used to calculate PFS. Data for patients without disease progression or death at the time of analysis will be censored at the time of the last valid tumor assessment. Data for patients without postbaseline tumor assessment will be censored at the time of randomization. Data for patients who start to receive new anticancer therapy or are lost to follow-up will be censored at the last valid tumor assessment date prior to the introduction of new therapy or loss to follow-up. Patients who have a clinical determination of progression should undergo a computed tomography(CT)/magnetic resonance imaging (MRI), if possible, to correlate radiographic findings with the clinical findings. If a clinical determination of progression for a patient is confirmed, the date of the CT/MRI scan will be considered as the progression date for that patient.

PFS per the IRC will be compared between tislelizumab with paclitaxel + carboplatin (Arm A) and paclitaxel + carboplatin (Arm C), and between tislelizumab with *nab*-paclitaxel + carboplatin (Arm B) and paclitaxel + carboplatin (Arm C), using stratified log-rank test methodology. The 2 primary hypothesis tests are formed as follows:



One-sided testing of PFS superiority of Arm A to Arm C:

The null hypothesis to be tested is:

$$H_0: \text{PFS in Arm A} \leq \text{PFS in Arm C}$$

Against the alternative hypothesis:

$$H_a: \text{PFS in Arm A} > \text{PFS in Arm C}$$

One-sided testing of PFS superiority of Arm B to Arm C:

The null hypothesis to be tested is:

$$H_0: \text{PFS in Arm B} \leq \text{PFS in Arm C}$$

Against the alternative hypothesis:

$$H_a: \text{PFS in Arm B} > \text{PFS in Arm C}$$

The p-values from a stratified log-rank tests will be presented using stratification factors with actual values as recorded in the electronic data capture (EDC) system at randomization. The hazard ratio (HR) for PFS for each comparison (ie, Arm A versus Arm C, Arm B versus Arm C) will be estimated using a stratified Cox regression model, respectively. The 95% confidence interval [CI] for the HR will be provided. Unstratified analysis will also be presented. Kaplan-Meier methodology will be used to estimate median PFS for each treatment arm, and a Kaplan-Meier curve will be constructed to provide a visual description of the difference among arms.

**Overall type-I-error control for 2 primary hypothesis tests**

The overall type I error will be strongly controlled at a one-sided  $\alpha$  of 0.025 within the 2 primary hypothesis tests. Initially,  $\alpha$  of 0.0125 and 0.0125 will be assigned to the primary hypothesis testing of PFS of A versus C and PFS of B versus C, respectively. There will be 1 planned interim analysis for efficacy for both comparisons. If PFS in either comparison (eg, A versus C or B versus C) is statistically significant at initial assigned  $\alpha$  of 0.0125, then the  $\alpha$  of 0.0125 will be passed on to the hypothesis test in the other comparison (eg, B versus C or A versus C), and PFS in that comparison will be able to be tested at an overall one-sided  $\alpha$  of 0.025. The method of  $\alpha$  allocation, including possible  $\alpha$  recycling, are described in [Section 9.2.1, Figure 2](#).

Subgroup analysis of the primary endpoint of PFS per the IRC will be conducted to determine whether the treatment effect is consistent across various subgroups. The HR estimates of PFS and its 95% CI will be estimated and plotted within each category of the following variables: PD-L1 expression by IHC in TC ( $\geq 50\%$  TC versus 1% to 49% TC versus  $< 1\%$  TC), Stage (IIIB versus IV), age ( $\leq 65$  versus  $> 65$  years), gender (female versus male), ECOG PS (0 versus 1), and smoking status (former versus current versus never).

**Secondary Efficacy Endpoint Analyses:**

**Overall survival**

OS is defined as the time from randomization to death from any cause. OS will be analyzed in the ITT Population. Data for patients who are not reported as having died at the time of analysis will be censored at the date last known to be alive. Data for patients who do not have postbaseline information will be censored at the date of randomization.

Similar methodology used to evaluate PFS per the IRC will be applied to OS analysis.

**Progression-free survival per the investigator**

PFS per the investigator is defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as determined per RECIST v1.1 in an ITT Population.

Similar methodology used to evaluate PFS per the IRC will be applied to analysis of PFS per the investigator.

#### **Objective response rate per the IRC**

ORR (confirmation not required according to RECIST v1.1) is the proportion of patients who had CR or PR as assessed by the IRC per RECIST v1.1 in all randomized patients with measurable disease at baseline. Patients without any postbaseline assessment will be considered nonresponders. The difference in ORR between arms in the ITT Population will be evaluated using the Cochran-Mantel-Haenszel (CMH) chi-square test with the actual stratification factors as strata. The two-sided 95% CIs for the odds ratio and the difference in ORR will be calculated, as well as Clopper-Pearson 95% CIs for the ORR within each arm.

#### **Objective response rate per the investigator**

ORR (confirmation not required according to RECIST v1.1) is the proportion of patients who had a CR or PR as assessed by the investigator per RECIST v1.1 in all randomized patients with measurable disease at baseline. Patients without any postbaseline assessment will be considered nonresponders. Similar methodology used to evaluate ORR per the IRC will be applied to analysis of ORR per the investigator.

#### **Duration of response per the IRC**

DOR per the IRC is defined for patients with an objective response at the time from the first documented objective response to documented disease progression as assessed by the IRC using RECIST v1.1, or death from any cause, whichever occurs first. Data for patients who are alive and who have not experienced disease progression at the time of analysis will be censored at the date of the last tumor assessment. If no tumor assessments were performed after the date of the first occurrence of the objective response (CR or PR), DOR will be censored at the date of the first occurrence of the objective response. DOR will be estimated using Kaplan-Meier methodology. Comparisons between Arm A versus Arm C and Arm B versus Arm C will be made using the stratified and unstratified log-rank test for descriptive purposes only.

#### **Duration of response per the investigator**

DOR per the investigator is defined for patients with an objective response at the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. Data for patients who are alive and who have not experienced disease progression at the time of analysis will be censored at the date of the last tumor assessment. If no tumor assessments were performed after the date of the first occurrence of the objective response (CR or PR), DOR will be censored at the date of the first occurrence of the objective response. Similar methodology used to evaluate DOR per the IRC will be applied to analysis of DOR per the investigator.

#### **Health-Related Quality of Life (HRQoL)**

European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire (EORTC QLQ-LC13 and EORTC QLQ-C30) postbaseline scores will be compared between Arm A versus Arm C and Arm B versus Arm C, using a mixed model with baseline score and time since the randomization as covariates. Significant interaction between treatment and time since randomization or quadratic term of time since randomization ( $p$ -value  $< 0.05$ ) will also be included in the final model.

In addition, changes from baseline in global health status/QoL of QLQ-C30 and functional/symptom scales of both C30 and LC13 will be summarized descriptively.

#### **PD-L1 expression as a predictive biomarker for response**

PD-L1 expression will be examined in the ITT Population. Association between PD-L1 expression and tislelizumab treatment effect over control (PFS, OS, ORR, DOR, DCR) will be explored.

### **Exploratory Efficacy Analyses:**

#### **Disease control rate per the investigator**

DCR is defined as the proportion of patients with objective response (CR or PR) or SD maintained for  $\geq 6$  weeks as assessed by the investigator using RECIST v1.1. The analysis methods for DCR will be the same as those for ORR per the investigator.

#### **Time to response per the investigator**

TTR per the investigator is defined for patients with an objective response as assessed by the investigator as the time from randomization to the first occurrence of a CR or PR as assessed by the investigator using RECIST v1.1. TTR will be summarized for descriptive purposes. The mean, standard error, median, and range of TTR will be provided.

### **Safety Analyses:**

Safety will be assessed by monitoring and recording all AEs graded by NCI-CTCAE v4.03. Laboratory values (eg, hematology, clinical chemistry, urinalysis), vital signs, electrocardiograms (ECGs), and physical examinations will also be used in determining safety. Descriptive statistics will be used to analyze all safety data in the Safety Population.

### **Sample Size Considerations**

The sample size calculation is based on the number of events required to demonstrate the PFS superiority of Arm A or Arm B to Arm C in the ITT Population. Exponential distribution is assumed for PFS. The estimates of the number of events required to demonstrate efficacy with regard to PFS are based on the following assumptions:

1. Median PFS of 6 months in the Arm C.
2. At a one-sided  $\alpha$  of 0.0125, 80% power to detect an HR of 0.6, corresponding to an improvement in median PFS from 6 months to 10 months, in the PFS of A versus C comparison.
3. At a one-sided  $\alpha$  of 0.0125, 80% power to detect an HR of 0.6, corresponding to an improvement in median PFS from 6 months to 10 months, in the PFS of B versus C comparison.
4. Randomization ratio: 1:1:1.
5. One interim analysis is planned for both A versus C and B versus C comparisons when  $\sim 67\%$  of total PFS events occurred, with Pocock boundary.

With these assumptions, a total of 162 PFS events is required for each primary comparison of Arm A versus Arm C or Arm B versus Arm C, corresponding to a total of 235 PFS events in the ITT Population, for the final analysis. Assuming 342 patients are to be enrolled over an 8.6-month period at a constant enrollment rate, the final analysis will occur at approximately 18.5 months after the first patient is randomized.

### **Interim Analyses:**

There will be 1 interim efficacy analysis of PFS performed in the ITT Population. The interim efficacy analysis will be performed when approximately 157 PFS events (67% of the target number of 235 PFS events, corresponding to approximately 109 PFS events in each of the comparison) are observed in the ITT Population. It is estimated that it will take approximately 11.7 months to reach time of interim analysis. The interim boundary is based on the Pocock boundary. The interim and final analysis timing, and stopping boundaries are summarized in [Section 9.7](#), [Table 8](#) for the scenario where  $\alpha$  is not recycled and in [Table 9](#) for the scenario where  $\alpha$  is recycled.

## LIST OF ABBREVIATIONS AND TERMS

Abbreviation	Definition
ADA	antidrug antibody
AE	adverse event
ALT	alanine aminotransferase
AST	aspartate aminotransferase
AUC	area under the plasma or serum concentration-time curve
CI	confidence interval
CR	complete response
CT	computed tomography
CPI	checkpoint inhibitor
DCR	disease control rate
DOR	duration of response
ECG	electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eCRF	electronic case report form
EDC	electronic data capture (system)
EORTC QLQ-C30	European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
EORTC QLQ-LC13	European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer-13
FDA	Food and Drug Administration
FDG	fluorodeoxyglucose
FFPE	formalin-fixed paraffin-embedded
HBV	hepatitis B virus
HCV	hepatitis C virus
HR	hazard ratio
ICF	informed consent form
ICH	International Council on Harmonisation
IDMC	Independent Data Monitoring Committee
IEC	Independent Ethics Committee
IgG	immunoglobulin G (eg, IgG1, IgG2, IgG3, IgG4); other types of immunoglobulins include IgD and IgM
irAE	immune-related adverse event
IRB	Institutional Review Board
IRC	Independent Review Committee
ITT	intent-to-treat
IV	intravenous(ly)

---

<b>Abbreviation</b>	<b>Definition</b>
MRI	magnetic resonance imaging
NCI-CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
NSCLC	non-small cell lung cancer
ORR	objective response rate
OS	overall survival
PD-1	programmed cell death protein-1
PD-L1	programmed cell death protein ligand-1
PD-L2	programmed cell death protein ligand-2
PET	positron emission tomography
PFS	progression-free survival
PK	pharmacokinetic(s)
PR	partial response
PS	performance status
PT	prothrombin time
RECIST	Response Evaluation Criteria in Solid Tumors
SAE	serious adverse event
SD	stable disease
SOC	system organ class
T <sub>1/2</sub>	half-life
TC	tumor cells
TEAE	treatment-emergent adverse event
TPS	tumor proportion score
TTR	time to response
ULN	upper limit of normal

## 1 INTRODUCTION

### 1.1 Background Information on Non-Small Cell Lung Cancer

Lung cancer is the most common cancer worldwide with approximately 1.8 million new diagnoses and 1.59 million deaths worldwide in 2012, which corresponds to the highest incidence among cancers and most common cancer-related mortality (Ferlay et al 2015). Globally, across all cancer types, lung cancer is more common in men (16.8%) compared to women (8.8%). In China, there were an estimated 733,300 new cases of lung cancer in 2015. Lung cancer is the leading cause of cancer-related death in both men and women with an estimated 610,200 deaths in China in 2015 (Chen et al 2016).

Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancers and originates from the epithelial cells of the lung with the following major histological subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, among which squamous cell carcinoma constitutes 20% to 30% of all NSCLC (PDQ Adult Treatment Editorial Board [NSCLC] 2017). Small cell lung cancer (SCLC) accounts for approximately 10% to 15% of all lung cancers (PDQ Adult Treatment Editorial Board [SCLC] 2017).

The prognosis for lung cancer patients is relatively poor. However, the prognosis depends greatly on the stage at which the cancer is detected. Currently, lung cancer staging is performed worldwide according to the seventh edition of tumor, node, metastasis (TNM) Classification of Malignant Tumors (Goldstraw et al 2007). If lung cancer is diagnosed in its earliest stages, cure is possible through surgery or chemo-radiation therapy. Unfortunately, cases of lung cancer are most often detected relatively late in the illness, which makes cure less likely. However, with appropriate treatment, survival and prognosis can be improved considerably. For patients with advanced NSCLC, 5-year survival rates are approximately 36% for Stage IIIA, 26% for Stage IIIB, 10% for Stage IVA, and 1% for Stage IVB (American Cancer Society 2017).

Traditionally, the treatment of lung cancer has been based on histologic type (NSCLC or small cell lung cancer), performance status (PS), and stage of disease. However, more recently, treatment decisions are being made based on molecular and histologic characteristics of the tumor. Specifically, the subclassification of NSCLC as squamous or nonsquamous is important in the context of newer treatments because clinical data have demonstrated more favorable differences in the tolerability and activity of these agents in nonsquamous NSCLC (Oliver et al 2015).

### 1.2 Current First-Line Treatment of Advanced NSCLC

Genotype-directed therapy has the potential to dramatically improve the balance of benefit and toxicity for selected patients with NSCLC characterized by alterations of driver oncogenes, including sensitizing epidermal growth factor (*EGFR*) mutations and anaplastic lymphoma kinase (*ALK*) rearrangements. However, these mutations are more prevalent in adenocarcinoma NSCLC and are very rare in squamous NSCLC. The frequency of *EGFR* mutation and *EML4-ALK*

translocation had been reported to be 48.5% and 6.4% in Chinese lung adenocarcinoma, respectively, but were rather low with only 4.3% and 2%, respectively, in squamous histology (Gou and Wu 2014). Randomized Phase 3 studies of gefitinib (IPASS), erlotinib (EURTAC), and afatinib (LUX-Lung 3) showed significant improvement of progression-free survival (PFS) and objective response rate (ORR) compared with platinum doublet chemotherapy (Fukuoka et al 2011; Rosell et al 2012; Sequist et al 2013). Similarly, the *ALK* inhibitors crizotinib, ceritinib, and alectinib have demonstrated efficacy in patients with NSCLC that is positive for *ALK* rearrangement as defined by fluorescence in situ hybridization (XALKORI® prescribing information; ZYKADIA prescribing information; ALECENSA prescribing information). Both *EGFR* tyrosine kinase inhibitors (TKIs) and *ALK* inhibitors have been shown to be generally well tolerated.

For first-line treatment of advanced NSCLC not harboring identified drug-sensitive gene dysregulation, 2-drug or doublet chemotherapy regimens are recommended (National Comprehensive Cancer Network [NCCN] 2017). No advantage has been noted with addition of a third cytotoxic drug. Platinum-containing doublet chemotherapy remains the standard of care for the majority of patients with advanced NSCLC (Fennell et al 2016). A meta-analysis of randomized studies comparing either cisplatin or carboplatin with a third-generation drug revealed that there was no apparent difference between a carboplatin-based or cisplatin-based chemotherapy when assessing overall survival (OS) or 1-year survival rates (American Cancer Society 2017). However, some differences in adverse event profile were noted so that the authors recommend factoring those into decisions regarding which is more appropriate for a given patient.

For patients with nonsquamous NSCLC that does not have a sensitizing mutation in *EGFR* or an *ALK* fusion oncogene, standard first-line therapy includes a chemotherapy doublet of cisplatin and pemetrexed, which has been shown to result in superior efficacy and reduced toxicity compared to cisplatin and gemcitabine. Median survival time in this study was 11.8 months for pemetrexed plus cisplatin in nonsquamous NSCLC compared to 10.4 months for gemcitabine plus cisplatin (hazard ratio [HR] = 0.81; 95% confidence interval [CI], 0.70 to 0.94; p = 0.005) (NCCN 2017; Scagliotti et al 2008).

Bevacizumab is a recombinant, humanized, monoclonal antibody that blocks the vascular endothelial growth factor (VEGF) (Ferrara et al 2004, Roviello et al 2017), has shown an improvement of PFS (HR 0.72, 95% CI 0.66 to 0.79) and OS (0.90, 0.81 to 0.99) when combined with chemotherapy in eligible patients with advanced nonsquamous NSCLC, but more significant toxicities were observed with bevacizumab/chemotherapy compared with chemotherapy alone (Soria et al 2013; NCCN 2017). Fatal hemorrhagic events have also been noted more frequently in patients with squamous cell histology with other antiangiogenic compounds such as sorafenib (Scagliotti et al 2010). Doublet chemotherapy regimens are recommended by the NCCN guideline and the Chinese guideline for patients with nonsquamous NSCLC who are lacking identified gene dysregulation and bevacizumab/chemotherapy is an additional treatment option for this group of population.

Immune checkpoint-inhibitory receptor, programmed cell death protein-1 (PD-1) is mainly expressed in activated T cells including CD8<sup>+</sup> cytotoxic T-lymphocytes and CD4<sup>+</sup> T-helper



lymphocytes (Topalian et al 2012; Bersanelli and Buti 2017). It is presumed that PD-1 plays an important role in immune modulation of tumor progression by regulating the key inhibitory signaling in the T cells when engaged by its ligands. The PD-1 signaling cascade negatively regulates T-cell receptor (TCR) and attenuates T-cell proliferation and functional activities, leading to T-cell exhaustion. Expression by PD-1 is markedly up-regulated in tumor-infiltrating lymphocytes, while the expression of PD-1 ligand, programmed cell death protein ligand-1 (PD-L1), is significantly increased in tumor cells (TCs) and tumor-associated immune cells in the presence of stimulating cytokines, such as interferon-alpha (IFN- $\alpha$ ) and interferon-gamma (IFN- $\gamma$ ) in the tumor microenvironment. Furthermore, increased PD-1 expression in tumor-infiltrating lymphocytes and/or PD-L1 expression in tumor and tumor-associated stromal cells have been observed in many types of solid tumors including NSCLC (Jin and Yoon 2016; Patel and Kurzrock 2015; Van Der Kraak et al 2016; McDaniel et al 2016; Gong et al 2011). These monoclonal antibodies have now been approved for the treatment of several cancers, including bladder, lung, head, and neck squamous cell carcinomas, as well as melanoma, in the US, Europe, and beyond.

The PD-1 inhibitors, pembrolizumab and nivolumab, are both immunoglobulin G4 (IgG4) antibodies, which bind to PD-1 to disrupt the interaction between PD-1 and its ligands (PD-L1 and program cell death protein ligand-2 [PD-L2]) and thereby impede inhibitory signals in T cells (Wang et al 2014; Garon et al 2015). Nivolumab is Food and Drug Administration (FDA)-approved for treatment as a single agent or in combination with ipilimumab (Cytotoxic T Lymphocyte-Associated Antigen 4 [CTLA-4] antagonist) for unresectable or metastatic melanoma, metastatic NSCLC that progresses on or after platinum-based chemotherapy, advanced renal cell carcinoma (RCC) after antiangiogenic therapy, classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem-cell transplantation (HSCT) and post-transplantation brentuximab vedotin, and head and neck squamous cell cancer (HNSCC) with disease progression on or after a platinum-based therapy (Antonia et al 2016; United States FDA 2017; Motzer et al 2015; Gettinger et al 2015; Weber et al 2015; Hodi et al 2016; Rizvi et al 2015, Hellmann et al 2017). A summary of approved anti-PD-1/PD-L1 monoclonal antibody (mAb) for the treatment of advanced NSCLC is presented in Table 1.



**Table 1. Approved Anti-PD-1 or Anti-PD-L1 Inhibitors for the Treatment of Advanced or Metastatic NSCLC**

Study	Second-line treatment for advanced or metastatic lung cancer									First-line treatment for advanced NSCLC			
	KEYNOTE10 (Herbst et al 2016)			CHECKMATE057 (Borghaei et al 2015)		CHECKMATE017 (Brahmer et al 2015)		OAK (Rittmeyer et al 2017)		KEYNOTE24 (Reck et al 2016)		KEYNOTE021 Cohort G (Langer et al 2016; Borghaei et al 2017)	
Patient	N=1034			N=582		N=272		N=1225		N=305		N=123	
Treatment	Pembrolizumab 2 mg/kg (n=345)	Pembrolizumab 10 mg/kg (n=346)	Docetaxel (n=343)	Nivolumab (n=287)	Docetaxel (n=268)	Nivolumab (n=131)	Docetaxel (n=129)	Atezo- lizumab (n=425)	Docetaxel (n=425)	Pembrolizumab monotherapy (n=154)	Platinum-based chemotherapy (n=151)	Pembrolizumab plus pemetrexed /carboplatin (n=60)	Chemotherapy only (n=63)
OS (months)	10.4 (9.4-11.9)	12.7 (10.0-17.3)	8.5 (7.5-9.8)	12.2	9.4	9.2	6	13.8 (95% CI 11.8-15.7)	9.6 (95% CI 8.6-11.2)	80.2	72.4	NR (22.8-NR)	20.9 (14.9-NR)
HR, (95% CI)	0.71, (0.58-0.88); p=0.0008	0.61, (0.49-0.75); p<0.0001	NA	0.73, (0.59-0.89), p = 0.002		0.59, (0.44-0.79), p < 0.001		0.74, (0.58-0.93), p = 0.0102		0.60 (0.41-0.89), p = 0.005		0.59, (0.34-1.05), p = 0.03	
mPFS (months)	3.9 (3.1-4.1)	4.0 (2.7-4.3)	4.0 (3.1-4.2)	2.3	4.2	3.5	2.8	2.8 (95% CI 2.6-3.0)	4.0 (95% CI 3.3-4.2)	10.3	6	19.0 (8.5-NR)	8.9 (6.2-11.8)
HR (95% CI)	0.88, (0.74-1.05, p = 0.068)	0.79, (0.66-0.94, p = 0.004)	NA	0.92, (0.77-1.1, p = 0.39)		0.62, (0.47-0.81, p < 0.001		0.95, (0.82-1.10)		0.50, (0.37-0.68, p < 0.001)		0.54, (0.33-0.88, p = 0.0067)	
ORR (%)	18 (14-23)	18 (15-23)	9 (7-13)	19	12	20	9	14	13	44.8	27.8	55 (95% CI = 42-68)	29 (95% CI = 18-41)
p value	p < 0.001	p < 0.001	NA	p = 0.021	NA	p = 0.008	NA	NA	NA	NA	NA	NA	NA
TEAE ≥ Grade 3 (%)	13	16	35	10	54	7	55	15	43	26.6	53.3	40	26

Abbreviations: HR, hazard ratio; mOS, overall survival duration in months; mPFS, progression-free survival duration in months; ORR, objective response rate; OS, overall survival; PD-1, programmed cell death protein-1 program cell death protein ligand-1; PD-L1, program cell death protein ligand-1; PFS, progression-free survival; NA, not applicable; NR, not reported; TEAE=treatment-emergent adverse event.

A Phase 1 multicohort study (CheckMate 012) was conducted to explore the safety and efficacy of nivolumab combined with current standard therapies, including a cohort of first-line advanced NSCLC (Hellmann et al 2016). Patients received nivolumab (intravenously [IV], plus platinum-based doublet chemotherapy concurrently Q3W for 4 cycles followed by nivolumab alone until progression or unacceptable toxicity. Regimens were nivolumab 10 mg/kg plus gemcitabine-cisplatin (squamous) or pemetrexed-cisplatin (nonsquamous) or nivolumab 5 or 10 mg/kg plus paclitaxel-carboplatin (all histologies). No dose-limiting toxicities occurred during the first 6 weeks of treatment. The safety profile of nivolumab plus platinum-based doublet chemotherapy was consistent with that expected for individual agents. The ORR in nonsquamous NSCLC group (n = 40) was 43%, median PFS was 6.0 months, PFS rate at 24 weeks was 53% and median OS was 21.5 months. Responses were independent of tumor PD-L1 expression at baseline (Rizvi et al 2016).

A Phase 3 randomized, open-label study (IMpower 150) evaluating the safety and efficacy of atezolizumab in combination with chemotherapy with or without bevacizumab in first-line advanced NSCLC (Reck et al 2017) met its coprimary endpoint of PFS and demonstrated that the combination of atezolizumab and bevacizumab plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to bevacizumab plus chemotherapy in the first-line treatment of patients with advanced NSCLC (HR, 0.617, 95% CI: 0.517 to .737, p<0.0001), in all populations. Atezolizumab in combination with chemotherapy ± bevacizumab appears to be well tolerated and its safety profile is consistent with known safety risks.

The recent development of checkpoint inhibitors (CPIs), as monotherapy, and in combination with other immunotherapeutic agents or chemotherapeutic agents, provides a new approach for patients with NSCLC, with similar efficacy and safety observed among various CPIs. However, there is still a critical need for predictive biomarkers to identify patients who would receive optimal benefit from the treatment of CPIs.

Pembrolizumab monotherapy was associated with significantly longer progression-free and OS than was platinum-based chemotherapy in chemo-naïve, PD-L1+ (> 50% TCs), *EGFR* and *ALK* wild-type NSCLC patients in the first-line setting (Reck et al 2016). In contrast, in CheckMate 026, it was reported that nivolumab failed to show any benefit compared with standard platinum-based chemotherapy in metastatic NSCLC patients with PD-L1 expression > 1% TC. The study was stratified by PD-L1 expression (< 5% versus ≥ 5% TC) and histology. Median PFS in the PD-L1 ≥5% NSCLC group was 4.2 months (nivolumab) versus 5.9 months (chemotherapy; HR, 1.15; 95% CI: 0.91 to 1.45, p = 0.25). No benefit was observed in the PD-L1 ≥ 50% subgroup either (Socinski et al 2016).

Pembrolizumab was also recently approved by the FDA in combination with pemetrexed and carboplatin for the first-line treatment of metastatic non-squamous NSCLC, irrespective of PD-L1 expression (Keytruda prescribing information). This is based on the positive results of the Phase 2 study KEYNOTE-021 Cohort G1 (Table 1). ORR was nearly double in the pembrolizumab + chemotherapy group versus pemetrexed/carboplatin alone: 55% (95% CI = 42 to 68) compared to 29% (95% CI = 18 to 41), respectively; all responses were partial responses (PRs).

The ORR was highest among patients with highest PD-L1 expressions (tumor proportion score [TPS]  $\geq 50\%$ ) with 80%, and 54% and 57% for TPS  $\geq 1\%$  or  $< 1\%$ , respectively, and, interestingly, lowest with ORR of 26% for intermediate expressors with TPS 1% to 49%. However, the overall and individual subgroup sample size was small and limiting the interpretation (Langer et al 2016; Borghaei et al 2017). Hence association of PD-L1 expression and responsiveness in the context of combination with chemotherapy remains less clear and an area of active investigation at the current time.

In general, PD-L1 expression has been associated with higher ORRs (range, 23% to 83%) to PD-1/PD-L1 inhibitors (Borghaei et al 2015; Garon et al 2015; Herbst et al 2014; Antonia et al 2014), but responses have also been observed among PD-L1-negative patients (ORRs, 9% to 20%) (Garon et al 2015; Herbst et al 2014; Antonia et al 2014; Garon et al 2014). Each PD-1/PD-L1 inhibitor in clinical development has used different anti-PD-L1 antibodies, different scoring cutoffs, and various scoring algorithms (Kerr et al 2015). Therefore, it remains to be explored if PD-L1 expression status is a predictive biomarker for patient selection.

### 1.3 Current Treatment for Advanced Squamous NSCLC

Based on currently available data, the standard of care for patients with newly diagnosed squamous NSCLC, with negative or unknown *EGFR*, *ALK*, protooncogene ROS (*ROS1*), proto-oncogene B-Raf (*BRAF*) alteration, or PD-L1 expression  $< 50\%$  or unknown status, remains to be platinum-based doublet chemotherapy (NCCN 2017). Therapeutic efficacy of chemotherapy for NSCLC has reached a plateau with no significant difference overall in efficacy among regimens (Derman et al 2015). Comparison of 4 different platinum-based doublets encompassing 1,155 patients with NSCLC, contemporary chemotherapy elicits a response rate of only 20%, with a median OS of less than 8 months (Schiller et al 2002).

As to safety, cisplatin-based chemotherapy has been associated with more severe nausea and vomiting and nephrotoxicity, while severe thrombocytopenia has been more frequent during carboplatin-based chemotherapy (Hotta et al 2004; Ardizzoni et al 2007). The risk of treatment-related deaths was greater in the cisplatin arm, but this increase was not statistically significant (Jiang et al 2007).

Despite some recent developments including albumin-based paclitaxel regimen, available data indicate that outcomes in patients with squamous NSCLC following frontline chemotherapy may be worse than those in patients with adenocarcinoma (Socinski et al 2012). During the initial Phase 2 studies investigating bevacizumab in the treatment of patients with NSCLC, the observation of a heightened propensity for life-threatening pulmonary hemorrhages was noted in the squamous cell subset and development of bevacizumab was temporarily halted in NSCLC. Subsequently, the Phase 3 E4599 study restricted the eligibility criteria to patients with nonsquamous histology due to the higher incidence of adverse outcomes observed in squamous NSCLC in the Phase 2 study (Johnson et al 2004). No difference in OS was found when gemcitabine/cisplatin was compared with pemetrexed/cisplatin but in a preplanned subset analysis, pemetrexed plus cisplatin demonstrated less benefit in patients with squamous NSCLC with a shorter OS. These observations

indicated that squamous NSCLC is a distinct clinical entity and emphasized the importance of a correct histologic diagnosis for NSCLC.

Solvent-based paclitaxel is commonly used in combination with a platinum agent for the treatment of advanced NSCLC, and is associated with a 15% to 32% ORR and a median OS of 7.9 to 10.06 months (Schiller et al 2002; Kelly et al 2001; Sandler et al 2006; Scagliotti et al 2010; Lilenbaum et al 2005). It is clinically active but has poor drug solubility and requires the use of the solvent Cremophor EL (CrEL; now known as Kolliphor EL) to create soluble paclitaxel (Taxol [paclitaxel] prescribing information) that has shown to cause hypersensitivity reactions and thus necessitates the use of premedication (ten Tije et al 2003).

*Nab*-paclitaxel was designed to address issues associated with the use of solvent-based paclitaxel and is formulated with high-pressure homogenization of paclitaxel and human serum albumin, resulting in a 130-nm particle colloidal suspension that can be reconstituted in normal saline (Ibrahim et al 2002). In late 2012, *nab*-paclitaxel was granted an indication by the FDA for the first-line treatment of locally advanced or metastatic NSCLC in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy (Abraxane [paclitaxel] prescribing information).

The approval was based on a multicenter Phase 3 study in which *nab*-paclitaxel + carboplatin (*nab*-PC), *nab*-paclitaxel given as 100 mg/m<sup>2</sup> on Day 1, D8, and D15 every 21 days and carboplatin given at area under the plasma or serum concentration-time curve (AUC) 6, significantly improved the ORR—the primary endpoint of the study—compared with solvent-based-paclitaxel + carboplatin (sb-PC); *nab*-PC also produced fewer incidences of Grade 3/4 neuropathy, neutropenia, arthralgia, and myalgia than sb-PC in patients with advanced NSCLC (Socinski et al 2012). This study also reported noninferiority of *nab*-paclitaxel compared with sb-paclitaxel in respect to PFS and OS. The PFS in the *nab*-PC arm was noninferior to PFS in the sb-PC arm (HR *nab*-PC/sb-PC 95% CI, upper bound, 1.086). The OS in the *nab*-PC arm was noninferior to the OS in the sb-PC arm (HR *nab*-PC/sb-PC 95% CI, upper bound, 1.066) (data presented in Table 2).

**Table 2. Clinical Data of *Nab*-Paclitaxel + Carboplatin versus Solvent-Based Paclitaxel + Carboplatin**

Treatment	<i>Nab</i> -paclitaxel + carboplatin	Solvent-based paclitaxel + carboplatin	HR
ORR (%)	33	25	response rate ratio: 1.31; 1.08-1.59; p < 0.01
PFS (months)	6.3 95% CI, 5.6 to 7.0	5.8 95% CI, 5.6 to 6.7	0.90 95% CI, 0.77-1.06 p = 0.21
OS (months)	12.1 95% CI, 10.8 to 12.9	11.2 95% CI, 10.3 to 12.6	0.92 95% CI, 0.80-1.07; p = 0.27

Treatment	Nab-paclitaxel + carboplatin	Solvent-based paclitaxel + carboplatin	HR
Notable Grade 3/4 AE	fewer neuropathy (p < 0.001), neutropenia (p < 0.001), arthralgia (p = 0.008), and myalgia (p = 0.011)	fewer Grade 3/4 thrombocytopenia (p < 0.001) and anemia (p < 0.001)	NA

Abbreviations: AE, adverse event; CI, confidence interval; HR, hazard ratio; overall survival; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; NA, not applicable; TEAE=treatment-emergent adverse event.

The efficacy and safety of first-line *nab*-PC compared with gemcitabine + carboplatin (GC) in 127 Chinese patients with advanced squamous NSCLC was reported in a randomized Phase 2 study (CTONG1002) (Yang et al 2014). *Nab*-paclitaxel was given as 135 mg/m<sup>2</sup> on D1 and D8, Q3W while gemcitabine was given at 1250 mg/m<sup>2</sup> on D1 and D8, Q3W, and carboplatin was given at AUC 5 on D1 Q3W in both arms. ORR of 46% for patients treated with *nab*-PC versus 30% for patients treated with GC (p = 0.085) was reported, the nonsignificance of the results was likely due to the small number of patients treated. Moreover, *nab*-PC produced an improvement in PFS of approximately 19% (median, 5.7 versus 4.8 months with GC; p = 0.657). *Nab*-PC was associated with a greater incidence of neutropenia and leukopenia than was GC because the dose/schedule might have added to the myelosuppressive effect of *nab*-paclitaxel in this study, however, no other significant differences in Grade 3/4 toxicities existed between the arms. The CTONG1002 study confirmed the effectiveness of *nab*-PC in patients with squamous NSCLC and the safety profile reported was consistent with that of the pivotal Phase 3 study (Socinski et al 2012).

#### 1.4 Unmet Medical Needs for Advanced Squamous NSCLC

Although progress continues to be made in the treatment of NSCLC, the majority regulatory approvals of both targeted and chemotherapeutic agents, and updates to clinical practice guidelines for advanced NSCLC have been focused on nonsquamous NSCLC (Section 1.2). Platinum-based chemotherapy doublets, generally associated with a median PFS of 4 to 6 months, and median OS of 8 to 10 months, remains the standard of care for patients with squamous NSCLC, who constitute 20% to 30% of all NSCLC, with a rather low frequency of *EGFR* mutation and *ALK* translocation (Kelly et al 2001; Sandler et al 2006; Scagliotti et al 2002; Scagliotti et al 2008; Schiller et al 2002; NCCN 2017; Gou and Wu 2014). In addition, because of safety concerns, patients with squamous NSCLC have been excluded from a number of clinical studies of investigational agents, particularly those targeting angiogenesis. In view of the overall poor prognosis, there is a significant unmet medical need for advanced squamous NSCLC.

The approval of pembrolizumab monotherapy as first-line treatment for NSCLC patients with high PD-L1 expression (TPS ≥ 50%), and in combination with pemetrexed and carboplatin as first-line treatment for nonsquamous NSCLC based on clinically meaningful improvements in PFS and ORR compared to standard of care have presented the potential to address the unmet medical needs of patients with NSCLC without *EGFR* or *ALK* alteration (Reck et al 2016). Incorporating anti-PD-1/anti-PD-L1 inhibitors with chemotherapeutic agents as front-line therapy may be a novel therapeutic approach that could bring clinical benefit for Chinese patients with advanced squamous NSCLC.

## 1.5 Background Information on Tislelizumab

### 1.5.1 Pharmacology

Tislelizumab (also known as BGB-A317) is a humanized, IgG4-variant monoclonal antibody against PD-1 under clinical development for the treatment of several human malignancies.

Tislelizumab acts by binding to the extracellular domain of human PD-1 with high specificity as well as high affinity (dissociation constant  $[K_D] = 0.15 \text{ nM}$ ). It competitively blocks binding efforts by both PD-L1 and PD-L2, thus inhibiting PD-1-mediated negative signaling in T cells.

[REDACTED]

[REDACTED]

[Labrijn et al 2009](#)

[Investigator's Brochure](#)

### 1.5.2 Toxicology

[REDACTED]

[REDACTED]

[Investigator's Brochure](#)

### 1.5.3 Clinical Pharmacology

[Redacted]

[Redacted]

[Redacted]

#### 1.5.3.1 Lack of Ethnic Differences

[Redacted]

[Section 1.5.3](#)

[Redacted]

[Redacted]

[Chiba et al 2014](#)

#### 1.5.4 Prior Clinical Experience of Tislelizumab

[Redacted]

[Investigator's Brochure](#)

[Redacted]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]



## 1.6 Study Rationales

### 1.6.1 Rationale for the Chemotherapy Regimens Administered With Tislelizumab in the Treatment of Advanced Squamous NSCLC

Currently, the standard first-line therapy for patients with advanced squamous NSCLC without targetable genetic aberrations is platinum-doublet chemotherapy (NCCN 2017).

Drugs targeting PD-1 and its ligand, PD-L1, have shown a manageable safety profile and robust efficacy including a significant prolongation of OS compared with docetaxel in patients whose disease progressed on platinum-based chemotherapy.

Increasing evidence suggests that the antitumor activity of chemotherapy is mediated not only through cytotoxic effects, but also through immunological effects, including reducing T-regulatory cell activity and enhancing cross-presentation of tumor antigens. Chemotherapy has also been shown to induce PD-L1 expression on tumor cells (Jin and Yoon 2016; Ono Pharmaceutical 2017; Patel and Kurzrock 2015; Van Der Kraak et al 2016; McDaniel et al 2016; Gong et al 2011). Combining immunotherapy and chemotherapy could thus additively improve the anticancer activity. The manageable safety profile and the promising antitumor activities observed in other PD-1 antibodies combined with chemotherapy as first-line therapy in patients with advanced NSCLC provide justification for this study design. Based on preliminary data with tislelizumab monotherapy in a Phase 1 study (BGB-A317\_Study\_001), tislelizumab appears comparable to other anti-PD-1 CPIs in terms of safety and preliminary activity in patients with advanced solid tumors. In addition, an ongoing Phase 1b study which evaluates the combination of tislelizumab and various standard of care chemotherapies in first-line NSCLC did not show new safety signals compared to other CPI plus chemotherapy (BeiGene data on file 2017a).

This Phase 3 study will assess whether the addition of tislelizumab to standard of care chemotherapy will improve the outcome of Chinese patients with advanced and metastatic squamous NSCLC, whose disease has a poor prognosis with standard of care chemotherapies alone.

### 1.6.2 Rationale for Selection of Tislelizumab Dose in Combination With Chemotherapy

The fixed dose of tislelizumab 200 mg Q3W was selected based on both nonclinical studies and available clinical data (efficacy, safety, and PK).

No tissue cross reactivity was found in either human or monkey tissues, and no effect on cytokine release was observed in human whole-blood assay. No apparent toxicity was noted in mice or monkeys following a single dose up to 100 mg/kg or in monkeys following a repeat dose up to 30 mg/kg biweekly for 13 weeks. The toxicokinetics profile was characterized in monkey studies and the systemic exposure appeared to be dose proportional without gender difference or accumulation over the dosing period. No apparent immunotoxicity was observed as no apparent changes in clinical pathology or histopathology were noted in these studies.

The tislelizumab dose is also informed by available clinical activity, safety, and PK data. The safety of tislelizumab has been tested across a range of doses in BGB-A317\_Study\_001 (0.5 mg/kg to 10 mg/kg Q2W [N = 62]; 2 mg/kg to 5 mg/kg Q3W [N = 41]) with no MTD defined at the highest

dose examined. Efficacy has also been demonstrated in 15 of 99 evaluable patients to date who had been diagnosed with a variety of tumor types and were treated with single agent tislelizumab at doses that ranged from 2 mg/kg to 5 mg/kg administered either Q2W or Q3W. According to the Phase 1a PK data in Australia, serum concentrations of tislelizumab showed linear relationships with doses from 0.5 mg/kg Q2W to 10 mg/kg Q2W. Because the clearance of tislelizumab was found to be independent of body weight, a 200-mg dose (body weight adjusted dose between 3 and 4 mg/kg) administered Q3W was expected to lead to serum exposures that fall between those observed after 2 mg/kg and 5 mg/kg doses. This prediction was corroborated with simulations conducted using the population PK analysis and further supported by preliminary PK data from 5 patients who received 200 mg Q3W (Phase 1a, Part 3). Tislelizumab concentrations after the first 200 mg dose were between the concentrations observed after 2 mg/kg and 5 mg/kg doses (in patients from Phase 1a, Parts 1 and 2). Additionally, as shown by available data from BGB-A317\_Study\_001 and BGB-A317\_Study\_102, the PK profile of tislelizumab is consistent between Asian (Chinese) and Caucasian patients (Section 1.5.3.1).

Simulations do not suggest any clinically meaningful differences in exposure following fixed dose or dose adjusted for weight (Bai et al 2012). Based on this analysis, a fixed dose of 200 mg is selected (equivalent to a weight-based dose of 3.3 mg/kg, calculated with 60 kg).

Selection of a Q3W dosing interval is both supported by this preliminary PK evaluation and allows for a convenient integration with common chemotherapeutic regimens.

The doses of all chemotherapy drugs are based on product labelling, literature, and local guidelines. Several Phase 1 and Phase 2 studies showed that the safety profile of anti PD-1 antibodies in combination with carboplatin-based doublet chemotherapy was consistent with that expected in individual agents. There were no known overlapping, significant toxicities or drug–drug interactions between anti-PD-1 antibodies and carboplatin or paclitaxel observed in these studies.

In conclusion, BGB-A317 200 mg Q3W is the recommended dose for this Phase 3 global safety study.

### 1.6.3 Rationale for Selection of *Nab*-Paclitaxel Dose and Schedule

The 7 cohorts of dose and schedule of *nab*-paclitaxel plus carboplatin as first-line therapy in patients with advanced NSCLC had been evaluated in a Phase 2 dose-finding study (Socinski et al 2010). Patients received first-line therapy with Q3W carboplatin (AUC 6) plus *nab*-paclitaxel Q3W at doses ranging from 225 to 340 mg/m<sup>2</sup> or weekly at 140 mg/m<sup>2</sup> (D1 and D8 of a 3-week cycle) or 100–125 mg/m<sup>2</sup> (D1, D8, and D15). The ORRs in the Q3W arms ranged from 24% to 40% and those in the weekly arms ranged from 36% to 56%. Median OS in the Q3W arms ranged from 8 to 15 months and those in the weekly arms ranged from 11 to 15 months. Median PFS in the Q3W arms ranged from 5 to 7 months and each of the weekly cohorts had a median PFS of approximately 6 months. The safety profiles were comparable between all cohorts.

The choice of *nab*-paclitaxel dosage and schedule is based on previous researches, and the Phase 3 study result (Socinski et al 2010, Socinski et al 2012).

#### 1.6.4 Rationale for Carboplatin Doublet Chemotherapy as the Comparator

As described in [Section 1.2](#), patients with squamous NSCLC that do not have a sensitizing mutation in *EGFR* or an *ALK* fusion oncogene typically receive a standard first-line therapy that includes a platinum-based chemotherapy doublet. The dose of carboplatin of AUC 5 and paclitaxel of 175 mg/m<sup>2</sup> on D1 of a 3-week cycle is the standard regimen in China ([Zhi et al 2012](#)).

#### 1.6.5 Rationale for Primary Endpoint of PFS as Assessed by the Independent Review Committee

PFS as an endpoint can reflect tumor growth and can be assessed before the determination of a survival benefit; in addition, its determination is not generally confounded by subsequent therapies. Meta-analyses based on 5 randomized studies comparing docetaxel-based chemotherapy with vinorelbine-based chemotherapy for the first-line treatment of NSCLC have indicated that PFS can be considered a good measure of clinical benefit for patients with locally advanced and/or metastatic NSCLC ([Laporte et al 2013](#)).

Whether an improvement in PFS represents a direct clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect and the benefit-risk of the new treatment compared with available therapies ([FDA 2007](#); [European Medicines Agency 2012](#)).

New treatment modalities, such as targeted therapies and immunotherapy as monotherapy in patients with highly expressing PD-L1 tumors or in combination with chemotherapy ([Section 1.2](#); [Table 1](#); [Langer et al 2016](#)), are emerging as highly effective regimens that are providing improvements in patient outcomes far beyond what has been achieved before ([Ellis et al 2014](#)). In particular, immunotherapy has been correlated or associated with durable responses, significant prolongation of PFS, and improvement of quality of life ([Langer et al 2016](#)). In addition, meta-analyses have indicated that PFS can be considered a good measure of clinical benefit for patients with locally advanced and/or metastatic NSCLC ([Laporte et al 2013](#)).

The subjectivity in the measurement of PFS assessments is acknowledged—with the fact that the assessment depends on frequency, accuracy, reproducibility, and completeness—and may affect the observed magnitude of effect and carry the risk of bias. Therefore, tumor assessment by the Independent Review Committee (IRC) per response evaluation criteria in solid tumors (RECIST) v1.1, scheduled every 6 weeks for the first 52 weeks, regardless of treatment delay until disease progression, is to be implemented in this study to ensure lack of bias when comparing Arm A versus Arm C, and Arm B versus Arm C.

#### 1.6.6 Rationale for Requiring PD-L1 Testing

The recent development of CPIs, as monotherapy, and in combination with other immunotherapeutic agents or chemotherapeutic agents, provides a new approach for patients with NSCLC, with similar efficacy and safety observed among various CPIs. However, there is still a critical need for predictive biomarkers to identify patients who would receive optimal benefit from the treatment of CPIs. As outlined in [Section 1.2](#), in general, increased PD-L1 protein expression has been associated with higher ORRs (range, 23% to 83%) and higher PFS (range, 5.2 months to

10.3 months) with PD-1/PD-L1 inhibitor monotherapy (Borghaei et al 2015; Garon et al 2015; Herbst et al 2014; Antonia et al 2014), but responses have also been observed among PD-L1-negative patients (ORRs, 9% to 20%) (Garon et al 2015; Herbst et al 2014; Antonia et al 2014; Garon et al 2014; Reck et al 2016). Data from KEYNOTE-021 Cohort G1 reported ORR was highest among patients with highest PD-L1 expressions (TPS  $\geq$  50%) with 80%, and 54% and 57% for TPS  $\geq$  1% or  $<$  1%, respectively, and, lowest with ORR of 26% for intermediate expressors with TPS 1% to 49%. However, the overall and individual subgroup sample size was small and limiting the interpretation (Langer et al 2016; Borghaei et al 2017). The association between PD-L1 expression and anti-PD-1/PD-L1 therapy in combination with chemotherapy is less clear and remains an area of active investigation.

Each PD-1/PD-L1 inhibitor in clinical development has used different anti-PD-L1 antibodies, different scoring cutoffs, and various scoring algorithms (Kerr et al 2015). The Blueprint study has reported that 3 PD-L1 antibody assays (28-8 for nivolumab, 22C3 for pembrolizumab, and SP263 for durvalumab) showed high concordance with regard to expression on tumor cell membranes in NSCLC (Hirsh et al 2016).

In this study we included PD-L1 expression by immunohistochemistry (IHC) using the SP263 assay as one of the stratification factors to ensure balanced enrollment, and to allow for the assessment of relationship between PD-L1 expression and efficacy outcome measures. Based on prevalence data from previous NSCLC studies, the cutoff at 3 levels ( $<$  1% TC versus 1% to 49% TC versus  $\geq$  50% TC) has been selected for this study. (Section 1.2).

### **1.6.7 Rationale for Allowing Crossover to Tislelizumab**

Despite recent improvements in treatments, the prognosis for patients with advanced squamous NSCLC remains dismal, with median OS of approximately 12.5 months (Sandler et al 2006). Patients who receive second-line treatment for their disease have an even more limited prognosis, with median survival duration of only 9 months in patients with a good performance status (Stinchcombe and Socinski 2008). Formerly approved therapies are associated with significant toxicities (eg, neuropathy, febrile neutropenia, myelosuppression, and alopecia) that negatively impact quality of life.

Anti-PD-1/PD-L1 monoclonal antibodies (mAbs) have shown superior efficacy to docetaxel by increasing the OS by about 2 to 3 months in advanced NSCLC patients who have disease progression during or after a platinum-containing regimen (Borghaei et al 2015, Brahmer et al 2015). However, there are no anti-PD-1/PD-L1 mAbs currently approved in China. Hence, patients randomized to the control arm have, at the time of IRC-confirmed tumor progression, the option to cross over to receive tislelizumab as second-line treatment and may potentially gain benefit from the treatment.

### **1.6.8 Rationale for Allowing Patients to Continue Tislelizumab Until Loss of Clinical Benefit**

Conventional response criteria may not adequately assess the activity of immunotherapeutic agents because progressive disease (determined by initial radiographic evaluation) does not necessarily

reflect therapeutic failure. A recent retrospective analysis of the Phase 3 OAK evaluated 332 patients who experienced disease progression per RECIST v1.1 while being treated with atezolizumab (Gandara et al 2017). The results showed that 51% (n=168) continued treatment with atezolizumab beyond progression. Of those 7% (12/168) achieved subsequent response in target lesions ( $\geq 30\%$  reduction from new baseline at disease progression) and 49% (83/168) had stable target lesions (best change between +20% and -30%). Median OS was 12.7 months (95% CI: 9.3, 14.9) post progressive disease for patients on atezolizumab treatment beyond progression, with a tolerable safety profile. That is in contrast to median overall survivals of 8.8 months (95% CI: 6.0, 12.1) and 2.2 months (95% CI: 1.9, 3.4) for patients who either received other (n = 94, 28%) or no anticancer treatment (n=70, 21%), respectively, at the time of progression. These data suggest considerable benefit from continued immunotherapy treatment past disease progression.

This study will allow patients randomized to the tislelizumab in combination with chemotherapy treatment arm to remain on tislelizumab-containing treatment, and those patients who cross over from the control arm (chemotherapy only) to receive tislelizumab monotherapy after apparent radiographic progression, provided the benefit-risk ratio is judged to be favorable. Patients should be discontinued for unacceptable toxicity or symptomatic deterioration attributed to disease progression as assessed by the investigator after an integrated assessment of radiographic data and clinical status (Section 7.4).

#### **1.6.9 Rationale for Patient-Reported Outcome Assessments**

Patient-reported outcome (PROs) assessments have been shown to provide the most robust descriptions of the treatment experience, with the incorporation of multiple modes of endpoint measurements in clinical studies, and would supplement the data derived from clinical reported CTCAEs (Dajczman et al 2008). With growing recognition of the importance of patient-centered care, PROs have also been reported to have positive effects on the well-being of patients with cancer (Basch et al 2016). Evidence of benefits of incorporating PROs in the chemotherapeutic setting, specifically in patients with lung cancer, would further characterize clinical benefit beyond radiographic measures.

The PRO instruments to be used in this study are the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLC-LC13.

#### **1.7 Benefit-Risk Assessment**

Available data from clinical studies of other anti-PD-1 antibodies, such as nivolumab and pembrolizumab, have demonstrated favorable benefit/risk profiles. Other immunotherapy targeting PD-1/PD-L1, such as atezolizumab and avelumab, showed similar manageable safety profiles and antitumor activity in patients with advanced lung cancer.

Tislelizumab data is currently limited; latest data collected from the Phase 1 study of BGB-A317\_Study\_001 showed that tislelizumab is overall well tolerated with a preliminary safety profile that is largely consistent with that of other anti-PD-1 antibodies, and antitumor activity has

been observed in a range of tumor types, with data presented at most recent scientific conferences (Desai et al 2017; Horvath et al 2017; Meniawy et al 2017).

Investigator's Brochure

Investigator's Brochure

BeiGene data on file 2017b The present study is a randomized study designed to compare the safety and efficacy of tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC with wild-type *EGFR*.

The benefit/risk assessment based on available tislelizumab Phase 1 data, the currently ongoing Phase 2 study, and the publications from Phase 3 studies of other anti-PD-1 antibodies is considered positive; the study design, which randomizes patients to tislelizumab combined with paclitaxel or *nab*-paclitaxel based chemotherapy compared with chemotherapy alone at 1:1:1 ratio, is considered justified from a benefit/risk perspective.

## 2 STUDY OBJECTIVES AND ENDPOINTS

### 2.1 Study Objectives

#### 2.1.1 Primary Objective

- To compare the PFS as assessed by the IRC per RECIST v1.1 in an Intent-to-Treat (ITT) Population between tislelizumab either combined with paclitaxel + carboplatin (Arm A) or combined with *nab*-paclitaxel + carboplatin (Arm B) and paclitaxel + carboplatin alone (Arm C) in patients with untreated Stage IIIB or Stage IV squamous NSCLC.

#### 2.1.2 Secondary Objectives

- To compare ORR as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone.
- To compare duration of response (DOR) as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or carboplatin + *nab*-paclitaxel and paclitaxel + carboplatin alone.



- To compare OS between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone in an ITT Population.
- To compare PFS as assessed by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone in an ITT Population.
- To compare health-related quality of life (HRQoL) between tislelizumab combined with paclitaxel + carboplatin or carboplatin-*nab*-paclitaxel and paclitaxel + carboplatin alone.
- To evaluate the safety and tolerability of tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin compared with paclitaxel + carboplatin alone.
- To evaluate the correlation between programmed death-ligand1 (PD-L1) expression levels by IHC and antitumor activity of tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin.

### 2.1.3 Exploratory Objectives

- To compare tumor assessment outcomes (eg, DCR, time to response [TTR]) between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone assessed by the investigator per RECIST v1.1.
- To assess tumor and blood-based biomarkers of tislelizumab response, resistance and patient prognosis.
- To characterize the PK of tislelizumab when given in combination with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin.
- To assess host immunogenicity to tislelizumab

## 2.2 Study Endpoints

### 2.2.1 Primary Endpoint

- PFS as assessed by the IRC—the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the IRC per RECIST v1.1 in an ITT Population

### 2.2.2 Secondary Endpoints

- ORR as assessed by the IRC and investigator—the proportion of patients who had complete response (CR) or PR as assessed by the IRC and investigator per RECIST v1.1 in all randomized patients with measurable disease at baseline.
- DOR as assessed by the IRC and investigator—the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as assessed by the IRC and investigator per RECIST v1.1 in all randomized patients with documented objective responses.
- OS—the time from the date of randomization to the date of death due to any cause in an ITT

Population.

- PFS as assessed by the investigator—the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1 in an ITT Population.
- HRQoL—measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) and Core 30 (EORTC QLQ-C30) as presented in patient-reported outcomes.
- Incidence and severity of treatment-emergent AEs (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03.
- PD-L1 expression by IHC as a predictive biomarker for response

### 2.2.3 Exploratory Endpoints

- DCR—the proportion of patients who had CR, PR, or SD as assessed by the investigator per RECIST v1.1.
- TTR—the time from randomization to the first occurrence of a documented objective response as assessed by the investigator per RECIST v1.1.
- Status of exploratory biomarkers including but not limited to: PD-L1, tumor mutation burden (TMB), and immune-related gene expression profiling (GEP) in archival and/or freshly obtained tumor tissues and blood (or blood derivatives) obtained before, during, or after treatment with tislelizumab or at progression, and the association with disease status and/or response to tislelizumab in combination with chemotherapy.
- Summary of serum concentrations of tislelizumab.
- Assessments of immunogenicity of tislelizumab by determining the incidence of antidrug antibodies (ADAs).

## 3 STUDY DESIGN

### 3.1 Summary of Study Design

This is an open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with carboplatin and either paclitaxel (Arm A) or *nab*-paclitaxel (Arm B) versus paclitaxel plus carboplatin alone (Arm C) as first-line treatment in approximately 342 patients with untreated Stage IIIB or IV squamous NSCLC.

The primary endpoint of the study is measured by PFS as assessed by the IRC in the ITT Population.

Patients who have histologically confirmed and are untreated for their locally advanced (Stage IIIB) or metastatic (Stage IV) squamous NSCLC are eligible. Patients with tumors of mixed non-small cell histology (squamous and nonsquamous) are eligible if the major histological component is confirmed to be squamous. Histology of squamous NSCLC will be confirmed at the investigator's



site. Patients with NSCLC tumors that have known *EGFR*-sensitizing mutation or *ALK* gene translocation are excluded but testing is not required if not known. Patients must be able to provide fresh or archival tumor tissues (formalin-fixed paraffin-embedded [FFPE] blocks or approximately 15 [ $\geq$  6] freshly cut unstained FFPE slides) with an associated pathological report.


Archival tumor specimens will be prospectively tested for PD-L1 expression by a central laboratory, and only patients who have evaluable PD-L1 results are eligible. If archived FFPE tissue is not sufficient for PD-L1 analysis, a fresh biopsy sample will be needed. PD-L1 status will be characterized as PD-L1 membrane staining on TC via the Ventana SP263 assay.

Eligible patients will be stratified by disease stage (IIIB versus IV), and PD-L1 expression (3 levels: < 1% TC versus 1% to 49% TC versus  $\geq$  50% TC) and randomized by a 1:1:1 ratio to receive one of the following treatment regimens:

- Arm A: Tislelizumab + paclitaxel + carboplatin
- Arm B: Tislelizumab + *nab*-paclitaxel + carboplatin
- Arm C: Paclitaxel + carboplatin

The study design schematic is presented in [Figure 1](#).

**Figure 1. Study Schema**



[Redacted text block]

Section 7 Appendix 1

### 3.2 Screening Period

Screening evaluations will be performed within 28 days prior to randomization. Patients who agree to participate in this study will sign the informed consent form (ICF) prior to undergoing any screening procedure. Screening evaluations may be repeated as needed within the screening period; the investigator is to assess preliminary patient eligibility according to the latest screening assessment results.

Archival tumor tissue must be collected for the purpose of biomarker analysis. If no archival samples are available, a fresh tumor biopsy at baseline is required ([Section 7.8](#)).

### 3.3 Treatment Period

After completing all screening activities, patients confirmed to be eligible by the sponsor will be randomized. Administration of 4 to 6 cycles will be at the investigator's discretion. Chemotherapy will be administered on a 3-week cycle until one of the following occurs (whichever occurs first): 1) completed administration of 4 to 6 cycles; 2) unacceptable toxicity; or 3) documented disease progression per RECIST v1.1.

For all patients in Arms A, B, C, if progression of disease is unconfirmed and the patient is clinically stable, it is at the discretion of the investigator to continue treating the patient with the assigned treatment per protocol until progression of disease is confirmed at least 28 days (or at the next scheduled tumor assessment) from the date of the scan suggesting progression of disease. If a patient has confirmed progression of disease by RECIST v1.1, the patient should not receive further chemotherapy treatment on study, and should follow the following guidance:

#### **For Arm A and Arm B (Experimental arms):**

Patients whose tumors show progressive disease per RECIST v1.1 during chemotherapy combination phase or thereafter while receiving tislelizumab monotherapy will be permitted to continue tislelizumab monotherapy provided they meet all the following additional criteria:

1. Evidence of clinical benefit as assessed by the investigator
2. Absence of symptoms and signs (including clinically significant worsening of laboratory values [eg, new, or worsening hypercalcemia]) indicating unequivocal progression of disease
3. No decline in ECOG PS that can be attributed to disease progression
4. Absence of tumor progression at critical anatomical sites (eg, CNS disease) that cannot be managed by protocol-allowed medical interventions
5. Patients must provide written consent to acknowledge deferring other treatment options in favor of continuing study treatment at the time of initial progression

#### **For Arm C (Control arm):**

Patients who develop radiographic disease progression per RECIST v1.1 at an initial or, if continued treatment, at the time of repeat CT scan, will be given the option to cross over to receive tislelizumab monotherapy ([Section 7.4](#)), provided disease progression has been confirmed by the IRC and as long as the following criteria are met:

1. ECOG PS  $\leq$  1
2. Absence of rapid progression of disease or of progressive tumor at critical anatomical sites (eg, CNS disease) that cannot be managed by protocol-allowed medical interventions
3. Patient provided written consent to acknowledge that tislelizumab is an experimental treatment used after failure of prior first-line platinum-containing regimen

**For All Arms:**

Once patients are receiving tislelizumab monotherapy, the investigator may consider continuing tislelizumab monotherapy beyond investigator-assessed progression, provided that patients meet the above outlined criteria, and upon discussion with the medical monitor.

The decision to continue tislelizumab beyond investigator-assessed progression must be documented in the study records.

Patients may continue tislelizumab until loss of clinical benefit as assessed by the investigator, withdrawal of consent, study termination by the sponsor, start a new anticancer therapy, or death, whichever occurs first.

All patients will undergo tumor assessments at baseline and every 6 weeks for the first 52 weeks following Cycle 1, Day 1, regardless of dose delays to manage toxicities. After completion of the Week 52 tumor assessment, tumor assessment will continue every 12 weeks. Patients will undergo tumor assessments until radiographic disease progression per RECIST v1.1, loss of clinical benefit (for tislelizumab-only patients who continue treatment after radiographic disease progression according to RECIST v1.1), withdrawal of consent, study termination by sponsor, start a new anticancer therapy, or death, whichever occurs first.

To determine the PK properties of tislelizumab and host immunogenic response to tislelizumab, blood samples will be collected at various timepoints as outlined in [Appendix 1](#).

Safety will be assessed throughout the study by monitoring AEs/serious adverse events (SAEs) (toxicity grades assigned per NCI-CTCAE v4.03), and laboratory results. Vital signs, physical examinations, ECOG PS change, electrocardiogram (ECG) results, and other examinations will also be used for safety assessment. Safety assessments are further detailed in [Section 7.5](#) and the Schedule of Assessments ([Appendix 1](#)).

### **3.4 Safety Follow-up**

Patients who discontinue treatment for any reason will be asked to return to the clinic for the Safety Follow-up Visit (to occur within 30 days [ $\pm$  7 days] after the last dose of study drug (including chemotherapy-only) or before the initiation of a new anticancer treatment, whichever occurs first. In addition, telephone contacts with patients should be conducted to assess AEs and concomitant medications (if appropriate, ie, associated with an AE or is a new anticancer therapy) at 60 days, and 90 days ( $\pm$  14 days) after the last dose of study drug (including chemotherapy-only), regardless of whether the patient starts a new anticancer therapy.

All adverse events, including SAEs, will be collected as described in [Section 8.7](#).

The End of Treatment (EOT) Visit at which a response assessment showed progressive disease, resulting in patient discontinuation, may be used as the Safety Follow-up Visit, if it occurred 30 days ( $\pm$  7 days) after the last study treatment. Patients who discontinue study treatment prior to disease progression will continue tumor assessments as outlined in [Section 7.6](#).

See [Appendix 1](#) for assessments to be performed at the Safety Follow-up Visit.

### **3.5 Survival Follow-up**

Patients who discontinue study drug for reasons other than disease progression (eg, toxicity) or death will continue to undergo tumor assessments according to [Section 7.6](#) and the Schedule of Assessments ([Appendix 1](#)), until the patient experiences disease progression, withdraws consent, is lost to follow-up, death, study termination, or starts a new anticancer therapy, whichever occurs first.

After patients are discontinued from study treatment, they are followed via telephone calls, patient medical records, and/or clinic visits for updates on survival and further anticancer therapy. Clinic visits occur approximately every 3 months ( $\pm$  14 days) after the Safety Follow-up Visit or as directed by the sponsor until death, loss to follow-up, withdrawal of consent, or study termination by the sponsor.

### **3.6 Patient, Treatment, Study, and Site Discontinuation**

Patients who discontinue study treatment early should be followed for assessments of antitumor activity ([Section 7.6](#)), safety ([Section 7.5](#)) and survival ([Section 3.5](#)), if possible.

#### **3.6.1 Discontinuation from Study Treatment**

Patients have the right to voluntarily withdraw from the study or discontinue study treatment at any time for any reason. In addition, the investigator has the right to discontinue a patient from the study treatment at any time. Patients who discontinue study treatment early should be followed for assessments of antitumor activity, safety, and survival, if possible.

Every effort should be made to obtain information on patients who discontinue the study treatment. The primary reason for discontinuation from the study treatment should be documented on the appropriate electronic case report form (eCRF).

Patients may discontinue from the study for reasons that include, but are not limited to, the following:

- Patient withdrawal of consent
- Any medical condition that the investigator determines may jeopardize the patient's safety, if he or she were to continue the study treatment
- Patient noncompliance

Patients must discontinue study treatment for reasons which may include, but are not limited to, the following:

- Symptomatic deterioration (eg, uncontrollable pain secondary to disease or unmanageable ascites, etc) attributed to disease progression as assessed by the investigator after integrated assessment of radiographic data, biopsy results, and clinical status.
- Intolerable toxicity related to both tislelizumab and chemotherapy, including development of an immune-mediated or chemotherapy-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event.
- Use of another nonprotocol anticancer therapy ([Section 6.2.2](#)).
- Pregnancy.

### 3.6.2 End of Study

The study termination is defined as the timepoint when data collection for the patient will stop. The primary analyses will be conducted when the predefined PFS events have been observed ([Section 9.2](#) and [Section 9.3](#)) for the efficacy and safety evaluation. The study will continue until the last patient has disease progression, is lost to follow up, or withdraws from study, or until sponsor decides to terminate the study, whichever occurs first. Patients who, in the opinion of the investigator, continue to benefit from tislelizumab at study termination, may continue treatment after discussion and agreement by the sponsor.

The sponsor has the right to terminate this study at any time. Reasons for terminating the study early may include but are not limited to the following:

- The incidence or severity of adverse events in this or other studies indicates a potential health hazard to patients
- Overall patient enrollment is unsatisfactory

The sponsor will notify each investigator if a decision is made to terminate the study. Should this be necessary, prematurely discontinued patients should be seen as soon as possible for an EOT Visit and Safety Follow-up Visit.

The investigators may be informed of additional procedures to be followed to ensure that adequate consideration is given to the protection of the patient's interests. The investigator will be responsible for informing Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) of the early termination of the study.

The sponsor has the right to close a site at any time. The decision will be notified to the site in advance. Reasons for closing a site may include but are not limited to the following:

- Excessively slow recruitment
- Poor protocol adherence
- Inaccurate or incomplete data recording
- Good Clinical Practice (GCP) noncompliance

- Study activity is completed (ie, all patients have completed and all obligations have been fulfilled)

## 4 STUDY POPULATION

The specific eligibility criteria for selection of patients are provided in [Section 4.1](#) and [Section 4.2](#). The sponsor will not grant any eligibility waivers.

### 4.1 Inclusion Criteria

Each patient eligible to participate in this study must meet all the following criteria:

1. Able to provide written informed consent by the patient or by the patient's legally acceptable representative and can understand and agree to comply with the requirements of the study
2. 18 to 75 years old on the day of signing the ICF
3. Histologically confirmed, locally advanced (Stage IIIB) not amenable to curative surgery or radiotherapy, or metastatic (Stage IV) squamous NSCLC
  - a. Patients with tumors of mixed non-small cell histology (squamous and nonsquamous) are eligible if the major histological component appears to be squamous.
4. Patients must be able to provide fresh or archival tumor tissues (FFPE blocks or approximately 15 [ $\geq 6$ ] freshly cut unstained FFPE slides) with an associated pathological report (squamous). In the absence of sufficient archival tumor tissues, a fresh biopsy of a tumor lesion at baseline is mandatory. PD-L1 expression will be assessed centrally, and patients who have evaluable PD-L1 results are eligible.
5. ECOG PS  $\leq 1$
6. Patients must have  $\geq 1$  measurable lesion as defined per RECIST v1.1.
7. Must be treatment-naive for locally advanced or metastatic squamous NSCLC.
  - a. Patients who have received prior neoadjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for nonmetastatic disease must have experienced a disease-free interval of  $\geq 6$  months from the last dose of chemotherapy and/or radiotherapy prior to randomization.
8. Life expectancy  $\geq 12$  weeks
9. Patients must have adequate organ function as indicated by the following laboratory values (obtained within 7 days prior to randomization):
  - a. Absolute neutrophil count (ANC)  $\geq 1.5 \times 10^9/L$ , platelets  $\geq 100 \times 10^9/L$ , hemoglobin  $\geq 90$  g/L. Note: Patients must not have required a blood transfusion or growth factor support  $\leq 14$  days before sample collection
  - b. International normalized ratio (INR) or prothrombin time (PT)  $\leq 1.5 \times$  upper limit of normal [ULN]
  - c. Activated partial thromboplastin time (aPTT)  $\leq 1.5 \times$  ULN
  - d. Serum total bilirubin  $\leq 1.5 \times$  ULN (total bilirubin must be  $< 3 \times$  ULN for patients with Gilbert's syndrome).

- e. Aspartate and alanine aminotransferase (AST and ALT)  $\leq 2.5 \times$  ULN or AST and ALT  $\leq 5 \times$  ULN for patients with liver metastases
- 10. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and 120 days after the last dose of tislelizumab, and have a negative urine or serum pregnancy test  $\leq 7$  days of randomization.
- 11. Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study and for 120 days after the last dose of tislelizumab.

#### 4.2 Exclusion Criteria

Patients who meet any of the following criteria must be excluded from this study:

1. Diagnosed with NSCLC that harbors an *EGFR*-sensitizing mutation or *ALK* gene translocation
2. Received any approved systemic anticancer therapy, including hormonal therapy within 28 days prior to initiation of study treatment
3. Received prior treatment with *EGFR* inhibitors or *ALK* inhibitors
4. Received prior therapies targeting PD-1 or PD-L1
5. Treatment with systemic immune-stimulatory agents (including but not limited to interferons, interleukin-2, and tumor necrosis factor) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to randomization (prior treatment with cancer vaccines is allowed)
6. Has received any Chinese herbal medicine or Chinese patent medicines used to control cancer within 14 days of randomization
7. With history of interstitial lung disease, noninfectious pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung diseases, etc.
8. Clinically significant pericardial effusion
9. Clinically uncontrolled pleural effusion or ascites that requires pleurocentesis or abdominal tapping for drainage within 2 weeks prior to randomization
10. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection, etc.
11. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
  - a. Patients with a history of treated and, at the time of screening, asymptomatic CNS metastases are eligible, provided they meet all the following:
    - i. Brain imaging at screening shows no evidence of interim progression
    - ii. Have measurable disease outside the CNS, only supratentorial metastases allowed
    - iii. No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose allowed
    - iv. No stereotactic radiation or whole-brain radiation within 14 days prior to randomization
  - b. Patients with new asymptomatic CNS metastases detected at the screening scan must receive radiation therapy and/or surgery for CNS metastases.
    - i. Following treatment, these patients may then be eligible, provided all other criteria, including those for patients with a history of brain metastases, are met.
12. Any major surgical procedure  $\leq 28$  days before randomization



13. Unresolved acute effects of prior therapy (eg adjuvant chemotherapy) greater than CTCAE Grade 1 at the time of randomization, except for alopecia, that are not likely to constitute safety risk
14. Any active malignancy, except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)  $\leq$  2 years before randomization
15. Known Human Immunodeficiency Virus infection
16. Patients with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is  $>$  500 IU/mL or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA  $<$  500 IU/mL), and cured hepatitis C patients can be enrolled.

	Eligible	
HBV	HBsAg (-)	
	HBsAg (+)	HBV DNA $<$ 500 IU/mL
HCV	HCV Ab (-) OR HCV Ab (+)	HCV RNA (-)

17. Active autoimmune diseases or history of autoimmune diseases that may relapse  
 Note: Patients with the following diseases are not excluded and may proceed to further screening:
  - a. Controlled Type I diabetes
  - b. Hypothyroidism (provided it is managed with hormone replacement therapy only)
  - c. Controlled celiac disease
  - d. Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)
  - e. Any other disease that is not expected to recur in the absence of external triggering factors
18. Any condition that required systemic treatment with either corticosteroids ( $>$  10 mg daily of prednisone or equivalent) or other immunosuppressive medication  $\leq$  14 days before randomization  
 Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:
  - a. Adrenal replacement steroid (dose  $\leq$  10 mg daily of prednisone or equivalent)
  - b. Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption
  - c. Short course ( $\leq$  7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a nonautoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen)
19. Any of the following cardiovascular criteria:
  - a. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily

- living,  $\leq 28$  days before randomization
- b. Symptomatic pulmonary embolism  $\leq 28$  days before randomization
  - c. Any history of acute myocardial infarction  $\leq 6$  months before randomization
  - d. Any history of heart failure meeting New York Heart Association Classification III or IV (Appendix 5)  $\leq 6$  months before randomization
  - e. Any event of ventricular arrhythmia  $\geq$  Grade 2 in severity  $\leq 6$  months before randomization
  - f. Any history of cerebrovascular accident  $\leq 6$  months before randomization
20. Prior allogeneic stem cell transplantation or organ transplantation
21. Was administered live vaccine  $\leq 4$  weeks before randomization
- Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines, and are not allowed.
22. Underlying medical conditions or alcohol or drug abuse or dependence that, in the investigator's opinion, will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or adverse events or result in insufficient compliance during the study according to the investigator's judgment
23. History of allergic reactions to carboplatin, other platinum-containing compounds, or paclitaxel
24. Grade  $\geq 2$  peripheral neuropathy, as defined by NCI-CTCAE v4.03 criteria
25. Creatinine clearance  $< 45$  mL/min
26. Concurrent participation in another therapeutic clinical study

## 5 STUDY TREATMENT

### 5.1 Formulation, Packaging, and Handling

#### 5.1.1 Tislelizumab

Tislelizumab is a monoclonal antibody formulated for IV injection in a single-use vial (20R glass, United States Pharmacopeia [USP] type I), containing a total of 100 mg of antibody in 10 mL of isotonic solution. Tislelizumab has been aseptically filled in single-use vials with a Flurotec-coated butyl rubber stopper and an aluminum cap. Each vial is packaged into a single carton box.

The label will include at a minimum: the drug name, dose strength, contents, sponsor, protocol number, kit number, batch number, directions for use, storage conditions, caution statements, retest or expiry date, and space to enter the patient number and name of the investigator. The contents of the label will be in accordance with all applicable local regulatory requirements.

The study drug must be kept at the temperature condition as specified on the label. Tislelizumab must be stored at temperatures between 2°C and 8°C and protected from light.

Refer to the Pharmacy Manual for details regarding IV administration, accountability, and disposal.

Investigator's Brochure

### **5.1.2 Chemotherapy Agents**

Management (ie, handling, storage, administration, and disposal) of these products will be in accordance with the relevant local guidelines and/or prescribing information.

For further details, see the manufacturer's prescribing information for the respective chemotherapy agents.

### **5.2 Dosage, Administration, and Compliance**

Dosing schedules for all study arms, broken out by individual arm, are provided in [Table 3](#). The first dose of study drug is to be administered within 2 business days of randomization. All patients will be monitored continuously for AEs. Treatment modifications (eg, dose delay, reduction, interruption or discontinuation) will be based on specific laboratory and adverse event criteria, as described in [Section 5.5](#).

For each cycle, tislelizumab will be administered before chemotherapy drugs. The order of chemotherapy drug administration will be conducted in accordance with the relevant local guidance and/or clinical practice.

Patients should receive antiemetics and IV hydration for carboplatin-based doublet treatments according to the local standard of care and manufacturer's instruction. Due to their immunomodulatory effects, premedication with steroids should be limited when clinically feasible. In addition, in the event of chemotherapeutic agent-related skin rash, topical steroid use is recommended as front-line treatment whenever it is clinically feasible.

In special situations (eg, when the administration is delayed due to management of adverse events or in the case of an infusion-related reaction), administration of the subsequent study drugs might be delayed to the second day of each cycle.

**Table 3. Selection and Timing of Dose for Each Patient**

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

The number of treatment cycles (4 to 6) will be at the discretion of the investigator.

### 5.2.1 Tislelizumab

Tislelizumab 200 mg will be administered on Day 1 of each 21-day cycle (Q3W).

Tislelizumab will be administered by IV infusion through an IV line containing a sterile, nonpyrogenic, low-protein-binding 0.2 or 0.22 micron in-line or add-on filter. Specific instructions for product preparation and administration are provided in the Pharmacy Manual.

As a routine precaution, after infusion of tislelizumab on Day 1 of Cycle 1 and Cycle 2, patients must be monitored for  $\geq 1$  hour afterward in an area with resuscitation equipment and emergency agents. From Cycle 3 onward, at least a 30-minute monitoring period is required in an area with resuscitation equipment and emergency agents.

The initial infusion (Cycle 1, Day 1) will be delivered over 60 minutes; if this is well tolerated, then the subsequent infusions may be administered over 30 minutes, which is the shortest period permissible for infusion. Tislelizumab must not be concurrently administered with any other drug (Section 6).

Guidelines for dose modification, treatment interruption, or discontinuation and for the management of irAE and infusion-related reactions are provided in detail in Section 8.8 and Appendix 6.

If a dose is delayed for tislelizumab for  $\leq 10$  days for a planned dosing cycle (eg, Cycle 3 Day 1), tislelizumab should be administered and all assessments should be conducted according to the original cycle (ie, Cycle 3); if the delay is  $> 10$  days, the patient should skip the tislelizumab dose, and tislelizumab will be administered on Day 1 of the next planned cycle (ie, Cycle 4 Day 1).

Refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, and administration.

### 5.2.2 Chemotherapy

Carboplatin will be administered after completion of paclitaxel or *nab*-paclitaxel.



Patients will be monitored continuously for AEs and will be instructed to notify their physician immediately for any and all AEs. Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of chemotherapy therapy. Guidelines for dosage modification and treatment interruption or discontinuation are provided in [Section 5.5](#).

### **5.3 Overdose**

Any overdose (defined as  $\geq 600$  mg of tislelizumab in a 24-hour period) or incorrect administration of study drug should be noted in the patient's chart and on the appropriate eCRF. AEs associated with an overdose or incorrect administration of study drug will be recorded on the eCRF. If an overdose or incorrect administration of study treatment takes place and adversely affects patients, the sponsor or designee is required to be notified within 24 hours of awareness via the SAE reporting process as described in [Section 8.7](#). Supportive care measures should be administered as appropriate.

### **5.4 Investigational Medicinal Product Accountability**

The investigational medicinal products (IMPs) required for completion of this study (tislelizumab, paclitaxel, *nab*-paclitaxel, and carboplatin) will be provided by the sponsor. The investigational site will acknowledge receipt of IMPs. Any damaged shipments will be replaced.

Accurate records of all IMP received, dispensed, returned, and disposed should be recorded on the site's Drug Inventory Log. Refer to the Pharmacy Manual for details of IMP management.

### **5.5 Dose Delay and Modification**

Every effort should be made to administer the study drug(s) according to the planned dose and schedule. In the event of significant toxicities, dosing may be delayed and/or reduced based on the guidelines provided below.

#### **5.5.1 General Guidance Regarding Dose Modifications**

The severity of adverse events will be graded according to the NCI-CTCAE v4.03 grading system.

- Dose modifications for chemotherapy should be performed per prescribing information and per local practice according to the treating physician's clinical judgment.
- Baseline body weight is used to calculate the required chemotherapy doses. Dose modifications are required if the patient's body weight changes by > 10% from baseline (or the new reference body weight). Chemotherapy doses should not be modified for any body weight change of less than 10%.
- For any adverse events already apparent at baseline, the dose modifications will apply according to the corresponding shift in toxicity grade, if the investigator feels it is appropriate. For example, if a patient has Grade 1 asthenia at baseline that increases to Grade 2 during treatment, this will be considered a shift of 1 grade and treated as Grade 1 toxicity for dose-modification purposes.
- When several toxicities with different grades of severity occur at the same time, the dose modifications should be according to the highest grade observed.
- If, in the opinion of the investigator, a toxicity is considered to be due solely to 1 component of the study treatment (ie, tislelizumab, carboplatin, paclitaxel, or *nab*-paclitaxel) and the dose of that component is delayed or modified in accordance with the guidelines below, other components may be administered if there is no contraindication.
- The tislelizumab infusions should remain synchronized with the chemotherapy ([Section 5.2.1](#)), except when tislelizumab is delayed for > 10 days. If that is the case, the patient should skip the tislelizumab dose, and tislelizumab will be administered on Day 1 of the next planned cycle.
- The tumor assessment schedule will not be altered if chemotherapy or tislelizumab is delayed.
- Every effort should be made to continue treatments in combination when the patient's condition allows, also taking into consideration the patient's preferences for the treatment schedule.
- Following either completion of or discontinuation from chemotherapy, tislelizumab should be continued as scheduled, if clinically appropriate ([Section 3.3](#)).
- Reasons for dose modifications or delays, the supportive measures taken, and the outcomes will be documented in the patient's chart and recorded on the eCRF. The severity of adverse events will be graded according to the NCI-CTCAE v4.03 grading system.

Dose modification guidelines for chemotherapy, described below ([Section 5.5.3](#)), depend on the severity of toxicity and an assessment of the risk versus benefit for the patient, with the goal of maximizing the patient's compliance and access to supportive care.

### 5.5.2 Dose Interruption for Tislelizumab

There will be no dose reduction for tislelizumab in this study.

Dose delays or interruptions of less than 12 weeks will be permitted. Investigators should make every effort to maintain dose intensity in patients.

The patient should resume tislelizumab treatment as soon as possible after the AEs recover to baseline or Grade 1 (whichever is more severe) within 12 weeks after last dose of tislelizumab. If the patient is unable to resume tislelizumab within 12 weeks after the last dose of tislelizumab, then the patient should be discontinued from treatment.

If a patient is benefiting from the study treatment while meeting the discontinuation criteria, resumption of study treatment may occur upon discussion and agreement with medical monitor.

Dose modification related to irAEs and infusion-related reactions are described in [Appendix 6](#) and [Section 8.8.1](#), respectively.

### 5.5.3 Dose Modifications of Chemotherapy Treatment

Study-drug-related toxicities must be resolved to baseline or Grade 0-1 prior to administering the next dose, except for alopecia or Grade 2 fatigue. A maximum of 2 dose reductions for each chemotherapeutic agent except for carboplatin are permitted. Only 1 dose reduction is permitted for carboplatin. Once the dose has been decreased, it should remain reduced for all subsequent administrations or further reduced if necessary. There will be no dose escalations in this study. If additional reductions are required, that chemotherapeutic agent must be discontinued. Chemotherapy treatment may be delayed up to 21 days, if the reason for the delay is toxicity/adverse event. All subsequent chemotherapy doses must be rescheduled according to the last chemotherapy dose administration date.

#### SELECTED PRECAUTIONS:

- Neutropenia: Fever or other evidence of infection must be assessed promptly and treated aggressively following the local clinical practice and/or the guidelines.
- Renal toxicity: carboplatin should not be administered to patients whose creatinine clearance is < 45 mL/min.
- Ototoxicity and sensory neural damage should be assessed prior to each cycle.
- For toxicities not listed above, dose modifications are permitted per local standards.

Guidance regarding dose modifications for certain toxicities is presented in detail in [Appendix 9](#).

Dosing interruptions are permitted in the case of medical/surgical events or logistical reasons not related to study therapy (eg, elective surgery, unrelated medical events, patient vacation, and/or holidays). Patients should be placed back on study therapy within 3 weeks of the scheduled interruption, unless otherwise discussed with the sponsor. The reason for interruption should be documented in the patient's study record.

### 5.6 Criteria for Discontinuing Chemotherapy Regimens

Except where specified above, both chemotherapy drugs in the carboplatin-based doublet regimen should be discontinued for any of the following:

- Any Grade 4 peripheral neuropathy.
- Persistent Grade 3 paraesthesia.
- Grade 3 or 4 drug-related thrombocytopenia associated with clinically significant bleeding

- Any drug-related liver function test abnormality value that meets any of the following criteria requires discontinuation:
  - AST or ALT > 5 to 10 x ULN for > 2 weeks
  - AST or ALT > 10 x ULN or
  - Total bilirubin > 5 x ULN or
  - Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN
- Any drug-related AE that recurs after 2 prior dose reductions (or 1 prior reduction for carboplatin) for the same drug-related AE requires discontinuation of the drug(s).
- Any Grade 3 or 4 drug-related hypersensitivity reaction or infusion reaction requires discontinuation of the drug(s) felt to be causing the reaction. The drug not felt to be related to the hypersensitivity reaction or infusion reaction may be continued.
- Any Grade 4 AE that the investigator considers related to study drug and inappropriate to be managed by dose reduction(s) requires discontinuation of drug(s). The drug not felt to be related to the event may be continued.
- If any toxicity does not resolve within 21 days, that component will be discontinued unless it is determined by the treating investigator that the patient might benefit from continuation of the component.

For toxicities not listed above, the investigator's medical judgment would determine whether chemotherapy regimen should be discontinued, in accordance with patient's well-being and local standards.

Refer to [Section 3.4](#) regarding safety follow-up procedures.

## 6 PRIOR AND CONCOMITANT THERAPY

### 6.1 Prior Therapy

The exclusion criteria ([Section 4.2](#)) specify that patients will not have received prior systemic therapy with *EGFR* inhibitors or *ALK* inhibitors or therapies targeting PD-1 or PD-L1.

### 6.2 Concomitant Therapy

#### 6.2.1 Permitted Concomitant Medications

Most concomitant medications and therapies deemed necessary and in keeping with local standards of medical care at the discretion of the investigator for the supportive care (eg, antiemetics, antidiarrheals) and in a patient's interest are allowed. Patients should receive full supportive care, including epoetin and other hematopoietic growth factors, transfusions of blood and blood products, antibiotics, antiemetics, and/or other applicable medications, as needed.

All prior and concomitant medications received within 30 days before randomization and 30 days after the last infusion or dose of study treatment should be recorded.



Systemic corticosteroids given for the control of irAEs must be tapered gradually ([Appendix 6](#)) and be at nonimmunosuppressive doses ( $\leq 10$  mg/day of prednisone or equivalent) before the next tislelizumab administration. The short-term use of steroids as prophylactic treatments (eg, patients with contrast allergies to diagnostic imaging contrast dyes) is permitted.

Bisphosphonates and RANK-L inhibitors are allowed for bone metastases if initiated prior to enrollment and at a stable dose. Bisphosphonates are permitted during the study for a nonmalignant indication.

Whole-brain radiation therapy and stereotactic radiosurgery are permitted for patients with disease progression limited to the CNS. Palliative (limited-field) radiation therapy is permitted, but only for pain control or prophylaxis of bone fracture to sites of bone disease present at baseline provided the following criteria are met:

- Repeat imaging demonstrates no new sites of bone metastases
- The lesion being considered for palliative radiation is not a target lesion for RECIST v1.1
- The case is discussed with the medical monitor, and the medical monitor agrees that the conditions required to receive palliative radiation are met

Palliative radiation or other focally ablative therapy for other non-target sites of the disease is permitted if clinically indicated per investigators' discretion and after consultation with the medical monitor.

### **6.2.2 Prohibited or Restricted Concomitant Medications**

The following medications are prohibited or restricted during the study:

- Immunosuppressive agents (except to treat a drug-related AE).
- Systemic corticosteroids  $> 10$  mg daily (prednisone or equivalent), except to treat or control a drug-related AE (per protocol) or for short-term use as prophylactic treatment.
- Any concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, or standard or investigational agents [including Chinese herbal medicine and Chinese patent medicines] for the treatment of cancer) is not allowed.
- Radiation therapy is not allowed, except for palliative radiation therapy described in [Section 6.2.1](#).
- Live vaccines within 28 days before randomization and 60 days following the last dose of study drug(s).
- Herbal remedies with immune-stimulating properties (ie, mistletoe extract) or that are known to potentially interfere with liver or other major organ functions (ie, hypericin). Patients must notify the investigator of all herbal remedies used during the study.

### 6.3 Potential Interactions Between the Study Drugs and Concomitant Medications

The potential for drug-drug interaction between the study drugs (tislelizumab) and small-molecule drug products is very low, given that tislelizumab is a therapeutic monoclonal antibody. Because tislelizumab is expected to be degraded into amino acids and recycled into other proteins, it is unlikely to influence drug metabolizing enzymes or transporters.

The metabolism of paclitaxel is catalyzed by cytochrome P-450(CYP)2C8 and CYP3A4. Caution should be exercised when administering paclitaxel or *nab*-paclitaxel concomitantly with medicines known to inhibit or induce either CYP2C8 or CYP3A4. Refer to manufacturer's prescribing information for the respective chemotherapy agents for drug-drug interaction information on the influence of drug metabolizing enzymes or transporters.

The major route of elimination of carboplatin is renal excretion. The renal effects of nephrotoxic compounds may be potentiated by carboplatin.

## 7 STUDY ASSESSMENTS AND PROCEDURES

A table of scheduled study assessments is provided in [Appendix 1](#). Patients will be closely monitored for safety and tolerability throughout the study. All assessments must be performed and documented in the medical record for each patient.

Dosing will occur only if the clinical assessment and local laboratory test values (that must be available before any dosing) have been reviewed and found to be acceptable per protocol guidelines.

If the timing of a protocol-mandated study visit coincides with a holiday, weekend, or other event, the visit should be scheduled on the nearest feasible date (the visit window is provided in [Appendix 1](#)) with subsequent visits rescheduled according to the last treatment administration date.

### 7.1 Screening

Screening evaluations will be performed within 28 days prior to randomization. Patients who agree to participate will sign the ICF prior to undergoing any screening procedure. Pulmonary function testing including spirometry and diffusion capacity is to be performed for all patients at baseline ([Appendix 1](#)). Screening evaluations may be repeated as needed within the screening period; the investigator is to assess patient eligibility according to the latest screening assessment results.

Results of routine assessment performed per standard of care prior to obtaining informed consent and  $\leq 28$  days prior to randomization may be used for the purposes of screening rather than repeating the standard of care tests unless otherwise indicated, that is provided they fulfill the specifications of baseline assessments.

Procedures conducted during the Screening Visit only are described in this section. For the description of other assessments that are conducted during screening, as well as throughout the study, refer to Safety Assessments ([Section 7.5](#)), Tumor and Response Evaluations ([Section 7.6](#)), and Biomarkers ([Section 7.8](#)).

Rescreening under limited conditions may be allowed after consultation with BeiGene; eg, when a patient narrowly misses a laboratory criterion and it is correctable and not due to rapidly deteriorating condition or disease progression. Rescreening is allowed only once.

### **7.1.1 Demographic Data and Medical History**

Demographic data will include age or date of birth, gender, and self-reported race/ethnicity.

Medical history includes any history of clinically significant disease, surgery, or cancer history; reproductive status (ie, of childbearing potential or no childbearing potential); history of alcohol consumption and tobacco (ie, former or current or never); and all medications (eg, prescription drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) used by the patient within 30 days before randomization. If appropriate, clinically significant disease should be graded according to NCI-CTCAE v 4.03 and reported in the Medical History eCRF.

Cancer history will include an assessment of prior surgery, prior radiotherapy, and prior drug therapy including start and stop dates, best response, and reason for discontinuation. Radiographic studies performed prior to study entry may be collected for review by the investigator.

### **7.1.2 Females of Childbearing Potential and Contraception**

Childbearing potential is defined as being physiologically capable of becoming pregnant. Refer to [Appendix 8](#) for contraception guidelines and definitions of “women of childbearing potential” and “no childbearing potential.”

### **7.1.3 Informed Consent and Screening Log**

Voluntary, written, informed consent for participation in the study must be obtained before performing any study-specific procedures. The ICFs for enrolled patients and for patients who are screened but not enrolled will be maintained at the study site.

All screening evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria before randomization. The investigator will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.

### **7.1.4 Pulmonary Function Tests**

Pulmonary function tests including spirometry and diffusion capacity are to be performed for all patients at baseline. Patients who are suspected of having serious/severe respiratory conditions or who exhibit significant respiratory symptoms unrelated to the underlying cancer should consult a pulmonologist. Respective test results and consultation report, if applicable, will need to be submitted to the medical monitor and/or designee, and will need to be discussed with the investigator and the sponsor for eligibility.

## **7.2 Enrollment**

### **7.2.1 Confirmation of Eligibility**

The investigator will assess and the sponsor will confirm the eligibility of each patient. All screening procedure results and relevant medical history must be available before eligibility can be determined. All inclusion criteria must be met and none of the exclusion criteria may apply. No eligibility waivers will be granted.

After a patient is screened and the investigator determines the patient is eligible for randomization, study site personnel will complete an Eligibility Authorization Packet and email it to the medical monitor or designee to approve the enrollment in writing. Study site personnel should ensure that a medical monitor-approved Eligibility Authorization Packet is in the patient's file before proceeding with study procedures.

### **7.2.2 Patient Numbering**

After obtaining informed consent, study site personnel will access the Interactive Response Technology (IRT) system to assign a unique patient number to a potential study participant.

### **7.2.3 Randomization**

Site personnel will access the IRT system to assign study drugs. Study treatment must commence within 2 business days after randomization/treatment assignment.

## **7.3 Tislelizumab and Chemotherapy Dispensation**

Tislelizumab and chemotherapy treatments will be dispensed and administered as described in [Section 5.2](#).

## **7.4 Crossover**

### **7.4.1 Crossover for Patients in Chemotherapy in Arm C With Documented and IRC Confirmed Disease Progression**

Patients who are randomized into the chemotherapy arm (Arm C) will have the opportunity to cross over to receive tislelizumab if they experience radiographic disease progression on chemotherapy; that is, if disease progression per RECIST v1.1 has been confirmed by the IRC and approval by the medical monitor has been obtained. Patients who permanently discontinue chemotherapy due to an adverse event, withdrawal of consent, or for any reason other than progressive disease will not be eligible for crossover. Crossover patients should not initiate treatment with tislelizumab prior to resolution of treatment-related toxicities to  $\leq$  Grade 1 (CTCAE) or baseline, with the exception of select chemotherapy-related toxicities such as hair loss, but should be initiated within 42 days (if applicable), and upon consultation with the medical monitor.

Patients who develop radiographic disease progression per RECIST v1.1 will be allowed to cross over to start tislelizumab provided that there is confirmation of progressive disease as assessed by the IRC and the patients meet all the following criteria:

1. ECOG PS  $\leq$  1
2. Absence of rapid progression of disease or of progressive tumor at critical anatomical sites (eg, CNS disease) that cannot be managed by protocol-allowed medical interventions
3. Patient provided written consent to acknowledge that tislelizumab is an experimental treatment used after failure of prior first-line platinum-containing regimen

Crossover is optional and is at the discretion of the investigator with the sponsor's agreement.

#### **7.4.2 Crossover Assessments and Procedures**

If a patient experiences radiographic disease progression per RECIST v1.1 while on chemotherapy (Arm C) the investigator should discuss treatment options with the patient, including the option to continue chemotherapy until confirmation of progression ([Section 3.3](#)), and determine whether there is desire and the patient meets criteria to cross over to tislelizumab monotherapy. If that is the case, the crossover ICF needs to be signed, and radiographic imaging scans need to be submitted to the IRC to obtain an independent assessment and confirmation of progressive disease. Note that radiographic imaging scans must be the most recent at time of progressive disease and, if not already transmitted, at minimum at time of baseline and sum of the longest diameter nadir.

Provided that there is IRC confirmation of progressive disease and sponsor's approval, patients can cross over. Procedures and assessments obtained at the time of assessing progressive disease may be used as appropriate for the start of the crossover phase of the study.

The tumor image used to determine progressive disease can be used as the new baseline image for the crossover phase if:

1. it occurred within 28 days prior to receiving the first dose of tislelizumab monotherapy, and
2. no study treatment was administered between the image and the first dose of tislelizumab monotherapy,

Otherwise a new baseline image must be performed prior to tislelizumab monotherapy treatment.

Patients who permanently discontinue the crossover phase will follow the same Safety Follow-up and Survival Follow-up periods.

### **7.5 Safety Assessments**

#### **7.5.1 Vital Signs**

Vital signs will include measurements of body temperature ( $^{\circ}$ C), pulse rate, and blood pressure (systolic and diastolic) while the patient is in a seated position after resting for 10 minutes.

Height (baseline only) and weight should be measured and recorded in the eCRF.

For the first 2 infusions of tislelizumab, the patient's vital signs should be determined within 60 minutes before the infusion and during and 30 minutes after the infusion. For subsequent infusions, vital signs will be collected within 60 minutes before infusion and, if clinically indicated, during and 30 minutes after the infusion. Patients will be informed about the possibility of delayed postinfusion symptoms and instructed to contact their study physician if they develop such

symptoms. Refer to [Section 5.2.1](#) regarding precautionary monitoring of patients post infusion of tislelizumab.

### 7.5.2 Physical Examinations

During the Screening Visit, a complete physical examination will be conducted including evaluation of 1) head, eyes, ears, nose, throat; 2) cardiovascular; 3) dermatological; 4) musculoskeletal; 5) respiratory, 6) gastrointestinal; and 7) neurological. Any abnormality identified during screening will be graded according to NCI-CTCAE v 4.03 and recorded on the Medical History eCRF with appropriate disease/condition terms.

In addition, investigators should solicit patients regarding changes in vision, visual disturbance, or ocular inflammation at each scheduled study visit during study treatment. For any change in vision, referral to an appropriate specialist will be made for further management guidance ([Appendix 6](#))

At subsequent visits (and as clinically indicated), limited, symptom-directed physical examinations will be performed. Changes from baseline will be recorded. New or worsened clinically significant abnormalities are to be recorded as AEs on the eCRF. Refer to [Section 8.4](#) regarding AE definitions and reporting and follow-up requirements.

### 7.5.3 Eastern Cooperative Oncology Group Performance Status

ECOG PS ([Appendix 2](#)) will be assessed during the study.

### 7.5.4 Laboratory Safety Tests

Local and/or central laboratory assessments of serum chemistry, hematology, coagulation, and urinalysis will be conducted. The same laboratory should be used throughout the study for each patient, except in emergency situations. Certain elements will be collected as specified below:

If laboratory tests at screening are not performed within 7 days prior to the administration of study drug(s) on Cycle 1, Day 1, these tests should be repeated and reviewed before study drug(s) administration. Hematology and serum chemistry (including liver function tests) as specified below should be performed weekly for the duration of chemotherapy treatment, and at the beginning of subsequent cycles upon completion of 4 to 6 cycles of chemotherapy or discontinuation of chemotherapy. After Cycle 1, results are to be reviewed within 48 hours before study drug administration.

Local laboratory assessments will include the following:

- Hematology (complete blood count [CBC], including red blood cell [RBC] count, hemoglobin, hematocrit, white blood cell [WBC] count with differential [neutrophils], and platelet count)
- Serum chemistry (glucose, blood urea nitrogen [BUN] or urea, creatinine, sodium, potassium, magnesium, chloride, calcium, phosphorus, direct bilirubin, total bilirubin, ALT, AST, alkaline phosphatase, lactate dehydrogenase (LDH), total protein, albumin)

- Coagulation test (international normalized ratio, prothrombin time, and activated partial thromboplastin time)
- Urine or serum pregnancy test (for women of childbearing potential, including premenopausal women who have had a tubal ligation) and within 7 days prior to randomization
- Urinalysis (complete [including, but not limited to specific gravity, pH, glucose, protein, ketones] and/or microscopic at screening and if clinically indicated)
- Thyroid function testing (thyroid stimulating hormone [TSH], free T3, free T4). Thyroid function tests will be performed at screening and every 3 cycles (ie, Day 1 of Cycles 4, 7, 10, etc), and at the Safety Follow-up Visit.

Details about sample collection and shipment will be provided in a separate instruction manual. Investigators should use results from the same local laboratories for assessing eligibility, safety monitoring, and dosing decision for each patient.

#### **7.5.5 Electrocardiograms**

For safety monitoring purposes, the investigator must review, sign, and date all ECG tracings. Paper or electronic copies of ECG tracings will be kept as part of the patient's permanent study file at the site.

When coinciding with blood draws, ECG assessment should be performed prior to blood draws. Patients should rest in semirecumbent supine position for  $\geq 10$  minutes prior to ECG measurement.

#### **7.5.6 Adverse Events**

Adverse events will be graded and recorded throughout the study according to NCI-CTCAE, Version 4.03 ([NCI-CTCAE 2010](#)). Characterization of toxicities will include severity, duration, and time to onset.

All adverse events, including SAEs, will be collected as described in [Section 8.7](#).

#### **7.5.7 Hepatitis B and C Testing**

Testing will be performed by a central laboratory and/or the local laboratory at screening and will include HBV/HCV serology (HBsAg, HBsAb, hepatitis B core antibody [HBcAb], and HCV antibody) and viral load assessment (HBV DNA and HCV RNA).

### **7.6 Tumor and Response Evaluations**

Tumor imaging will be performed within 28 days before randomization. Results of standard of care tests or examinations performed prior to obtaining informed consent and  $\leq 28$  days prior to randomization may be used for the purposes of screening rather than repeating the standard of care tests. During the study, tumor imaging will be performed approximately every 6 weeks ( $\pm 7$  days) for the first 52 weeks, then every 12 weeks ( $\pm 7$  days) after 52 weeks based on RECIST v1.1.



Screening assessments and each subsequent assessment must include computed tomography (CT) scans (with oral/IV contrast, unless contraindicated) or magnetic resonance imaging (MRI) of the brain, chest, abdomen, and pelvis. Other known or suspected sites of disease must be included in the imaging assessments (neck, etc).

Tumor assessments must include CT scans (with oral/IV contrast, unless contraindicated) or MRI, with preference for CT, of the chest, abdomen, and pelvis. All measurable and evaluable lesions should be assessed and documented at the Screening Visit and reassessed at each subsequent tumor evaluation. The same radiographic procedure used to assess disease sites at screening are required to be used throughout the study (eg, the same contrast protocol for CT scans).

- MRI of the brain at baseline ( $\leq 28$  days of informed consent) is required for all screened patients unless contraindicated, then a CT of head may suffice.
- For a patient with known and previously treated brain metastases the scan should be within 14 days of planned Cycle 1, Day 1.
- If a patient is known to have a contraindication to CT contrast media or develops a contraindication during the study, a noncontrast CT of the chest plus a contrast-enhanced MRI (if possible) of abdomen and pelvis should be performed.
- If a CT scan for tumor assessment is performed in a positron emission tomography (PET)/CT scanner, the CT acquisition must be consistent with the standards for a full-contrast diagnostic CT scan.
- Bone scans (Technetium-99m [TC-99m]) or PET should be performed at screening if clinically indicated. If bone metastases are present at screening and cannot be seen on CT or MRI scans afterwards, or if clinically indicated, TC-99m or PET bone scans should be repeated when a CR is suspected in target lesion or when progression in bone is suspected.
- CT scans of the neck or extremities should also be performed if clinically indicated and followed throughout the study, if there is evidence of metastatic disease in these regions at screening. At the investigator's discretion, other methods of assessment of target lesions and nontarget lesions per RECIST v1.1 may be used.

For subsequent tumor assessments, the same radiographic procedures used to assess disease sites at screening are required to be used throughout the study (eg, the same contrast protocol for CT scans). All known sites of disease must be documented at screening and reassessed at each subsequent tumor evaluation.

Response will be assessed by the IRC and the investigator using RECIST v1.1 ([Appendix 3](#)). The same evaluator should perform assessments, if possible, to ensure internal consistency across visits.

After first documentation of response (CR or PR), confirmation of tumor response should occur at 4 weeks or later after the first response or at the next scheduled assessment timepoint.

For immune therapies such as tislelizumab, pseudoprogression may occur due to immune-cell infiltration and other mechanisms leading to apparent increase of existing tumor masses or appearance of new tumor lesions. Thus if radiographic progressive disease is suspected by the



investigator to reflect pseudoprogression, the patient may continue treatment with tislelizumab until progressive disease is confirmed by repeated imaging at  $\geq 4$  weeks later but not exceeding 6 to 8 weeks from the date of initial documentation of progressive disease:

- Absence of clinical symptoms and signs of disease progression (including clinically significant worsening of laboratory values)
- Stable ECOG PS  $\leq 1$
- Absence of rapid progression of disease or of progressive tumor at critical anatomical sites (eg, CNS disease) that cannot be managed by protocol-allowed medical interventions

Investigators must obtain written informed consent for treatment beyond radiologic disease progression and inform patients that this practice is not considered standard in the treatment of cancer

The decision to continue tislelizumab beyond investigator-assessed progression must be discussed with the sponsor's medical monitor and documented in the study records.

Patients who discontinue study treatment early for reasons other than disease progression (eg, toxicity) will continue to undergo tumor assessments following the original plan until the patient begins a subsequent anticancer treatment, experiences disease progression, withdraws consent, is lost to follow up, death, or until the study terminates, whichever occurs first.

Tumor assessments are required to be performed on schedule regardless of whether study treatment has been administered or held.

### 7.7 Pharmacokinetic and Antidrug Antibody Testing

Tislelizumab may elicit an immune response. Patients with signs of any potential immune response to tislelizumab will be closely monitored. Validated screening and confirmatory assays will be employed to detect ADAs at multiple timepoints throughout the study ([Appendix 1](#)). The immunogenicity evaluation will utilize a risk-based immunogenicity strategy ([Koren et al 2008](#); [Worobec and Rosenberg 2004a](#); [Worobec and Rosenberg 2004b](#)) to characterize ADA responses to tislelizumab in support of the clinical development program. This tiered strategy will include an assessment of whether ADA responses correlate with relevant clinical endpoints. Implementation of ADA characterization assays will depend on the safety profile and clinical immunogenicity data.

The following assessments will be performed at a central laboratory:

- ADA assays: serum samples will be tested for the presence of ADAs to tislelizumab using a validated immunoassay
- PK assay: serum samples will be assayed for tislelizumab concentration with use of a validated immunoassay

Shipping, storage, and handling of samples for the assessment of tislelizumab PK and ADA assays will be managed through a central laboratory. Instruction manuals and supply kits will be provided for all central laboratory assessments.

## 7.8 Biomarkers

Shipping, storage, and handling of blood, archival tumor, fresh tumor, and leftover tumor tissue for the assessment of biomarkers will be managed through a central laboratory. Refer to the laboratory manual for details of sample handling.

Archival tumor tissue (FFPE or approximately 15 [ $\geq$  6] unstained slides) must be sent to central laboratory for central IHC assessment of PD-L1 status. In addition to PD-L1 expression, other exploratory predictive biomarkers, such as tumor mutation load and immune-related GEP that are related to response or clinical benefit of tislelizumab may also be evaluated. If no archival samples are available, a fresh tumor biopsy at baseline is required. For fresh biopsy specimens, acceptable samples include core needle biopsies for deep tumor tissue or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions.

Optional biopsies will also be taken for the patients treated with tislelizumab who have confirmed disease progression during the study from accessible tumor sites to obtain samples to explore resistance mechanism. If feasible, any follow-up biopsy should be ideally taken from the same tumor lesion as the baseline biopsy. Written patient consent is required for fresh tumor biopsies.

Tumor tissue should be of good quality based on total and viable tumor content. Fine-needle aspiration, brushing, cell pellets from pleural effusion, and lavage samples are not acceptable.

Optional blood samples will be taken at baseline (predose at Day 1 of Cycle 1), at the time of first tumor response, and at the time of disease progression (10 mL each timepoint) for all randomized patients to explore the association of blood-based biomarkers with response, resistance and prognosis to tislelizumab in combination with chemotherapy or chemotherapy alone. Written patient consent is required for blood sample collections.

## 7.9 Patient-Reported Outcomes

Patients will be asked to complete the EORTC QLQ-LC13, EORTC QLQ-C30 questionnaires before any clinical activities are performed during on-study clinic visits according to the schedule in [Appendix 1](#). The questionnaires will be provided in the patient's preferred language.

## 7.10 Visit Windows

All visits must occur within  $\pm$  3 days from the scheduled date, unless otherwise noted ([Appendix 1](#)). All assessments will be performed on the day of the specified visit unless an acceptable time window is specified. Assessments scheduled on the day of study treatment administration (Day 1) of each cycle should be performed prior to study treatment infusion/dose unless otherwise noted. Laboratory results are required to be reviewed prior to dosing.

If the timing of a protocol-mandated study visit coincides with a holiday, weekend, or other events, the visit should be scheduled on the nearest feasible date. The visit window is provided in [Appendix 1](#).

### 7.11 Unscheduled Visits

Unscheduled visits may be performed at any time at the patient's or the investigator's request and may include vital signs/focused physical examination; ECOG PS; AE review; concomitant medications and procedures review; radiographic assessments; physical examination of liver, spleen, and lymph nodes; disease-related constitutional symptoms; and hematology and chemistry laboratory assessments. The date and reason for the unscheduled visit must be recorded in the source documentation.

If an unscheduled visit is necessary to assess toxicity or for suspected disease progression, then diagnostic tests may be performed based on the investigator assessment as appropriate, and the results of these tests should be entered on the unscheduled visit eCRF.

## 8 SAFETY MONITORING AND REPORTING

The investigator is responsible for the monitoring and documentation of events that meet the criteria and definition of an AE or SAE as provided in this protocol.

### 8.1 Risks Associated With Tislelizumab

Tislelizumab is an investigational agent that is currently in clinical development. Limited safety data are available in patients, and the full safety profile has not been characterized. The following recommendation is based on results from nonclinical and clinical studies with tislelizumab and published data on other molecules within the same biologic class.

The PD-L1/PD-1 pathway is involved in peripheral immune tolerance; therefore, such therapy may increase the risk of irAEs, specifically the induction or enhancement of autoimmune conditions. AEs observed with anti-PD-1 therapy are presented in [Section 8.8.3](#).

Although most irAEs observed with immunomodulatory agents have been mild and self-limiting, such events should be recognized early and treated promptly to avoid potential major complications. Suggested workup procedures for suspected irAEs are provided in [Appendix 6](#).

### 8.2 Risks Associated With Carboplatin and Paclitaxel or *Nab*-Paclitaxel

For NSCLC patients who were treated with paclitaxel in a first-line setting, frequent (> 5%) Grade 3 or 4 drug-related toxicities were neutropenia, anemia, nausea, vomiting, and fatigue ([Scagliotti et al 2008](#)). For NSCLC patients who were treated with carboplatin in a first line setting, frequent (> 5%) Grade 3 or 4 toxicities were leukopenia, neutropenia, anemia, thrombocytopenia, febrile neutropenia, nausea, vomiting, anorexia and constipation ([Ohe et al 2007](#)). Although not life-threatening, these AEs can severely impact the physical, psychological, and social well-being of patients receiving chemotherapy and can lead to dose reductions and discontinuations.

Please refer to [Table 4](#) below for the reported toxicity of the respective chemotherapeutic agents. The investigator should refer to the respective prescribing information for additional details.

**Table 4. Commonly and Specific Reported Toxicity of the Chemotherapeutic Agents**

Agents	Common toxicity	Specific toxicity
Carboplatin	Myelodepression with leukopenia, thrombocytopenia and anemia; infectious complications; nausea/vomiting and other gastrointestinal toxicity; hepatic impairment; fatigue; anorexia; constipation	Ototoxicity and peripheral neuropathies
Paclitaxel		Nephrotoxicity; skin rash
<i>Nab</i> -paclitaxel		Peripheral neuropathy

### 8.3 General Plan to Manage Safety Concerns

#### 8.3.1 Eligibility Criteria

Eligibility criteria were selected to guard the safety of patients in this study. Results from the nonclinical toxicology studies and clinical data with tislelizumab, as well as the nonclinical/clinical data from other PD-L1/PD-1 inhibitors, were considered. Specifically, patients at risk for study-emergent active autoimmune diseases or with a history of autoimmune diseases that may relapse, and patients who have received a live viral vaccine within 28 days before randomization are excluded from the study. Patients with contraindications for carboplatin doublet chemotherapy treatment are also excluded from the study. Refer to [Section 4.2](#) for the full list of exclusion criteria.

#### 8.3.2 Safety Monitoring Plan

Safety will be evaluated in this study through the monitoring of all adverse events, defined and graded according to NCI-CTCAE v4.03. Patients will be assessed for safety (including laboratory values) according to the schedule in [Appendix 1](#). Clinical laboratory results must be reviewed prior to the start of each cycle.

In this study, all enrolled patients will be evaluated clinically and with standard laboratory tests before and at regular intervals during their participation in this study. Safety evaluations will consist of medical interviews, recording of AEs, physical examinations, laboratory measurements (hematology, chemistry, etc) and other assessments. In addition, patients will be closely monitored for the development of any signs or symptoms of autoimmune conditions and infection.

Serum samples will be drawn for determination of ADAs to tislelizumab in patients randomized to the tislelizumab arm. Administration of tislelizumab will be performed in a setting where emergency medical equipment and staff who are trained to respond to medical emergencies are available ([Section 5.2.1](#)).

AEs will be recorded during the study (AEs from the time of the first dose and SAEs from the time of signing of informed consent) and for up to 30 days after the last dose of study drug, including carboplatin doublet chemotherapy, or until the initiation of another anticancer therapy, whichever occurs first. At the EOT, ongoing adverse events considered related to study treatment will be

followed until the event has resolved to baseline or  $\leq$  Grade 1, the event is assessed by the investigator as stable, the patient is lost to follow-up, the patient withdraws consent, or it has been determined that study treatment or participation is not the cause of the adverse event.

Immune-related AEs will be recorded up to 90 days after the last dose of tislelizumab, regardless of whether the patient starts a new anticancer therapy. All drug-related SAEs will be recorded by the investigator after treatment discontinuation until patient death, withdrawal of consent, or loss to follow up, whichever occurs first.

Investigators are instructed to report all adverse events (including pregnancy-related AEs).

The potential safety issues anticipated in this study, as well as measures intended to avoid or minimize such toxicities, are outlined in the following sections.

## **8.4 Adverse Events**

### **8.4.1 Definitions and Reporting**

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not.

Examples of AEs include:

- Worsening of a chronic or intermittent pre-existing condition, including an increase in severity, frequency, duration, and/or has an association with a significantly worse outcome
- New conditions detected or diagnosed after study drug administration even though it may have been present before the start of the study
- Signs, symptoms, or the clinical sequelae of a suspected interaction
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug or a concurrent medication (overdose per se should not be reported as an AE or SAE)

When an AE or SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory results, and diagnostics reports) relative to the AE or SAE. The investigator will then record all relevant information regarding an AE or SAE in the eCRF. However, there may be instances when copies of medical records for certain cases are requested by the sponsor. In this instance, all patient identifiers will be blinded on the copies of the medical records prior to submission to the sponsor.

### **8.4.2 Assessment of Severity**

The investigator will assess the severity for each AE and SAE reported during the study. AEs and SAEs should be assessed and graded based upon the NCI-CTCAE v4.03.

Toxicities that are not specified in the NCI-CTCAE will be defined as follow:

- Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated

- Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL)
- Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL
- Grade 4: Life-threatening consequences; urgent intervention indicated
- Grade 5: Death related to AE

Note: The terms “severe” and “serious” are not synonymous. Severity is a measure of intensity (for example, grade of a specific AE, mild [Grade 1], moderate [Grade 2], severe [Grade 3], or life-threatening [Grade 4]), whereas seriousness is classified by the criteria based on the regulatory definitions. Seriousness serves as the guide for defining regulatory reporting obligations from the sponsor to applicable regulatory authorities as described in [Section 8.7.2.3](#).

### 8.4.3 Assessment of Causality

The investigator is obligated to assess the relationship between the study drug and the occurrence of each AE or SAE, using best clinical judgment. Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the AE or SAE to the study drug should be considered and investigated.

#### Investigator's Brochure

There may be situations when an SAE has occurred and the investigator has minimal information to include in the initial report to the sponsor. However, it is very important that the investigator always makes an assessment of causality for every SAE prior to transmission of the SAE report to the sponsor, since the causality assessment is one of the criteria used when determining regulatory reporting requirements. The investigator may change his/her opinion of causality considering follow-up information, amending the SAE report accordingly.

Investigators must also systematically assess the causal relationship of AEs to study drug (including any other nonstudy drugs, radiation therapy, etc) using the following definitions:

- Definitely related: There is clear evidence to suggest a causal relationship to the study drug, and there is reasonable temporal relationship; the occurrence of AE is definitely attributed to the pharmacological effect of study treatment.
- Probably related: There is a reasonable temporal relationship to suggest a causal relationship to the study drug; the occurrence of AE could not be explained by the patient's medical history, concurrent medical condition, or other the patient's signs or symptoms.
- Possibly related: There is some evidence to suggest a causal relationship to the study drug (eg, the AE occurred within a reasonable time after administration of the study drug). However, the influence of other factors may have contributed to the AE such as the patient's clinical condition, other concomitant AEs.
- Unlikely related: There is little evidence to suggest a causal relationship to the study drug. There is another reasonable explanation for the AE such as disease or other drugs.

- Unrelated: An AE will be considered “not related” to the use of the study drug if any of the following criteria are met:
  - An unreasonable temporal relationship between administration of the drug and the onset of the AE (eg, the AE occurred either before, or too long after administration of the drug for it to be considered drug-related);
  - A causal relationship between the drug and the AE is biologically implausible (eg, death as a passenger in an automobile accident);
  - A clearly more likely alternative explanation for the AE is present (eg, typical adverse reaction to a concomitant drug and/or typical disease-related AE).

The causality for cases that were assessed using the 5-point scale will be mapped to 2-point scale during aggregate safety data analysis according to the BeiGene latest mapping rule.

#### **8.4.4 Following Adverse Events**

After the initial AE or SAE report, the investigator is required to proactively follow each patient and provide further information to the sponsor on the patient’s condition.

All AEs and SAEs documented at a previous visit/contact and designated as ongoing will be reviewed at subsequent visits/contacts.

All AEs and SAEs will be followed until resolution, the condition stabilizes or is considered chronic, the AE or SAE is otherwise explained, the patient is lost to follow-up, or the patient withdraws consent. The investigator will ensure that follow-up includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE or SAE. This may include additional laboratory tests or investigations, histopathological examinations, radiographic imaging, or consultation with other health care professionals.

The sponsor may request that the investigator perform or arrange for the conduct of supplemental measurements and/or evaluations to elucidate as fully as possible the nature and/or causality of the AE or SAE. The investigator is obligated to assist. If a patient dies during participation in the study or during a recognized follow-up period, the sponsor will be provided with a copy of any postmortem findings, including histopathology.

New or updated information should be reported to the sponsor according to the SAE instructions provided by the sponsor within the time frames outlined in [Section 8.7.2](#).

#### **8.4.5 Laboratory Test Abnormalities**

Only abnormal laboratory findings (eg, clinical chemistry, CBC, coagulation, or urinalysis) or other abnormal assessments (eg, ECGs, X-rays, or vital signs) that are judged by the investigator as clinically significant will be recorded as AEs or SAEs if they meet the definition of an AE ([Section 8.4](#)) or an SAE ([Section 8.5](#)). Clinically significant abnormal laboratory findings or other abnormal assessments that are detected during the study or are present at baseline and significantly worsen following the start of the study will be reported as AEs or SAEs. However, clinically



significant abnormal laboratory findings or other abnormal assessments that are associated with the disease being studied, unless judged by the investigator as more severe than expected for the patient's condition, or that are present or detected at the start of the study and do not worsen, will not be reported as AEs or SAEs.

## 8.5 Definition of a Serious Adverse Event

An SAE is any untoward medical occurrence that, at any dose:

- Results in death
- Is life threatening

Note: The term "life threatening" in the definition of "serious" refers to an AE in which the patient was at risk of death at the time of the AE. It does not refer to an AE, which hypothetically might have caused death, if it were more severe.

- Requires hospitalization or prolongation of existing hospitalization

Note: In general, hospitalization signifies that the patient was admitted (usually involving at least an overnight stay) to the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or outpatient setting

- Results in disability/incapacity

Note: The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle), which may interfere or prevent everyday life functions but do not constitute a substantial disruption.

- Is a congenital anomaly/birth defect
- Is considered a significant medical AE by the investigator based on medical judgement (eg, may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above)

The following are NOT considered SAEs:

- Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline
- Hospitalization for social/convenience considerations
- Scheduled therapy for the target disease of the study, including admissions for transfusion support or convenience

## 8.6 Suspected Unexpected Serious Adverse Reaction

A suspected unexpected serious adverse reaction (SUSAR) is a serious adverse reaction that is both unexpected (ie, not present in the product's Reference Safety Information [RSI]) and meets the



definition of an SAE/serious adverse drug reaction (ADR),

[Investigator's Brochure](#)

## 8.7 Timing, Frequency, and Method of Capturing Adverse Events and Serious Adverse Events

### 8.7.1 Adverse Event Reporting Period

After informed consent has been signed but prior to the administration of the study drug, only SAEs should be reported.

After initiation of study drug, all AEs and SAEs, regardless of relationship to study drug, will be reported until either 30 days after last dose of study treatment or initiation of new anticancer therapy, whichever occurs first. An irAE (serious or nonserious) should be reported until 90 days after the last dose of tislelizumab, regardless of whether the patient starts a new anticancer therapy. The investigator should report any SAEs that are assessed as related to tislelizumab treatment, at any time after treatment discontinuation.

### 8.7.2 Reporting Serious Adverse Events

#### 8.7.2.1 Prompt Reporting of Serious Adverse Events

As soon as the investigator determines that an AE meets the protocol definition of an SAE, the event must be reported promptly (within 24 hours) to the sponsor or designee as described in [Table 5](#).

**Table 5. Timeframes and Documentation Methods for Reporting Serious Adverse Events to the Sponsor or Designee**

	Timeframe for making initial report	Documentation method	Timeframe for making follow-up report	Documentation method
All SAEs	Within 24 hours of first knowledge of the AE	SAE Report	As expeditiously as possible	SAE Report

Abbreviations: AE, adverse event; SAE, serious adverse event.

#### 8.7.2.2 Completion and Transmission of the Serious Adverse Event Report

Once an investigator becomes aware that an SAE has occurred in a patient, he/she is to report the information to the sponsor within 24 hours as outlined above in [Section 8.7.2](#). The SAE Report will always be completed as thoroughly as possible with all available details of the event, and forwarded to the sponsor or designee within the designated time frames.

If the investigator does not have all information regarding an SAE, he/she is not to wait to receive additional information before notifying the sponsor or designee of the SAE and completing the form. The form will be updated when additional information is received.

The investigator must always provide an assessment of causality at the time of the initial report as described in [Section 8.4.3](#).

If the electronic data capture (EDC) system is nonoperational, the paper SAE form will be sent via either email or fax to the sponsor. After the EDC system becomes operational again, the investigator must enter the SAE information there.

The sponsor will provide contact information for SAE receipt.

### **8.7.2.3 Regulatory Reporting Requirements for Serious Adverse Events**

The investigator will promptly report all SAEs to the sponsor in accordance with the procedures detailed in [Section 8.7.2.1](#). The sponsor has a legal responsibility to notify, as appropriate, both the local regulatory authority and other regulatory agencies about the safety of a product under clinical investigation.

The investigator, or responsible person according to local requirements, will comply with the applicable local regulatory requirements related to the reporting of SAEs to regulatory authorities and the IRB/IEC.

All SUSARs ([Section 8.6](#)), will be submitted to all applicable regulatory authorities and investigators for tislelizumab studies.

When a study center receives an initial or follow-up safety report or other safety information (eg, revised Investigator's Brochure) from the sponsor, the investigator or designated responsible person is required to promptly notify his/her IRB or IEC. The investigator should place copies of Safety Reports from the sponsor in the Investigator Site File.

### **8.7.3 Eliciting Adverse Events**

The investigator or designee will ask about AEs by asking the following standard questions:

- How are you feeling?
- Have you had any medical problems since your last visit?
- Have you taken any new medicines since your last visit?

### **8.7.4 Recording Disease Progression**

Disease progression is expected in this study population, and the term "disease progression" should not be reported as an AE term. When disease progression is identified, the AE that is associated with the disease progression should be reported as the AE term. For instance, for a patient who has a seizure that is determined to be associated with a brain metastasis: the term "seizure" should be recorded as the AE instead of disease progression or brain metastasis. Deaths that are assessed by the investigator as likely due to disease progression should be recorded in the eCRF. The term "death" should not be reported as an AE or SAE term, but rather as an outcome of an event.

### **8.7.5 Recording Deaths**

When recording a death as an SAE, the AE that caused or contributed to fatal outcome should be recorded as the single medical concept. If the cause of death is unknown and cannot be ascertained at the time of reporting, record "unexplained death."

### 8.7.6 Recording Pregnancies

If a female patient or the partner of a male patient becomes pregnant while receiving investigational therapy or within 120 days after the last dose of tislelizumab or within 30 days after the last dose of chemotherapeutic agents, a pregnancy report form is required to be completed and expeditiously submitted to the sponsor to facilitate outcome follow-up. Information on the status of the mother and child will be forwarded to the sponsor. Generally, follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any premature termination of the pregnancy will be reported.

While pregnancy itself is not considered to be an adverse event, any pregnancy complication or elective termination of a pregnancy for medical reasons will be recorded as an AE or SAE.

An abortion, whether accidental, therapeutic, or spontaneous should be always reported as an SAE. Similarly, any congenital anomaly/birth defect in a child born to a patient exposed to the study drug should be recorded and reported as an SAE.

### 8.7.7 Recording Poststudy Adverse Events

A poststudy AE or SAE is defined as any AE that occurs outside of the AE/SAE reporting period that is defined in [Section 8.7.1](#).

Investigators are not obligated to actively seek AEs or SAEs in former patients. However, if the investigator learns of any SAE, including a death, at any time after a patient has been discharged from the study, and he/she considers the SAE related to the study drug, the investigator will notify the sponsor.

### 8.7.8 Expedited Reporting to Health Authorities, Investigators, Institutional Review Boards, and Independent Ethics Committees

The sponsor will promptly assess all SAEs against cumulative study drug experience to identify and expeditiously communicate new safety findings to regulatory authorities, investigators, IRBs, and IECs based on applicable legislation.

To determine the reporting requirements for individual SAEs, the sponsor will assess the expectedness of the SAEs using the following reference safety information (RSI) documents:

- Tislelizumab Investigator's Brochure
- Carboplatin label
- Paclitaxel label
- *Nab*-paclitaxel label

### 8.7.9 Assessing and Recording Immune-Related Adverse Events

Since treatment with anti-PD-1 therapy can cause autoimmune disorders, AEs considered by the investigator to be immune-related ([Section 8.8.3](#)) should be classified as irAEs and identified as such in the eCRF AE page until Day 90, after treatment discontinuation.

Investigators should consult the guidance on diagnostic evaluation and management of irAEs, which are commonly seen with immune CPIs, in [Appendix 6](#).

An extensive list of potential irAEs appears in [Section 8.8.3, Table 7](#). All conditions similar to those listed should be evaluated to determine whether they are irAEs, based on a similar diagnostic process to those reactions that are presented in more detail in [Appendix 6](#).

## **8.8 Management of Adverse Events of Special Interest**

As a routine precaution, after infusion of tislelizumab on Day 1 of Cycle 1 and Cycle 2, patients must be monitored for  $\geq 1$  hour afterwards in an area with resuscitation equipment and emergency agents. From Cycle 3 onward, a minimum of a 30-minute monitoring period is required in an area with resuscitation equipment and emergency agents.

The management of infusion-related reactions, severe hypersensitivity reactions, and irAEs according to the NCI-CTCAE criteria are outlined below.

### **8.8.1 Infusion-Related Reactions**

The symptoms of infusion-related reactions include fever, chills/rigor, nausea, pruritus, angioedema, hypotension, headache, bronchospasm, urticaria, rash, vomiting, myalgia, dizziness, or hypertension. Severe reactions may include acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock. Patients should be closely monitored for such reactions. Immediate access to an intensive care unit (ICU) or equivalent environment and appropriate medical therapy (including epinephrine, corticosteroids, IV antihistamines, bronchodilators, and oxygen) must be available to treat infusion-related reactions.

Treatment modification for symptoms of infusion-related reactions due to study drug(s) is provided in [Table 6](#).

**Table 6. Treatment Modification for Symptoms of Infusion-Related Reactions Due to Study Drug(s)**

NCI-CTCAE grade	Treatment modification for tislelizumab
<b>Grade 1 or 2</b> Mild transient reaction; infusion interruption not indicated; intervention not indicated.	Decrease infusion rate by 50%. Any worsening is closely monitored. Medical management as needed. Subsequent infusions should be given after premedication and at the reduced infusion rate.
<b>Grade 2</b> Therapy or infusion interruption indicated but responds promptly to symptomatic treatment (eg, antihistamines, NSAIDs, narcotics, IV fluids); prophylactic medications indicated for ≤ 24 hrs.	Stop infusion. Infusion may be resumed at 50% of previous rate once infusion-related reactions has resolved or decreased to at least Grade 1 in severity. Any worsening is closely monitored. Proper medical management should be instituted as described below. Subsequent infusions should be given after premedication and at the reduced infusion rate.
<b>Grade 3–severe</b> Prolonged (eg, not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae.	Immediately stop the infusion. Proper medical management should be instituted as described below. The patient should be withdrawn from study drug(s) treatment.
<b>Grade 4–life threatening</b> Life-threatening consequences; urgent intervention indicated.	Immediately stop the infusion. Proper medical management should be instituted as described below. The patient should be withdrawn from study drug(s) treatment. Hospitalization is recommended.

Abbreviations: IV, intravenous; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Event; NSAIDs, nonsteroidal anti-inflammatory drugs.

Once the tislelizumab infusion rate has been decreased by 50% or suspended due to an infusion-related reaction, it must remain decreased for all subsequent infusions with premedication. If the patient has a second infusion-related reaction (≥ Grade 2) on the slower infusion rate, infusion should be discontinued, and the patient should be withdrawn from tislelizumab treatment.

**CTCAE Grade 1 or 2 infusion reaction:** Proper medical management should be instituted, as indicated per type of the reaction. This includes but is not limited to an antihistamine (eg, diphenhydramine or equivalent), antipyretic (eg, paracetamol or equivalent), and, if indicated, oral or IV glucocorticoids, epinephrine, bronchodilators, and oxygen. In the next cycle, patients should receive oral premedication with an antihistamine (eg, diphenhydramine or equivalent) and an antipyretic (eg, paracetamol or equivalent), and they should be closely monitored for clinical signs and symptoms of an infusion reaction.

**CTCAE Grade 3 or 4 infusion reaction:** Proper medical management should be instituted immediately, as indicated per type and severity of the reaction. This includes but is not limited to oral or IV antihistamine, antipyretic, glucocorticoids, epinephrine, bronchodilators, and oxygen.

### 8.8.2 Severe Hypersensitivity Reactions and Flu-Like Symptoms

If hypersensitivity reaction occurs, the patient must be treated according to the best available medical practice as described in the complete guideline for emergency treatment of anaphylactic reactions according to the Working Group of the Resuscitation Council (UK) (Soar et al 2008). Patients should be instructed to report any delayed reactions to the investigator immediately.

In the event of a systemic anaphylactic/anaphylactoid reaction (typically manifested within minutes following administration of the drug/antigen, and characterized by: respiratory distress; laryngeal edema; and/or intense bronchospasm; and often followed by vascular collapse or shock without antecedent respiratory difficulty; cutaneous manifestations such as pruritus and urticaria with/without edema; and gastrointestinal manifestations such as nausea, vomiting, crampy abdominal pain, and diarrhea), the infusion must be immediately stopped and the patient discontinued from the study.

The patients will be administered epinephrine injection and dexamethasone infusion if hypersensitivity reaction is observed and then the patient should be placed on monitor immediately and ICU should be alerted for possible transfer if needed.

For prophylaxis of flu-like symptoms, a dose of 25 mg indomethacin or a comparable dose of nonsteroidal anti-inflammatory drugs (ie, 600 mg ibuprofen, 500 mg naproxen sodium) may be administered 2 hours before and 8 hours after the start of each dose of study drugs(s) infusion. Alternative treatments for fever (ie, paracetamol) may be given to patients at the discretion of the investigator.

### 8.8.3 Immune-Related Adverse Events

Immune-related AEs are of special interest in this study. If the events listed below or similar events occur, the investigator should exclude alternative explanations (eg, combination drugs, infectious disease, metabolic, toxin, disease progression or other neoplastic causes) with appropriate diagnostic tests, which may include but are not limited to serologic, immunologic, and histologic (biopsy) data. If alternative causes have been ruled out; the AE required the use of systemic steroids, other immunosuppressants, or endocrine therapy and is consistent with an immune mediated mechanism of action, the irAE indicator in the eCRF AE page should be checked.

A list of potential irAEs is shown below in [Table 7](#). All conditions similar to those listed should be evaluated in patients receiving tislelizumab to determine whether they are immune-related.

Recommendation for diagnostic evaluation and management of irAEs is based on a recent European Society for Medical Oncology (ESMO) guideline (Haanen et al 2017), and common immune-related toxicities are detailed in [Appendix 6](#). For any adverse events not included in [Appendix 6](#), please refer to the recent ESMO guideline (Haanen et al 2017) for further guidance on diagnostic evaluation and management of immune-related toxicities.

**Table 7. Immune-Related Adverse Events**

Body System Affected	Events
Skin (mild-common)	pruritus or maculopapular rash; vitiligo
Skin (moderate)	follicular or urticarial dermatitis; erythematous/lichenoid rash; Sweet's syndrome
Skin (severe-rare)	full-thickness necrolysis/Stevens-Johnson syndrome
Gastrointestinal	colitis (includes diarrhea with abdominal pain or endoscopic/radiographic evidence of inflammation); pancreatitis; hepatitis; aminotransferase (aspartate aminotransferase/alanine aminotransferase) elevation; bowel perforation
Endocrine	thyroiditis, hypothyroidism, hyperthyroidism; hypophysitis with features of hypopituitarism, eg, fatigue, weakness, weight gain; insulin-dependent diabetes mellitus; diabetic ketoacidosis; adrenal insufficiency
Respiratory	pneumonitis/diffuse alveolitis
Eye	episcleritis; conjunctivitis; iritis/uveitis
Neuromuscular	arthritis; arthralgia; myalgia; neuropathy; Guillain-Barre syndrome; aseptic meningitis; myasthenic syndrome/myasthenia gravis, meningoencephalitis; myositis
Blood	anemia; leukopenia; thrombocytopenia
Renal	interstitial nephritis; glomerulonephritis; acute renal failure
Cardiac	pericarditis; myocarditis; heart failure

Recommendations for managing irAEs are detailed in [Appendix 6](#).

If a toxicity does not resolve to  $\leq$  Grade 1 within 12 weeks, study drug(s) should be discontinued after consultation with the sponsor. Patients who experience a recurrence of any event at the same or higher severity grade with rechallenge should permanently discontinue treatment.

## 9 STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION

The statistical analyses will be performed by the sponsor or designee after the study is completed and the database is locked and released. Data will be listed and summarized using SAS<sup>®</sup> Version 9.3 or higher (SAS Institute, Inc., Cary, North Carolina) per sponsor agreed reporting standards, where applicable. Details of the statistical analyses will be included in a separate Statistical Analysis Plan (SAP).

### 9.1 Statistical Analysis

#### 9.1.1 Randomization Methods

As discussed in [Section 7.2.3](#), patients will be randomized using the IRT system for this study by permuted block stratified randomization with stratification factors of Stage (IIIB versus IV) and PD-L1 expression in TC ( $\geq 50\%$  TC versus 1% to 49% TC versus  $< 1\%$  TC).



### 9.1.2 Analysis Populations

The ITT Population includes all randomized patients. Patients will be analyzed according to their randomized treatment arms. This will be the primary analysis population for efficacy analysis.

The Safety Population includes all patients who received  $\geq 1$  dose of study drug; it will be the population for the safety analyses.

The PK Population includes all patients who receive  $\geq 1$  dose of tislelizumab per the protocol, for whom any postdose PK data are available.

### 9.1.3 Patient Disposition

The number of patients randomized, treated, and discontinued from study drug and/or study and those with major protocol deviations will be counted. The primary reason for study drug and/or the study being discontinued will be summarized according to the categories in the eCRF. The end-of-study status (alive, dead, withdrew consent or lost to follow-up) at the data cutoff date will be summarized using the data from the eCRF.

Major protocol deviations will be summarized and listed by each category.

### 9.1.4 Demographic and Other Baseline Characteristics

Demographic and other baseline characteristics of the ITT Population will be summarized using descriptive statistics. Continuous variables include age, weight, vital signs, time since initial cancer diagnosis, and time since advanced/metastatic disease diagnosis. Categorical variables include histology; prior neoadjuvant or adjuvant therapy; stage of disease; PD-L1 expression in TC; gender; ECOG PS; race; smoking status; prior systemic therapies; and metastatic site.

### 9.1.5 Prior and Concomitant Medications

Concomitant medications will be coded using the WHO Drug Dictionary drug codes. Concomitant medications will be further coded to the appropriate Anatomical Therapeutic Chemical (ATC) code indicating therapeutic classification. Prior and concomitant medications will be summarized and listed by drug and drug class in the clinical study report (CSR) for this protocol. Prior medications will be defined as medications that stopped before the day of first dose of study drug. Concomitant medications will be defined as medications that 1) started before the first dose of study drug and were continuing at the time of the first dose of study drug or 2) started on or after the date of the first dose of study drug up to 30 days after the patient's last dose (as of the Safety Follow-up Visit). A listing of prior and concomitant medications will be included in the CSR for this protocol.

## 9.2 Efficacy Analyses

### 9.2.1 Primary Efficacy Analysis

#### **PFS per the IRC in ITT Population:**

PFS per the IRC is defined as the time from randomization to the first documented disease progression as assessed by the IRC with the use of RECIST v1.1, or death from any cause,



whichever occurs first. The actual tumor assessment visit date will be used to calculate PFS. Data for patients without disease progression or death at the time of analysis will be censored at the time of the last valid tumor assessment. Data for patients without postbaseline tumor assessment will be censored at the time of randomization. Data for patients who start to receive new anticancer therapy or are lost to follow-up will be censored at the last valid tumor assessment date prior to the introduction of new therapy or loss to follow-up. Patients who have a clinical determination of progression should undergo a CT/MRI, if possible, to correlate radiographic findings with the clinical findings. If a clinical determination of progression for a patient is confirmed, the date of the CT/MRI scan will be considered as the progression date for that patient.

PFS per the IRC will be compared between tislelizumab with paclitaxel + carboplatin (Arm A) and paclitaxel + carboplatin (Arm C), and between tislelizumab with *nab*-paclitaxel + carboplatin (Arm B) and paclitaxel + carboplatin (Arm C), using stratified log-rank test methodology. The 2 primary hypothesis tests are formed as follows:

One-sided testing of PFS superiority of Arm A to Arm C:

The null hypothesis to be tested is:

$$H_0: \text{PFS in Arm A} \leq \text{PFS in Arm C}$$

Against the alternative hypothesis:

$$H_a: \text{PFS in Arm A} > \text{PFS in Arm C}$$

One-sided testing of PFS superiority of Arm B to Arm C:

The null hypothesis to be tested is:

$$H_0: \text{PFS in Arm B} \leq \text{PFS in Arm C}$$

Against the alternative hypothesis:

$$H_a: \text{PFS in Arm B} > \text{PFS in Arm C}$$


The p-values from a stratified log-rank test will be presented using stratification factors with actual values as recorded in the EDC at randomization. The median PFS will be calculated for each treatment arm and presented with two-sided 95% CIs. Kaplan-Meier survival probabilities for each arm will be plotted over time. The HR for PFS for each comparison (ie, Arm A versus Arm C, Arm B versus Arm C) will be estimated using a stratified Cox regression model, with treatment arm as a factor and stratified by the actual value of the stratification factors as recorded in eCRF. The 95% CI for the HR will be provided. Unstratified analysis will also be presented.

**Overall Type-I-Error Control for 2 Primary Hypothesis Tests**

The overall type I error will be strongly controlled at a one-sided  $\alpha$  of 0.025 within the 2 primary hypothesis tests. Initially,  $\alpha$  of 0.0125 and 0.0125 will be assigned to the primary hypothesis testing of PFS of A versus C and PFS of B versus C, respectively. There will be 1 planned interim analysis for efficacy for both comparisons. If PFS in either comparison (eg, A versus C or B versus C) is statistically significant at initial assigned  $\alpha$  of 0.0125, then the  $\alpha$  of 0.0125 will be passed on to the

hypothesis test in the other comparison (eg, B versus C or A versus C), and PFS in that comparison will be able to be tested at an overall one-sided  $\alpha$  of 0.025. The method of  $\alpha$  allocation (Burman et al 2009), including possible  $\alpha$  recycling, is described below.

**Figure 2. Type-I-Error Control Scheme**



$\alpha$ -recycling: if PFS results positive in A versus C comparison, the  $\alpha=0.0125$  can be passed on to hypothesis testing in PFS of B versus C and thus can be tested under  $\alpha=0.025$ ; Alternatively, the same applies.

### **Subgroup Analysis for PFS per the IRC**

Subgroup analysis of primary endpoint of PFS per the IRC will be conducted to determine whether the treatment effect is consistent across various subgroups, and the HR estimates of OS and its 95% CI will be estimated and plotted within each category of the following variables: PD-L1 expression in TC ( $\geq 50\%$  TC versus  $1\%$  to  $49\%$  TC versus  $< 1\%$  TC), Stage (IIIB versus IV), age ( $\leq 65$  versus  $> 65$  years), gender (female versus male), ECOG PS (0 versus 1), and smoking status (former versus current versus never).

### **9.2.2 Secondary Efficacy Analysis**

#### **Overall Survival**

OS is defined as the time from randomization to death from any cause. Data for patients who are not reported as having died at the time of analysis will be censored at the date last known to be alive. Data for patients who do not have postbaseline information will be censored at the date of randomization.

Similar methodology used to evaluate PFS per the IRC will be applied to OS analysis.

#### **Progression-Free Survival per Investigator**

PFS per the investigator is defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as determined per RECIST v1.1 in an ITT Population. Similar methodology used to evaluate PFS per the IRC will be applied to analysis of PFS per the investigator.

#### **Objective Response Rate per the IRC**

ORR (confirmation not required according to RECIST v1.1) is the proportion of patients who had a CR or PR as assessed by the IRC per RECIST v1.1 in all randomized patients with measurable disease at baseline. Patients without any postbaseline assessment will be considered nonresponders. The difference in ORR between Arm A versus Arm C and Arm B versus Arm C in the ITT Population will be evaluated using the Cochran-Mantel-Haenszel (CMH) chi-square test with the actual stratification factors as strata. The two-sided 95% CIs for the odds ratio and the difference in ORR will be calculated, as well as Clopper-Pearson 95% CIs for the ORR within each arm.

#### **Objective Response Rate per the Investigator**

ORR (confirmation not required according to RECIST v1.1) is the proportion of patients who had CR or PR as assessed by the investigator per RECIST v1.1 in all randomized patients with measurable disease at baseline. Patients without any postbaseline assessment will be considered nonresponders. Similar methodology used to evaluate ORR per the IRC will be applied to analysis of ORR per the investigator.

#### **Duration of Response per the IRC**

DOR per the IRC is defined for patients with an objective response as the time from the first documented objective response to documented disease progression as assessed by the IRC using RECIST v1.1, or death from any cause, whichever occurs first. Data for patients who are alive and who have not experienced disease progression at the time of analysis will be censored at the date of the last tumor assessment. If no tumor assessments were performed after the date of the first occurrence of the objective response (CR or PR), DOR will be censored at the date of the first occurrence of the objective response. DOR will be estimated using Kaplan-Meier methodology. Comparisons between treatment arms will be made using the stratified and unstratified log-rank test for descriptive purposes only.

#### **Duration of Response per the Investigator**

DOR per the investigator is defined for patients with an objective response as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. Data for patients who are alive and who have not experienced disease progression at the time of analysis will be censored at the date of the last tumor assessment. If no tumor assessments were performed after the date of the first occurrence of the objective response (CR or PR), DOR will be censored at the date of the first occurrence of the objective response. Similar methodology used to evaluate DOR per the IRC will be applied to analysis of DOR per the investigator.

#### **Health-Related Quality of Life**

EORTC Quality of Life Cancer Questionnaire (EORTC QLQ-LC13 and EORTC QLQ-C30) postbaseline scores will be compared between the 2 treatment arms, using a mixed model with baseline score and time since the randomization as covariates. Significant interaction between treatment and time since randomization or quadratic term of time since randomization ( $p < 0.05$ ) will also be included in the final model.

In addition, changes from baseline in global health status/quality of life of QLQ-C30 and domain scores of both C30 (eg, physical, emotional scores) and LC13 (symptom scores) will be summarized descriptively.

### **PD-L1 Expression as a Predictive Biomarker for Response**

Distribution of PD-L1 expression in TC will be examined in the ITT Population. Association between PD-L1 expression and tislelizumab treatment effect over control (PFS, OS, ORR, DOR, DCR) will be explored.

### **9.2.3 Exploratory Efficacy Analysis**

#### **Disease Control Rate per the Investigator**

DCR is defined as the proportion of patients with objective response (CR or PR) or SD maintained for  $\geq 6$  weeks as assessed by the investigator using RECIST v1.1. The analysis methods for DCR will be the same as those for ORR per the investigator.

#### **Time to Response per the Investigator**

TTR per the investigator is defined for patients with an objective response by the investigator as the time from randomization to the first occurrence of a CR or PR as assessed by the investigator using RECIST v1.1. TTR will be summarized for descriptive purposes. The mean, standard error, median, and range of TTR will be provided.

### **9.3 Safety Analyses**

Safety will be assessed by monitoring and recording of all AEs graded by NCI-CTCAE v4.03. Laboratory values (eg, hematology, clinical chemistry, urinalysis), vital signs, ECGs, and physical examinations will also be used in determining safety. Descriptive statistics will be used to analyze all safety data in the Safety Population.

#### **9.3.1 Extent of Exposure**

Extent of exposure to each study drug will be summarized descriptively as the number of cycles received (number and percentage of patients), duration of exposure (days), cumulative total dose received per patient (mg), and relative dose intensity.

The number (percentage) of patients requiring dose reduction, interruption, dose delay, and drug discontinuation due to AEs will be summarized for each study drug. Frequency of the above dose adjustments and discontinuation will be summarized by category.

Patient data listings will be provided for all dosing records and for calculated summary statistics.

#### **9.3.2 Adverse Events**

The AE verbatim descriptions (the investigator's description from the eCRF) will be coded using Medical Dictionary for Regulatory Activities (MedDRA). Adverse events will be coded to MedDRA (Version 20.1 or higher) by lower-level term, preferred term, and primary system organ class (SOC).

A TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation (Safety Follow-up Visit) or initiation of new anticancer therapy, whichever comes first. For the tislelizumab arm, the TEAE classification also applies to irAEs that are recorded up to 90 days after discontinuation from tislelizumab, regardless of whether the patient starts a new anticancer therapy. Only those AEs that were treatment emergent will be included in summary tables. All AEs, treatment emergent or otherwise, will be presented in patient data listings.

The incidence of TEAEs will be reported as the number (percentage) of patients with TEAEs by SOC and preferred term. A patient will be counted only once by the highest severity grade per NCI-CTCAE v4.03 within an SOC and preferred term, even if the patient experienced > 1 TEAE within a specific SOC and preferred term. The number (percentage) of patients with TEAEs will also be summarized by relationship to the study drug. Treatment-related AEs include those events considered by the investigator to be related to study treatment or with missing assessment of the causal relationship. SAEs, deaths, TEAE with  $\geq$  Grade 3 severity, irAE, treatment-related TEAEs and TEAEs that led to treatment discontinuation, dose interruption, dose reduction, or dose delay will be summarized.

### 9.3.3 Laboratory Analyses

Clinical laboratory (eg, hematology, serum chemistry) values will be evaluated for each laboratory parameter as appropriate. Abnormal laboratory values will be flagged and identified as those outside (above or below) the normal range. Reference (normal) ranges for laboratory parameters will be included in the CSR for this protocol. Descriptive summary statistics (eg, n, mean, standard deviation, median, minimum, maximum for continuous variables; n [%] for categorical variables) for laboratory parameters and their changes from baseline will be calculated. Laboratory values will be summarized by visit and by worst postbaseline visit.

Laboratory parameters that are graded in NCI-CTCAE v4.03 will be summarized by NCI-CTCAE grade. In the summary of laboratory parameters by NCI-CTCAE grade, parameters with NCI-CTCAE grading in both high and low directions (eg, glucose, potassium, sodium) will be summarized separately.

### 9.3.4 Vital Signs

Descriptive statistics for vital sign parameters (systolic and diastolic blood pressure, heart rate, respiratory rate, temperature, weight) and changes from baseline will be presented by visit for all visits. Vital signs will be listed by patient and visit.

## 9.4 Pharmacokinetic Analysis

Pharmacokinetic samples will be collected in this study as outlined in [Appendix 1](#).

Tislelizumab postdose and trough serum concentration ( $C_{\text{trough}}$ ) data will be tabulated and summarized by visit/cycle at which these concentrations are collected. Descriptive statistics will include means, medians, ranges, and standard deviations, as appropriate.

Additional PK analyses, including population PK analyses and exposure-response (efficacy, safety endpoints) analyses may be conducted as appropriate and the results of such analysis may be reported separately from the CSR.

### **9.5 Immunogenicity Analyses**

Samples to assess anti-tislelizumab antibodies will be collected only in patients randomized to receive tislelizumab.

The immunogenicity results will be summarized using descriptive statistics by the number and percentage of patients who develop detectable ADA. The incidence of positive ADA and neutralizing ADA will be reported for evaluable patients. The effect of immunogenicity on PK, efficacy, and safety may be evaluated if data allow.

### **9.6 Sample Size Consideration**

The sample size calculation is based on the number of PFS events required to demonstrate the PFS superiority of Arm A or Arm B to Arm C in the ITT Population. Exponential distribution is assumed PFS. The estimates of the number of events required to demonstrate efficacy with regard to for PFS based on the following assumptions:

- 1 Median PFS of 6 months in the Arm C.
- 2 At a one-sided  $\alpha$  of 0.0125, 80% power to detect a, HR of 0.6, corresponding to an improvement in median PFS from 6 months to 10 months, in the PFS of A versus C comparison.
- 3 At a one-sided  $\alpha$  of 0.0125, 80% power to detect an HR of 0.6, corresponding to an improvement in median PFS from 6 months to 10 months, in the PFS of B versus C comparison.
- 4 Randomization ratio: 1:1:1
- 5 One interim analysis is planned for both A versus C and B versus C comparisons when ~67% of total PFS events occurred, with Pocock boundary.

With these assumptions, a total of 162 PFS events is required for each primary comparison of Arm A versus Arm C or Arm B versus Arm C, corresponding to a total of 235 PFS events in the ITT Population, for the final analysis. Assuming 342 patients are to be enrolled over an 8.6-month period at a constant enrolment rate, the final analysis will occur at approximately 18.5 months after first patient randomized.

### **9.7 Interim Analyses**

There will be 1 interim efficacy analysis of PFS performed in the ITT Population. The interim efficacy analysis will be performed when approximately 157 PFS events (67% of the target number of 235 PFS events, corresponding to approximately 109 PFS events in each of the comparison) are observed in the ITT Population. It is estimated that it will take approximately 11.7 months to reach time of interim analysis. The interim boundary is based on Pocock boundary. The interim and final

analysis timing, and stopping boundaries are summarized in [Table 8](#) below for the scenario where  $\alpha$  is not recycled and in [Table 9](#) for the scenario where  $\alpha$  is recycled.

**Table 8 Analysis Timing and Stopping Boundaries for PFS in Each of the Primary Testing at One-Sided  $\alpha=0.0125$  (Initial  $\alpha$  Assignment)**

Type of analysis	Time (months)	# Events	Testing boundary	
			p-value boundary	Approx. hazard ratio threshold
Interim analysis	11.7	109	0.0096	0.638
Final analysis	18.5	162	0.0057	0.672

**Table 9. Analysis Timing and Stopping Boundaries for PFS in Each of the Primary Testing at One-Sided  $\alpha=0.025$  ( $\alpha$  recycled at interim)**

Type of analysis	Time (months)	# Events	Testing boundary	
			p-value boundary	Approx. hazard ratio threshold
Interim analysis	11.7	109	0.0192	0.672
Final analysis	18.5	162	0.0123	0.703

## 10 STUDY COMMITTEES AND COMMUNICATION

### 10.1 Blinded Independent Central Review

A Blinded Independent Central Review (BICR) committee will be established to perform an independent review of all radiological images for the efficacy analysis and to determine all instances of response and disease progression based on RECIST v1.1 criteria, in addition to the local investigator review of radiographs. The results from the investigator's review of radiographic images will be used to determine whether patients should be enrolled or should continue study treatment. The tumor assessment by the BICR will be used for the reporting of the study results.

All decisions made during the performance of the study will be based on the local investigator's assessment of radiographic images, clinical status, and relevant examination of the patients. Sites will submit specific radiographic image files to the centralized data review facility during the study at an ongoing basis or at the sponsor's request. Detailed rules and guidelines for radiographic imaging and tumor assessments by the BICR are outlined separately in the Imaging Manual and the BICR Charter.

### 10.2 Independent Data Monitoring Committee

Safety monitoring and interim efficacy data review will be performed by an Independent Data Monitoring Committee (IDMC). The first safety monitoring and review will occur after the first



30 patients recruited have been on treatment for  $\geq 1$  month or completed at least 1 cycle of study treatment. Thereafter, IDMC will review data approximately every 4 months, or more frequently if indicated or requested by the medical monitor based on ongoing safety monitoring of patients on study. The IDMC may recommend study modification including early termination of the study due to safety concerns, or for evidence of compelling efficacy at a preplanned interim analysis. The function and membership of the IDMC will be described in the IDMC charter.

In addition to the planned IDMC review(s), ad hoc reviews may take place based on new information.

Following IDMC review and discussion, the sponsor will make all final decisions regarding any change in study conduct. Please see the details in the IDMC charter.

## **11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS**

The investigator must maintain adequate and accurate records to ensure that the conduct of the study may be fully documented. Such records include but are not limited to the protocol, protocol amendments, ICFs, and documentation of IRB/IEC and governmental approvals. In addition, at the end of the study, the investigator will receive patient data, which will include an audit trail containing a complete record of all changes to such data.

### **11.1 Access to Information for Monitoring**

In accordance with International Council for Harmonisation (ICH) GCP guidelines, the study monitor and/or designee must have direct access to the investigator's source documentation to verify the data recorded in the eCRFs for consistency.

The monitor is responsible for routine review of the eCRFs at regular intervals throughout the study to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them. The monitor should have access to any patient records needed to verify the entries on the eCRFs. The investigator agrees to cooperate with the monitor to ensure that any problems detected while these monitoring visits are resolved.

### **11.2 Access to Information for Auditing or Inspections**

Representatives of regulatory authorities or of BeiGene may conduct inspections or audits any time during or after completion of this clinical study. If the investigator is notified of an inspection by a regulatory authority the investigator agrees to notify the sponsor or its designee immediately. The investigator agrees to provide to representatives of a regulatory agency or BeiGene access to records, facilities, and personnel for the effective conduct of any inspection or audit.



---

## **12 QUALITY ASSURANCE AND QUALITY CONTROL**

### **12.1 Regulatory Authority Approval**

The sponsor will obtain approval to conduct the study from the appropriate regulatory agency in accordance with any applicable country-specific regulatory requirements or file the protocol to the appropriate regulatory agency before the study is initiated at a study center in that country.

### **12.2 Quality Assurance**

To ensure compliance with GCP and all applicable regulatory requirements, the sponsor may conduct a quality assurance audit. Regulatory agencies may also conduct a regulatory inspection of this study. Such audits/inspections can occur at any time during or after completion of the study. If an audit or inspection occurs, the investigator and institution agree to allow the auditor/inspector direct access to all relevant documents and to allocate his/her time and the time of his/her personnel to the auditor/inspector to discuss findings and any relevant issues.

### **12.3 Study Site Inspections**

This study will be organized, performed, and reported in compliance with the protocol, standard operating procedures, working practice documents, and applicable regulations and guidelines. Site audits may be made periodically by the sponsor's or the contract research organization's (CRO's) qualified compliance auditing team, which is an independent function from the study team responsible for conduct of the study.

Site visits will be conducted by the sponsor or an authorized representative to inspect study data, patients' medical records, and eCRFs. The investigator is to permit national and local health authorities; sponsor study monitors, representatives, and collaborators; and IRB/IEC members to inspect all facilities and records relevant to this study.

### **12.4 Drug Accountability**

The investigator or designee (ie, pharmacist) is responsible for ensuring adequate accountability of all used and unused study drug. This includes acknowledgment of receipt of each shipment of study product (quantity and condition), patient drug dispensation records, and returned or destroyed study product. Dispensation records will document quantities received from BeiGene's designated depot and quantities dispensed to patients, including batch number, date dispensed, patient identifier number, patient initials, and the initials of the person dispensing the medication.

At study initiation, the monitor will evaluate the site's standard operating procedure for study drug disposal/destruction to ensure that it complies with BeiGene requirements. At the end of the study, following final drug inventory reconciliation by the monitor, the study site will dispose of and/or destroy all unused study drug supplies, including empty containers, according to these procedures. If the site cannot meet BeiGene's requirements for disposal, arrangements will be made between the site and BeiGene or its representative for destruction or return of unused study drug supplies.

All drug supplies and associated documentation will be periodically reviewed and verified by the study monitor over the course of the study.

## **13 ETHICS/PROTECTION OF HUMAN PATIENTS**

### **13.1 Ethical Standard**

This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki or the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).

### **13.2 Institutional Review Board/Independent Ethics Committee**

This protocol, the ICFs, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/IEC by the principal investigator and reviewed and approved by the IRB/IEC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/IEC.

The principal investigator is responsible for providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC. Investigators are also responsible for promptly informing the IRB/IEC of any protocol amendments. In addition to the requirements for reporting all AEs to the sponsor, investigators must comply with requirements for reporting SAEs to the local health authority and IRB/IEC. Investigators may receive written investigational new drug safety reports or other safety-related communications from the sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed in accordance with health authority requirements and the policies and procedures established by their IRB/IEC and archived in the site's study file.

#### **13.2.1 Protocol Amendments**

Any protocol amendments will be prepared by the sponsor. All protocol modifications must be submitted to competent authorities according to local requirements and to the IRB/IEC together with, if applicable, a revised model ICF in accordance with local requirements. Written documentation from competent authorities (according to local requirements) and from the IRB/IEC and required site approval must be obtained by the sponsor before changes can be implemented, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (eg, change in medical monitor or contact information).

Information on any change in risk and/or change in scope must be provided to patients already actively participating in the study, and they must read, understand, and sign each revised ICF confirming willingness to remain in the study.

### 13.3 Informed Consent

The sponsor's sample ICF will be provided to each site. If applicable, it will be provided in a certified translation of the local language. The final IRB/IEC-approved ICFs must be provided to the sponsor for health authority submission purposes according to local requirements.

The ICFs must be signed and dated by the patient or the patient's legally authorized representative before his or her participation in the study. The case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study.

The ICFs will be revised whenever there are changes to study procedures or when new information becomes available that may affect the willingness of the patient to participate. The final revised IRB-/IEC-approved consent forms must be provided to the sponsor for health authority submission purposes.

Patients must be reconsented to the most current version of the ICFs (or to a significant new information/findings addendum in accordance with applicable laws and IRB/IEC policy) during their participation in the study. For any updated or revised ICFs, the case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained using the updated/revised ICFs for continued participation in the study.

A copy of each signed ICF must be provided to the patient or the patient's legally authorized representative. All signed and dated ICFs must remain in each patient's study file or in the site file and must be available for verification by study monitors at any time.

### 13.4 Patient and Data Confidentiality

The sponsor will maintain confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This approach ensures that patients' names are not included in any data set transmitted to any sponsor location.

Patient medical information obtained by this study is confidential and may only be disclosed to third parties as permitted by the signed ICF (or a separate authorization for the use and disclosure of personal health information that has been signed by the patient), unless permitted or required by law.

Medical information may be given to a patient's personal physician or other appropriate medical personnel responsible for the patient's welfare, for treatment purposes.

Data generated by this study must be available for inspection upon request by representatives of the FDA, China FDA, and all other national and local health authorities; by sponsor monitors, representatives, and collaborators; and by the IRBs/IECs for each study site, as appropriate.

The investigator must assure that patients' anonymity will be strictly maintained and that their identities are protected from unauthorized parties. The investigator agrees that all information received from the sponsor, including but not limited to the [REDACTED] this protocol, eCRFs, the investigational new drug, and any other study information, remains the sole and

exclusive property of sponsor during the conduct of the study and thereafter. This information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study, or as required by law) without prior written consent from the sponsor. The investigator further agrees to take all reasonable precautions to prevent the disclosure by any employee or agent of the study site to any third party or otherwise into the public domain.

### **13.5 Financial Disclosure**

Investigators are required to provide the sponsor with sufficient accurate financial information in accordance with regulations to allow the sponsor to submit complete disclosure or certification to the absence of certain financial interest of the clinical investigators and/or disclose those financial interests, as required to the appropriate health authorities. This is intended to ensure financial interests and arrangements of the clinical investigators with BeiGene that could affect reliability of data submitted to health authorities are identified and disclosed by the sponsor. Investigators are responsible for providing information about their financial interests before participation in the study, and to update this information if any relevant changes occur during the study and for 1 year after completion of the study (ie, last patient, last visit).

## **14 DATA HANDLING AND RECORD KEEPING**

### **14.1 Data Collection and Management Responsibilities**

#### **14.1.1 Data Collection**

Data required by the protocol will be entered into an EDC system.

Data collection in the eCRF should follow the instructions described in the eCRF Completion Guidelines (eCCGs). The investigator has ultimate responsibility for the collection and reporting of all clinical data entered in the eCRF. The investigator must sign the completed casebooks to attest to its accuracy, authenticity, and completeness.

Data contained in the eCRFs are the sole property of BeiGene and should not be made available in any form to third parties without written permission from BeiGene, except for authorized representatives of BeiGene or appropriate regulatory authorities.

#### **14.1.2 Data Management/Coding**

All final patient data, both eCRF and external data (eg, laboratory data), collected according to the protocol, will be stored at BeiGene at the end of the study.

Standard procedures (including following data review guidelines, computerized validation to produce queries, and maintenance of an audit file which includes all database modifications) will be followed to support accurate data collection. Data will be reviewed for outliers, logic, data inconsistencies, and completeness.

During the study, a study monitor (clinical research associate [CRA]) will make site visits to review protocol compliance, compare eCRFs against individual patient's medical records, and ensure that the study is being conducted according to pertinent regulatory requirements.

The eCRF entries will be verified with source documentation. The review of medical records will be performed in a manner to ensure that patient confidentiality is maintained. Checking the eCRFs for completeness, clarity, and cross checking with source documents is required to monitor the progress of the study. Direct access to source data is also required for inspections and audits and will be carried out with due consideration given to data protection and medical confidentiality.

AEs will be coded using the MedDRA Version 20.1 or higher. Concomitant medications will be coded using the World Health Organization Drug Dictionary. Concomitant diseases/medical history will be coded using the World Health Organization Drug Dictionary.

#### **14.2 Data Integrity and In-house Blinding**

Due to the open-label design of the study, access to the patient level clinical data in the EDC system will be assigned to predefined study personnel only. Functions/persons with access to the EDC system shall be prohibited from using the EDC system to generate unnecessary listings/summaries that may introduce unwanted bias, or share such outputs from the EDC system with other functions/persons who do not have access to the EDC. Although the study is open label, analyses or summaries generated by randomized treatment assignment and actual treatment received will be limited and documented.

#### **14.3 Study Records Retention**

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified. These documents should be classified into at least the following 2 categories: 1) the investigator's study file and 2) the patient clinical source documents.

The investigator's study file will contain the protocol/amendments, eCRF and query forms, IRB/IEC, and governmental approval with correspondence, informed consent, drug records, staff curriculum vitae and authorization forms, and other appropriate documents and correspondence.

Patient clinical source documents (usually defined by the project in advance to record key efficacy/safety parameters independent of the eCRFs) would include documents such as (although not be limited to) the following: patient hospital/clinic records, physician's and nurse's notes, appointment book, original laboratory reports, ECG, electroencephalogram, X-ray, pathology and special assessment reports, consultant letters, screening and enrollment log, etc.

Following closure of the study, the investigator must maintain all study records in a safe and secure location. The records must be maintained to allow easy and timely retrieval, when needed (eg, audit or inspection) and, whenever feasible, to allow any subsequent review of data in conjunction with assessment of the facility, supporting systems, and personnel. Where permitted by local laws/regulations or institutional policy, some of these records can be maintained in a format other than hard copy (eg, microfiche, scanned, electronic); however, caution needs to be exercised before

such action is taken. The investigator must assure that all reproductions are legible, are a true and accurate copy of the original, and meet accessibility and retrieval standards, including regenerating a hard copy, if required. Furthermore, the investigator must ensure that there is an acceptable backup of these reproductions and that an acceptable quality-control process exists for making these reproductions.

The sponsor will inform the investigator of the period for retaining these records to comply with all applicable regulatory requirements. The minimum retention time will meet the strictest standard applicable to that study center for the study, as dictated by any institutional requirements or local laws or regulations, or the sponsor's standards/procedures; otherwise, the retention period will default to 5 years.

The investigator must notify the sponsor of any changes in the archival arrangements, including, but not limited to archival at an off-site facility or transfer of ownership of the records in the event the investigator leaves the study center.

If the investigator cannot guarantee this archiving requirement at the study site for any or all of the documents, special arrangements must be made between the investigator and BeiGene to store these in sealed containers outside of the site so that they can be returned sealed to the investigator in case of a regulatory audit. When source documents are required for the continued care of the patient, appropriate copies should be made for storage outside of the site.

#### **14.4 Protocol Deviations**

The investigator is responsible for ensuring that the study is conducted in accordance with the procedures and evaluations described in this protocol. Investigators assert that they will apply due diligence to avoid protocol deviations.

The investigator is to document and explain any deviations from the approved protocol. The investigator must promptly report any major deviations that might impact patient safety and/or data integrity to the sponsor and to the IRB/IEC, in accordance with established IRB/IEC policies and procedures.

#### **14.5 Publication and Data-Sharing Policy**

A CSR will be prepared and provided to the regulatory agency(ies). BeiGene will ensure that the report meets the standards set out in the ICH Guideline for Structure and Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in certain cases.

The results of this study will be published or presented at scientific meetings in a timely, objective, and clinically meaningful manner that is consistent with good science, industry, and regulatory guidance, and the need to protect the intellectual property of BeiGene (sponsor), regardless of the outcome of the study. The data generated in this clinical study are the exclusive property of the sponsor and are confidential. For multicenter studies, the first publication or disclosure of study results shall be a complete, joint, multicenter publication or disclosure coordinated by the sponsor. Thereafter, any secondary publications will reference the original publication(s). Authorship will be determined by mutual agreement and all authors must meet the criteria for authorship established by

the International Committee of Medical Journal Editors Uniform Requirements for Manuscripts or stricter local criteria ([International Committee of Medical Journal Editors 2016](#)).

After conclusion of the study and without prior written approval from BeiGene, investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media *only after the following conditions have been met*:

- The results of the study in their entirety have been publicly disclosed by or with the consent of BeiGene in an abstract, manuscript, or presentation form; or
- The study has been completed at all study sites for  $\geq 2$  years.
- No such communication, presentation, or publication will include BeiGene's confidential information.
- Each investigator agrees to submit all manuscripts or congress abstracts and posters/presentations to the sponsor prior to submission. This allows the sponsors to protect proprietary information, provide comments based on information from other studies that may not yet be available to the investigator, and ensure scientific and clinical accuracy. The details of the processes of producing and reviewing reports, manuscripts, and presentations based on the data from this study will be presented in the investigator's clinical study agreement.

#### **14.6 Study and Study Center Closure**

Upon completion of the study, the monitor will conduct the following activities in conjunction with the investigator or study center personnel, as appropriate:

- Return of all study data to the sponsor
- Resolve and close all data queries
- Accountability, reconciliation, and arrangements for unused study drug(s)
- Review of study records for completeness
- Return of treatment codes to the sponsor
- Shipment of PK samples to assay laboratories

In addition, the sponsor reserves the right to suspend or prematurely discontinue this study or suspend enrollment either at a single study center or at all study centers at any time for reasons including, but not limited to, safety or ethical issues or severe noncompliance. If the sponsor determines such action is needed, the sponsor will discuss this with the investigator (including the reasons for taking such action) at that time. When feasible, the sponsor will provide advance notification to the investigator of the impending action prior to it taking effect.

The sponsor will promptly inform all other investigators and/or institutions conducting the study if the study is suspended or terminated for safety reasons, and will also inform the regulatory authorities of the suspension or termination of the study and the reason(s) for the action. If required



by applicable regulations, the investigator must inform the IEC/IRB promptly and provide the reason for the suspension or termination.

If the study is prematurely discontinued, all study data must be returned to the sponsor. In addition, arrangements will be made for all unused study drug(s) in accordance with the applicable sponsor procedures for the study.

Financial compensation to the investigators and/or institutions will be in accordance with the agreement established between the investigator and the sponsor.

#### **14.7 Information Disclosure and Inventions**

All information provided by the sponsor and all data and information generated by the study center as part of the study (other than a patient's medical records) are the sole property of the sponsor.

All rights, title, and interests in any inventions, know-how, or other intellectual or industrial property rights which are conceived or reduced to practice by the study center personnel while or because of the study are the sole property of the sponsor and are hereby assigned to the sponsor.

If a written contract for the conduct of the study which includes ownership provisions inconsistent with this statement is executed between the sponsor and the study center, that contract's ownership provisions shall apply rather than this statement.

All information provided by the sponsor and all data and information generated by the study center as part of the study (other than a patient's medical records) will be kept confidential by the investigator and other study center personnel. This information and data will not be used by the investigator or other study center personnel for any purpose other than conducting the study without the prior written consent of the sponsor.

These restrictions do not apply to:

- Information which becomes publicly available through no fault of the investigator or study center personnel
- Information which is necessary to disclose in confidence to an IEC/IRB solely for the evaluation of the study
- Information which is necessary to disclose to provide appropriate medical care to a patient
- Study results which may be published as described in [Section 14.5](#)

If a written contract for the conduct of the study which includes provisions inconsistent with this statement is executed, that contract's provisions shall apply rather than this statement.





- Chen W, Zheng R, Baade P, et al. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016;66(2):115-32.
- Chiba K, Yoshitsugu H, Kyosaka Y, et al. A comprehensive review of the PK of approved therapeutic monoclonal antibodies in Japan: Are Japanese Phase 1 studies still needed? *J Clin Pharmacol*. 2014;54(5):483-94.
- Crino L, Kim D, Riely GJ, et al. Initial Phase 2 results with crizotinib in advanced ALK positive non-small cell lung cancer (NSCLC): PROFILE 1005. *J Clin Oncol* 2011;29: abstract 7514.
- Dajczman E, Kasymjanova G, Kreisman H, et al. Should patient-rated performance status affect treatment decisions in advanced lung cancer? *J Thorac Oncol*. 2008;3(10):1133-6.
- Derman BA, Mileham KF, Bonomi PD, et al. Treatment of advanced squamous cell carcinoma of the lung: a review. *Transl Lung Cancer Res*. 2015;4(5):524-32.
- Desai J, Millward M, Chao Y, et al. Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). European Society of Medical Oncology Meeting 2017, poster 387P, *Annals of Oncology*. 2017;28 (suppl5): v122-41.
- Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol* 2014;32:1277-80.
- European Medicines Agency Guideline on the evaluation of anticancer medicinal products in man. EMA/CHPM/205/95/Rev.4 (December 2012).
- Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. *Cancer Treatment Rev*. 2016;44:42-50.
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-86.
- Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov* 2004;3:391-400.
- Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. May 2007. Available from: <http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071590.pdf>
- Food and Drug Administration. Product labels for FDA approved drug products are available online: <http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed 01 February 2017.
- Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a Phase 3, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol* 2011;29:2866-74.
- Gandara DR, Pawel JV, Sullivan R, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: results from the randomized Phase III OAK study. *J Clin Oncol*. 2017;35(suppl\_15):9001.

Garon E, Gandhi L, Rizvi N, et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). *Ann Oncol* 2014; 25:1-41.

Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med* 2015;372:2018-28.

Gaschler-Markefski B, Sikken P, Heymach JV, et al. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. *ESMO Open*. 2017;2(1):e000102.

Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. *J Clin Oncol*. 2015;33(18):2004-12.

Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007;2(8):706-14.

Gong W, Song Q, Lu X, et al. Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway. *J Chemother*. 2011;23(5):295-9.

Gou LY, Wu YL. Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China. *Lung cancer (Auckl)*. 2014;5:1-9.

Haanen JBAG, Carbone F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. *Ann Oncol*. 2017;28(suppl4):iv119-42.

Hellmann, M, et al. Gettinger S, Goldman J, et al. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. *J Clin Oncol*. 2016;34(suppl15):3001.

Hellmann M, Rizvi, NA, Goldman, JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *The Lancet Oncology* 2017;18:31-41.

Herbst RS, Soria JC, Kowanetz M, et al. Pre-dictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature*. 2014;515:563-7.

Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016;387(10027):1540-50.

Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. *J Thorac Oncol*. 2017;12(2):208-22.

Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *The Lancet Oncology* 2016;17(11):1558-68.

- Horvath L, Desai J, Sandhu S, et al. Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). European Society of Medical Oncology Meeting 2017, poster 388P, *Annals of Oncology*. 2017;28(suppl5): v122-41.
- Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer. *J Clin Oncol* 2004;22:3852-9.
- Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI- 007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. *Clin Cancer Res* 2002;8:1038-44.
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. 2016. Available online: <http://www.icmje.org>. Accessed 08 August 2017.
- Jiang L, Yang K, Mi D, et al. Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis. *Clin Lung Cancer* 2007;8:497-501.
- Jin Z, Yoon HH. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. *J Gastrointest Oncol*. 2016;7:771-88.
- Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol*. 2004;22:2184-91.
- Kelly K, Crowley J, Bunn PA Jr, et al: Randomized Phase 3 trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. *J Clin Oncol*. 2001;19:3210-18.
- Kerr K, Tsao M, Nicholson A, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art? *J Thorac Oncol*. 2015;10:985–9.
- Keytruda [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2014.
- Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. *J Immuno Methods*. 2008;333:1-9.
- Labrijn AF, Buijsse AO, van den Bremer ET, et al., Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. *Nat Biotechnol*. 2009;27(8):767-71.
- Langer C, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomized , phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol* 2016; 17:1497-508.
- Laporte S, Squifflet P, Baroux N, et al. Prediction of survival benefits from progression free survival benefits in advanced non-small cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomized trials. *BMJ Open* 2013;3:1-6.
- Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). *J Clin Oncol*. 2005; 23(1):190–6.

McDaniel AS, Alva A, Zhan T, et al. Expression of PD-L1 (B7-H1) before and after neoadjuvant chemotherapy in urothelial carcinoma. *Euro Urol Focus*. 2016;1(3):265–8.

Meniawy T, Richardson G, Townsend A, et al. Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). European Society of Medical Oncology Meeting 2017, Poster 389P, *Annals of Oncology*. 2017;28(suppl5): v122-41.

Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2015;373(19):1803-13.

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Health.

[https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_8.5x11.pdf](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).

Accessed 25 December 2017.

National Comprehensive Cancer Network: NSCLC Guidelines v7. 2017. [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp#nsc1](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nsc1)

Ohe Y, Ohashi Y, Kubota K, et al., Randomized Phase 3 study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol*. 2007;18(2):317-23.

Oliver TG, Patel J, Akerley W. Squamous non-small cell lung cancer as a distinct clinical entity. *Am J Clin Oncol*. 2015;38(2):220-6.

Ono Pharmaceutical Co, Ltd. Available online:

[https://www.ono.co.jp/eng/news/pdf/sm\\_cn161227.pdf](https://www.ono.co.jp/eng/news/pdf/sm_cn161227.pdf). Accessed 01 February 2017.

Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. *Mol Cancer Ther*. 2015;14(4):847–56.

PDQ Adult Treatment Editorial Board. Non-Small Cell Lung Cancer Treatment (PDQ<sup>®</sup>): Health Professional Version. 2017 Dec 1. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. <https://www.ncbi.nlm.nih.gov/books/NBK65865/>. Accessed 01 December 2017.

PDQ Adult Treatment Editorial Board. Small Cell Lung Cancer Treatment (PDQ<sup>®</sup>): Health Professional Version. 2017 Jan 20. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. <https://www.ncbi.nlm.nih.gov/books/NBK65909/>. Accessed 21 December 2017.

Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small cell lung cancer. *N Eng J Med*. 2016;375:1823-33.

Reck M, Socinski MA, Cappuzzo F, et al. LBA1\_PR Primary PFS and safety analyses of a randomized phase III study of carboplatin+ paclitaxel+/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150). *Annals of Oncology*. 2017 Dec 1;28(suppl\_11):mdx760-002.

Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*. 2017;389(10066):255-65.

Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *The Lancet Oncology*. 2015;16:257-65.

Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, et al. Nivolumab in combination with platinum - based doublet chemotherapy for first-line treatment of advanced non - small-cell lung cancer. *Journal of Clinical Oncology*. 2016 Jun 27;34(25):2969-79.

Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2012;13(3):239-46.

Roviello G, Bachelot T, Hudis CA, et al. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. *Eur J Cancer*. 2017;75:245-58.

Sandler S, Gray R, Perry M, et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *NEJM*. 2006;355:2542-50.

Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*. 2002;346:92-8.

Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. *J Clin Oncol*. 2002;20(21):4285-42.

Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus peme-trexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol*. 2008;26:3543–51.

Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. *J Clin Oncol*. 2010; 28: 1835–42.

Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *Journal of clinical oncology*. 2013;31(27):3327-34.

Shaw AT, Kim DW, Nakagawa K, et al. Phase 3 study of crizotinib versus pemetrexed or docetaxel in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). *European Society of Medical Oncology Meeting 2012:abstract LBA1*.

Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. *Resuscitation*. 2008;77(2):157-69.



Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. *J Thorac Oncol*. 2010;5(6):852-61.

Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol*. 2012;30(17):2055-62.

Socinski, M, Creelan B, Horn L, et al. CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)- positive NSCLC. *Ann Oncol*. 2016;27(suppl6):LBA7\_PR.

Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. *Ann Oncol*. 2013; 24(1): 20–30.

Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. *Oncologist*. 2008;13 Suppl 1:28-36.

Taxol (paclitaxel) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2011.

ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. *Clin Pharmacokinet*. 2003;42(7):665-85.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012;366(26):2443-54.

Van Der Kraak L, Goel G, Ramanan K, et al. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. *J Immunother Cancer*. 2016;4:65.

Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. *Cancer Immunol Res*. 2014;2(9):846-56.

Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2015;16:375-84.

Worobec AS, Rosenberg AS. A risk-based approach to immunogenicity concerns of therapeutic protein products: Part 1. Considering consequences of the immune response to a protein. *BioPharm Intl*. 2004a;17(11):22-26.

Worobec AS, Rosenberg AS. A risk-based approach to immunogenicity concerns of therapeutic protein products, Part 2: Considering host-specific and product-specific factors impacting immunogenicity. *BioPharm Intl*. 2004b;17(12) :34-42.

XALKORI® (crizotinib) [prescribing information]. US, Pfizer.

Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX Lung 2): a Phase 2 trial. *Lancet Oncol* 2012;13:539-48.

Yang J, Huang C, Song Y, et al. A phase II trial of first-line nab-paclitaxel/carboplatin versus gemcitabine/carboplatin in advanced squamous cell carcinoma of the lung (CTONG1002). *J Clin Oncol*. 2014;32(suppl 5):abstract 8085.

Zhi XY, Wu YL, Bu H, et al. Chinese guidelines on the diagnosis and treatment of primary lung cancer (2011). *J Thorac Dis*. 2012;4(1):88-101.

ZYKADIA® (ceritinib) [prescribing information]. East Hanover, New Jersey; Novartis Pharmaceuticals Corporation.



**APPENDIX 1. SCHEDULE OF ASSESSMENTS**

Assessment	Screening <sup>1</sup>	Treatment Cycles					Safety Follow-up <sup>3</sup>	Survival Follow-up <sup>4</sup>
		Cycles 1 to 4 (every 21 days)			Cycle 5 and subsequent cycles (every 21 days)	End of Treatment Visit <sup>2</sup>		
Days (Window)	-28 to ~-1	1	8	15	1 (± 3)	0 to 7 Days	30 ± 7 Days After Last Dose	Every 3 Months
Informed consent	X							
Inclusion/exclusion criteria	X							
Randomization		X <sup>5</sup>						
Demographics/medical history/prior medications <sup>6</sup>	X							
Vital signs/ height and weight <sup>7</sup>	X	X			X	X	X	
Physical examination <sup>8</sup>	X	X			X	X	X	
ECOG Performance Status	X	X			X	X	X	
12-lead ECG <sup>9</sup>	X						X	
Adverse events <sup>10</sup>	X	X	X	X	X	X	X	X
Concomitant medications	X	X	X	X	X	X	X	
Hematology <sup>11</sup>	X <sup>1</sup>	X	X	X	X	X <sup>2</sup>	X	
Serum chemistry <sup>11</sup>	X <sup>1</sup>	X	X	X	X	X <sup>2</sup>	X	
Coagulation parameters <sup>11,12</sup>	X	X			X	X <sup>2</sup>	X	
Urinalysis <sup>11</sup>	X	As clinically indicated						
Pregnancy test <sup>13</sup>	X					X		
Thyroid function (every 3 cycles) <sup>14</sup>	X <sup>1</sup>				X <sup>14</sup>		X	
HBV/HCV tests <sup>15</sup>	X	As clinically indicated						
Pulmonary function tests <sup>16</sup>	X							

Assessment	Screening <sup>1</sup>	Treatment Cycles					Safety Follow-up <sup>3</sup>	Survival Follow-up <sup>4</sup>
		Cycles 1 to 4 (every 21 days)			Cycle 5 and subsequent cycles (every 21 days)	End of Treatment Visit <sup>2</sup>		
Days (Window)	-28 to ~-1	1	8	15	1 (± 3)	0 to 7 Days	30 ± 7 Days After Last Dose	Every 3 Months
Pharmacokinetics <sup>17</sup>		X			X		X	
Anti-tislelizumab antibodies <sup>18</sup>		X			X		X	
Tumor assessment <sup>19</sup>	X				X	X <sup>2</sup>		X
Archival/fresh tumor tissue <sup>20</sup>	X					X (optional)		
Blood collection (optional) <sup>21</sup>		X						
Tislelizumab administration <sup>22</sup>		X			X			
Carboplatin and paclitaxel administration <sup>23</sup>		X			X <sup>23</sup>			
<i>Nab</i> -paclitaxel administration <sup>23</sup>		X	X	X	X <sup>23</sup>			
EORTC QLQ-C30 <sup>24</sup>	X	X			X	X		
EORTC QLQ-LC 13 <sup>24</sup>	X	X			X	X		
Survival status								X

Abbreviations: ADA, antidrug antibody; AE, adverse event; AUC, area under the plasma or serum concentration-time curve; ECG, electrocardiogram; ECOG, Eastern Cooperative Oncology Group; EORTC QLQ-LC 13, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer-13 Questions; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; FPPE, formalin-fixed paraffin-embedded; HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HBsAb, hepatitis B surface antibody; IEC, Independent Ethics Committee; irAE, immune-related adverse event; IRB, Institutional Review Board; IRC, Independent Review Committee; IRT, interactive response technology; IV, intravenous; MRI, magnetic resonance imaging; PET, 18F-sodium fluoride position emission tomography; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; PK, pharmacokinetic; Q3W, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumors; SAE, serious adverse event; tumor mutation burden; TSH, thyroid stimulating hormone; v, version.

1. Written informed consent is required prior to performing any study-specific tests or procedures. Results of standard of care tests or examinations performed prior to obtaining informed consent and within 28 days prior to randomization may be used for screening assessments rather than repeating such tests. Fresh tumor biopsy is permitted to be conducted up to 42 days prior to Cycle 1 Day 1, if no archival tumor tissue is available.
2. The End of Treatment Visit is conducted when the Investigator determines that tislelizumab and/or chemotherapy will no longer be used. If routine laboratory tests (eg, hematology, serum chemistry) are completed within 7 days before the End of Treatment Visit, tests need not be repeated. Tumor assessment is not required at the End of Treatment Visit provided that fewer than 6 weeks have passed since the last assessment.
3. The Safety Follow-up Visit is required to be conducted 30 days (± 7 days) after the last dose of tislelizumab and/or chemotherapy, or before the initiation of a new anticancer treatment, whichever occurs first.

4. Survival Follow-up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months after the Safety Follow-up Visit until death, loss to follow-up, withdrawal of consent, or study termination by sponsor. All patients will be followed for survival and subsequent anticancer therapy information unless a patient requests to be withdrawn from follow-up.
5. Patients will be randomized into either Arm A or Arm B or Arm C via IRT. All patients are required to receive study treatment within 2 business days of randomization.
6. Includes age or date of birth, gender, and self-reported race/ethnicity; history of treatment for the primary diagnosis, including prior medication, loco-regional treatment(s), and surgical treatment(s). Information on radiographic studies performed prior to study entry may be collected for review by the Investigator.
7. Vital signs collected on study include temperature, pulse rate, and blood pressure. The patient's vital signs are required to be recorded within 60 minutes before; during; and 30 minutes after the first 2 infusion of tislelizumab. For subsequent infusions, vital signs will be collected within 60 minutes before infusion and if clinically indicated, during and 30 minutes after the infusion. Height should only be measured and recorded during screening.
8. During the Screening Visit, a complete physical examination will be conducted. At subsequent visits (and as clinically indicated), limited, symptom-directed physical examinations will be performed.
9. The ECG recordings will be obtained during screening, the Safety Follow-up Visit, and as clinically indicated at other timepoints. When coinciding with blood draws, ECG assessment should be performed prior to blood draws. Patients should be resting in semirecumbent supine position for  $\geq 10$  minutes prior to each ECG measurement.
10. The AEs and laboratory abnormalities will be graded per NCI-CTCAE v4.03. All AEs will also be evaluated for seriousness. After the informed consent form has been signed, but prior to the administration of study drug, only SAEs should be reported. After the first dose of study drug, all AEs and SAEs, regardless of their assessed relationship to study drug, are to be reported until either 30 days after the last dose of study treatment (including chemotherapy) or the initiation of new anticancer therapy, whichever occurs first. In addition, telephone contacts with patients should be conducted to assess AEs and concomitant medications (if appropriate, ie, associated with an AE or is a new anticancer therapy) at 60 days, and 90 days ( $\pm 14$  days) after the last dose of study drug (including chemotherapy-only), regardless of whether the patient starts a new anticancer therapy. Immune-related AEs (serious or nonserious) will be reported until 90 days after the last dose of tislelizumab, regardless of whether the patient starts a new anticancer therapy. The investigator should report any SAEs that are assessed as related to tislelizumab treatment, at any time after treatment discontinuation.
11. Local and/or central laboratory assessments on serum chemistry, hematology, coagulation, and urinalysis will be conducted, of which certain elements will be collected as specified in Section 7.5.4. If laboratory tests at screening are not performed within 7 days of randomization, these tests should be repeated and reviewed before randomization. Hematology and serum chemistry (including liver function tests) will be performed weekly for the duration of chemotherapy treatment, and at the beginning of subsequent cycles upon completion of 4 to 6 cycles of chemotherapy or discontinuation of chemotherapy (data collected as specified in Section 7.5.4). After Cycle 1, results are to be reviewed within 48 hours before study drug administration. Urinalysis is to be conducted during the treatment period only if clinically warranted. Refer to Section 8.4.5 for additional information regarding clinical assessment and management of clinical laboratory abnormalities.
12. Includes international normalized ratio, prothrombin time, and activated partial thromboplastin time.
13. Urine or serum pregnancy test (for women of childbearing potential, including women who have had a tubal ligation) must be performed and documented as negative within 7 days prior to randomization. Urine pregnancy tests will be performed at each visit prior to dosing. A serum pregnancy test must be performed if the urine pregnancy test is positive or equivocal.
14. Analysis of free T3, free T4, and TSH will be performed by a central laboratory or the local study site laboratory. Thyroid function tests will be performed at screening and every 3 cycles (ie, Day 1 of Cycles 4, 7, 10, etc), and at the Safety Follow-up Visit.
15. Testing will be performed by a central laboratory and/or the local laboratory at screening and will include HBV/HCV serology (HBsAg, HBsAb, HBcAb, and HCV antibody) and viral load assessment (HBV DNA and HCV RNA).

16. Pulmonary function test including spirometry and diffusion capacity is to be performed for all patients at baseline. Patients who are suspected to have serious/severe respiratory conditions or exhibit significant respiratory symptoms unrelated to the underlying cancer should consult a pulmonologist. Respective test results and consultation report, if applicable, will need to be submitted to the medical monitor and/or designee, and will need to be discussed with investigator and sponsor for eligibility.
17. PK samples will be collected only in patients randomized to receive tislelizumab and in sites that are able to adequately perform PK sampling and handling. For tislelizumab, predose (within 60 minutes before starting infusion) samples are required to be collected at Day 1 of Cycles 1, 2, 5, 9 and 17; A postdose (within 30 minutes after completing tislelizumab infusion) sample is required to be collected at Day 1 of Cycles 1 and 5. An additional PK sample is required to be collected at the mandatory Safety Follow-up. Should a patient present with any  $\geq$  Grade 3 irAE, an additional blood PK sample may be taken to determine the serum concentration of tislelizumab. These tests are required when it is allowed by local regulations/IRBs/IECs.
18. ADA samples will be collected only in patients randomized to receive tislelizumab combined chemotherapy patients and in sites that are able to adequately perform ADA sampling and handling. Blood used to test for anti-tislelizumab antibodies should be collected within 60 minutes before beginning the Day 1 infusion of Cycles 1, 2, 5, 9 and 17, and at the mandatory Safety Follow-up Visit. All samples should be drawn at the same time as blood collection for predose PK analysis. These tests are required when it is allowed by local regulations/IRBs/IECs.
19. Radiological images captured as standard of care prior to obtaining written informed consent and within 28 days of randomization may be used rather than repeating tests, provided they meet the protocol specifications. All measurable and evaluable lesions are required to be assessed and documented at the Screening Visit and reassessed at each subsequent tumor evaluation. An MRI (or CT scan if MRI is contraindicated or not readily available) of the head is required at screening; bone scan or PET is required if clinically indicated. The same radiographic procedure must be used throughout the study for each patient.  
The Investigator must review radiograph results before dosing at the next cycle. Patients will undergo tumor assessments approximately every 6 weeks ( $\pm$  7 days) during Year 1 and every 12 weeks ( $\pm$  7 days) from Year 2 onwards (based on RECIST v1.1 assessment). The Investigator may perform additional scans or more frequent assessments if clinically indicated. See [Section 7.6](#) for more information. Patients who discontinue study treatment early for reasons other than disease progression (eg, toxicity) will continue to undergo tumor assessments following the original plan until the patient experiences disease progression, withdraws consent, dies, or until the study terminates, whichever occurs first.
20. Patients are required to provide archival tumor tissues (FFPE blocks or approximately 15 [ $\geq$  6] unstained slides) for biomarker analysis. Fresh biopsy: In the absence of sufficient archival tumor tissues, a fresh biopsy of a tumor lesion at baseline (within 42 days before randomization) is mandatory (written informed consent is required prior to fresh tumor biopsies). See [Section 7.8](#) for more information. Patients who have progressive disease will be asked to provide optional biopsy for the assessment of mechanism of resistance (written informed consent is required prior to fresh tumor biopsy).
21. Optional blood samples will be taken at baseline (predose, on Cycle 1 Day 1), at the time of first tumor response and at the time of disease progression (10 mL each timepoint) for all randomized patients to explore the association with response, resistance and prognosis to tislelizumab in combination with chemotherapy or chemotherapy alone. Written patient consent is required for blood sample collection.
22. Tislelizumab will be given IV Q3W for patients in Arm A and Arm B. The initial infusion (Cycle 1, Day 1) will be delivered over 60 minutes, and then can be administered over 30 minutes for subsequent infusions if well tolerated. Patients must be monitored for  $\geq$  1 hour after infusion of tislelizumab on Day 1 of Cycle 1 and Cycle 2; from Cycle 3 onward, a monitoring period of  $\geq$  30 minutes is required. Treatment could continue beyond progression if clinical benefit is seen and treatment is tolerated per the investigator's discretion. Patients should sign an informed consent form for continued treatment beyond RECIST v1.1. Patients in Arm C who will be receiving tislelizumab following crossover after IRC confirmed radiographic disease progression on chemotherapy should not initiate treatment with tislelizumab prior to resolution of treatment-related toxicities to  $\leq$  Grade 1 or baseline, with the exception of select chemotherapy-related toxicities such as hair loss, but should be initiated within 42 days (if applicable), and upon consultation with the medical monitor. Patients in Arm C should follow the same schedule of assessments. Refer to [Section 7.4](#) for further specifications regarding crossover.
23. Chemotherapy will be given IV for all patients for 4 to 6 cycles. Carboplatin AUC 5, D1; paclitaxel 175 mg/m<sup>2</sup>, D1; nab-paclitaxel 100 mg/m<sup>2</sup>, D1, D8, and D15. Refer to [Section 5.2.2](#) for detail dose and schedule.

24. To be completed prior to any clinical activities during on-study site visits. EORTC QLQ-C30, and EORTC QLQ-LC 13 will be completed at screening and/or baseline, at every other cycle through Cycle 12, then every 4 cycles thereafter, and at the end of treatment.

---

## APPENDIX 2. ECOG PERFORMANCE STATUS

Grade	Description
0	Fully active, able to carry on all predisease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light housework, office work
2	Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about > 50% of waking hours
3	Capable of only limited self-care, confined to bed or chair > 50% of waking hours
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5	Dead

As published by Oken MM, Creech RH, Tormey DC, et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.

---

### APPENDIX 3. THE RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST) GUIDELINES, VERSION 1.1

The text below was obtained from the following reference:

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1). *Eur J Cancer*. 2009;45:228-247.

#### DEFINITIONS

Response and progression will be evaluated in this trial using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee (v1.1). Changes in only the largest diameter (uni-dimensional measurement) of the tumor lesions are used in RECIST criteria.

Note: Lesions are either measurable or nonmeasurable using the criteria provided below. The term “evaluable” in reference to measurability will not be used because it does not provide additional meaning or accuracy.

#### Measurable Disease

Tumor lesions: Must be accurately measured in at least 1 dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of:

- 10 mm by CT scan (irrespective of scanner type) and MRI (no less than double the slice thickness and a minimum of 10 mm)
- 10 mm caliper measurement by clinical exam (when superficial)
- 20 mm by chest X-ray (if clearly defined and surrounded by aerated lung)

Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be  $\geq 15$  mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will be measured and followed.

#### Nonmeasurable Disease

All other lesions (or sites of disease), including small lesions (longest diameter  $\geq 10$  to  $< 15$  mm with conventional techniques or  $< 10$  mm using spiral CT scan), are considered nonmeasurable disease. Leptomeningeal disease, ascites, pleural, or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical examination that is not measurable by reproducible imaging techniques are all nonmeasurable.

Bone lesions:

- Bone scan, PET scan, or plain films are not considered adequate imaging techniques to measure bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.



- Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft-tissue components that can be evaluated by cross sectional imaging techniques such as CT or MRI can be considered as measurable lesions if the soft tissue component meets the definition of measurability described above.
- Blastic bone lesions are nonmeasurable.

Cystic lesions:

- Lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor nonmeasurable) since they are, by definition, simple cysts.
- Cystic lesions thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above. However, if noncystic lesions are present in the same patient, these are preferred for selection as target lesions.

Lesions with prior local treatment:

- Tumor lesions situated in a previously irradiated area, or in an area patiented to other loco-regional therapy, are usually not considered measurable unless there has been demonstrated progression in the lesion. Trial protocols should detail the conditions under which such lesions would be considered measurable.

Target Lesions

All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total should be identified as target lesions and recorded and measured at baseline. Target lesions should be selected based on their size (lesions with the longest diameter) and be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements.

Lymph nodes merit special mention since they are normal anatomical structures which may be visible by imaging even if not involved by tumor. Pathological nodes which are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of  $\geq 15$  mm by CT scan. Only the short axis of these nodes will contribute to the baseline sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is involved by solid tumor. Nodal size is normally reported as 2 dimensions in the plane in which the image is obtained (for CT scan, this is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. For example, an abdominal node which is reported as being 20 mm x 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis  $\geq 10$  mm but  $< 15$  mm) should be considered nontarget lesions. Nodes that have a short axis  $< 10$  mm are considered nonpathological and should not be recorded or followed.

A sum of the diameters (longest for nonnodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be included in the sum, then as noted above, only the short axis is added into the sum. The baseline

sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.

### Nontarget Lesions

All other lesions (or sites of disease) including pathological lymph nodes should be identified as nontarget lesions and should also be recorded at baseline. Measurements are not required and these lesions should be followed as “present,” “absent,” or in rare cases “unequivocal progression” (more details to follow). In addition, it is possible to record multiple nontarget lesions involving the same organ as a single item on the case record form (eg, “multiple enlarged pelvic lymph node” or “multiple liver metastases”).

### **GUIDELINES FOR EVALUATION OF MEASURABLE DISEASE**

All measurements should be recorded in metric notation, using calipers if clinically assessed. All baseline evaluations should be performed as close as possible to the treatment start and never > 4 weeks before the beginning of the treatment.

The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow-up. Imaging based evaluation should always be done rather than clinical examination unless the lesion(s) being followed cannot be imaged but are accessible by clinical examination.

Clinical lesions: Clinical lesions will only be considered measurable when they are superficial and P10 mm diameter as assessed using calipers (eg, skin nodules). For the case of skin lesions, documentation by color photography including a ruler to estimate the size of the lesion is suggested. As noted above, when lesions can be evaluated by both clinical examination and imaging, imaging evaluation should be undertaken since it is more objective and may also be reviewed at the end of the trial.

- Chest X-ray: Chest CT is preferred over chest X-ray, particularly when progression is an important endpoint, since CT is more sensitive than X-ray, particularly in identifying new lesions. However, lesions on chest X-ray may be considered measurable if they are clearly defined and surrounded by aerated lung.
- CT, MRI: CT is the best currently available and reproducible method to measure lesions selected for response assessment. This guideline has defined measurability of lesions on CT scan based on the assumption that CT slice thickness is 5 mm or less. When CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations (eg, for body scans).
- Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a method of measurement. Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same technique and measurements will be taken from one assessment to the next. If new lesions are identified by ultrasound while the study, confirmation by CT or

MRI is advised. If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances.

- Endoscopy, laparoscopy: The utilization of these techniques for objective tumor evaluation is not advised. However, they can be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials where recurrence following complete response or surgical resection is an endpoint.
- Tumor markers: Tumor markers alone cannot be used to assess objective tumor response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response. Because tumor markers are disease specific, instructions for their measurement should be incorporated into protocols on a disease specific basis. Specific guidelines for both CA-125 response (in recurrent ovarian cancer) and prostate-specific antigen response (in recurrent prostate cancer), have been published. In addition, the Gynecologic Cancer Intergroup has developed CA-125 progression criteria which are to be integrated with objective tumor assessment for use in first-line trials in ovarian cancer.
- Cytology, histology: These techniques can be used to differentiate between PR and CR in rare cases if required by protocol (for example, residual lesions in tumor types such as germ cell tumors, where known residual benign tumors can remain). When effusions are known to be a potential adverse effect of treatment (eg, with certain taxane compounds or angiogenesis inhibitors), the cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment can be considered if the measurable tumor has met criteria for response or stable disease to differentiate between response (or stable disease) and progressive disease.

## RESPONSE CRITERIA

### Evaluation of Target Lesions

- Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm.
- Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of  $\geq 5$  mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
- Lymph nodes: Lymph nodes identified as target lesions should always have the actual short axis measurement recorded (measured in the same anatomical plane as the baseline

examination), even if the nodes regress to below 10 mm on study. This means that when lymph nodes are included as target lesions, the “sum” of lesions may not be zero even if complete response criteria are met, since a normal lymph node is defined as having a short axis of < 10 mm. Case report recorded in a separate section where, to qualify for CR, each node must achieve a short axis < 10 mm. For PR, SD and PD, the actual short axis measurement of the nodes is to be included in the sum of target lesions.

- Target lesions that become “too small to measure.” While on study, all lesions (nodal and non-nodal) recorded at baseline should have their actual measurements recorded at each subsequent evaluation, even when very small (eg, 2 mm). However, sometimes lesions or lymph nodes which are recorded as target lesions at baseline become so faint on CT scan that the radiologist may not feel comfortable assigning an exact measure and may report them as being “too small to measure.”

When this occurs, it is important that a value be recorded on the eCRF. If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm. If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned (Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable size when normal and are frequently surrounded by fat such as in the retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned in this circumstance as well). This default value is derived from the 5 mm CT slice thickness (but should not be changed with varying CT slice thickness). The measurement of these lesions is potentially non-reproducible, therefore providing this default value will prevent false responses or progressions based upon measurement error. To reiterate, however, if the radiologist can provide an actual measure, that should be recorded, even if it is below 5 mm.

- Lesions that split or coalesce on treatment: When non-nodal lesions “fragment,” the longest diameters of the fragmented portions should be added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximal longest diameter for the “coalesced lesion.”

#### Evaluation of Nontarget Lesions

While some nontarget lesions may be measurable, they need not be measured and instead should be assessed only qualitatively at the timepoints specified in the protocol.

- CR: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be nonpathological in size (< 10 mm short axis).
- PD: Unequivocal progression (as detailed below) of existing nontarget lesions. (Note: the appearance of one or more new lesions is also considered progression.)

- Non-CR/Non-PD: Persistence of one or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits.
- When the patient also has measurable disease: In this setting, to achieve “unequivocal progression” based on the nontarget disease, there must be an overall level of substantial worsening in nontarget disease such that, even in presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest “increase” in the size of one or more nontarget lesions is usually not sufficient to qualify for unequivocal progression status. The designation of overall progression solely based on change in nontarget disease in the face of SD or PR of target disease will therefore be extremely rare.
- When the patient has only non-measurable disease: This circumstance arises in some Phase 3 trials when it is not a criterion of trial entry to have measurable disease. The same general concepts apply here as noted above; however, in this instance there is no measurable disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by definition: if all lesions are truly non-measurable), a useful test that can be applied when assessing patients for unequivocal progression is to consider if the increase in overall disease burden based on the change in non-measurable disease is comparable in magnitude to the increase that would be required to declare progressive disease for measurable disease: ie, an increase in tumor burden representing an additional 73% increase in “volume” (which is equivalent to a 20% increase diameter in a measurable lesion).
- Examples include an increase in a pleural effusion from “trace” to “large,” an increase in lymphangitic disease from localized to widespread, or may be described in protocols as “sufficient to require a change in therapy.” If “unequivocal progression” is seen, the patient should be considered to have had overall progressive disease at that point. While it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of that disease makes it impossible to do so, therefore the increase must be substantial.

### New Lesions

The appearance of new malignant lesions denotes disease progression; therefore, some comments on detection of new lesions are important. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal: ie, not attributable to differences in scanning technique, change in imaging modality or findings thought to represent something other than tumor (for example, some “new” bone lesions may be simply healing or flare of pre-existing lesions). This is particularly important when the patient’s baseline lesions show partial or complete response. For example, necrosis of a liver lesion may be reported on a CT scan report as a “new” cystic lesion, which it is not.

A lesion identified on a follow-up trial in an anatomical location that was not scanned at baseline is considered a new lesion and will indicate disease progression. An example of this is the patient who has visceral disease at baseline and while on trial has a CT or MRI brain ordered which reveals

metastases. The patient's brain metastases are evidence of progressive disease even if he/she did not have brain imaging at baseline.

If a new lesion is equivocal, for example because of its small size, continued therapy and follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is a new lesion, then progression should be declared using the date of the initial scan.

While fluorodeoxyglucose (FDG)-PET response assessments need additional study, it is sometimes reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in assessment of progression (particularly possible "new" disease). New lesions based on FDG-PET imaging can be identified according to the following algorithm:

Negative FDG-PET at baseline, with a positive FDG-PET at follow-up, is a sign of progressive disease based on a new lesion.

- No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at follow-up corresponds to a new site of disease confirmed by CT, this is progressive disease. If the positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up CT scans are needed to determine if there is truly progression occurring at that site (if so, the date of progressive disease will be the date of the initial abnormal FDG-PET scan). If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT that is not progressing based on the anatomic images, this is not progressive disease.

#### Evaluation of Best Overall Response

The best overall response is the best response recorded from the start of the study drug treatment until the EOT considering any requirement for confirmation. On occasion, a response may not be documented until after the end of therapy so protocols should be clear if post-treatment assessments are to be considered in determination of best overall response. Protocols must specify how any new therapy introduced before progression will affect best response designation. The patient's best overall response assignment will depend on the findings of both target and nontarget disease and will also take into consideration the appearance of new lesions. Furthermore, depending on the nature of the trial and the protocol requirements, it may also require confirmatory measurement. Specifically, in nonrandomized trials where response is the primary endpoint, confirmation of PR or CR is needed to deem either one the "best overall response."

The best overall response is determined once all the data for the patient is known. Best response determination in trials where confirmation of complete or partial response IS NOT required: Best response in these trials is defined as the best response across all timepoints (for example, a patient who has SD at first assessment, PR at second assessment, and progressive disease on last assessment has a best overall response of PR). When SD is believed to be best response, it must also meet the protocol specified minimum time from baseline. If the minimum time is not met when SD is otherwise the best timepoint response, the patient's best response depends on the subsequent assessments. For example, a patient who has SD at first assessment, progressive disease at second and does not meet minimum duration for SD, will have a best response of progressive disease. The



same patient lost to follow-up after the first SD assessment would be considered inevaluable.

Target Lesions	Non-target Lesions	New Lesions	Overall Response
CR	CR	No	CR
CR	Non-CR/non-PD	No	PR
CR	Not evaluated	No	PR
PR	Non-PD or not all evaluated	No	PR
SD	Non-PD or not all evaluated	No	SD
Not all evaluated	Non-PD	No	SD
PD	Any	No	NE
Any	PD	Yes or No	PD
Any	Any	Yes or No	PD
Any		Yes	PD

Abbreviations: CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.

When nodal disease is included in the sum of target lesions and the nodes decrease to “normal” size (< 10 mm), they may still have a measurement reported on scans. This measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes. As noted earlier, this means that patients with CR may not have a total sum of “zero.”

In trials where confirmation of response is required, repeated “NE” timepoint assessments may complicate best response determination. The analysis plan for the trial must address how missing data/assessments will be addressed in determination of response and progression. For example, in most trials it is reasonable to consider a patient with timepoint responses of PR-NE-PR as a confirmed response.

Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as “symptomatic deterioration”. Every effort should be made to document objective progression even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an objective response: it is a reason for stopping trial therapy.

Conditions that define “early progression, early death, and inevaluability” are trial specific and should be clearly described in each protocol (depending on treatment duration, treatment periodicity).

In some circumstances, it may be difficult to distinguish residual disease from normal tissue. When the evaluation of complete response depends upon this determination, it is recommended that the residual lesion be investigated (fine needle aspirate/biopsy) before assigning a status of complete response. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring. The use of FDG-PET in this circumstance should be prospectively described in the protocol and supported by disease specific medical literature for the indication. However, it must be acknowledged that



both approaches may lead to false positive CR due to limitations of FDG-PET and biopsy resolution/ sensitivity.

For equivocal findings of progression (eg, very small and uncertain new lesions; cystic changes, or necrosis in existing lesions), treatment may continue until the next scheduled assessment. If at the next scheduled assessment, progression is confirmed, the date of progression should be the earlier date when progression was suspected.

## **CONFIRMATORY MEASUREMENT/DURATION OF RESPONSE**

### Confirmation

In nonrandomized trials where response is the primary endpoint, confirmation of PR and CR is required to ensure responses identified are not the result of measurement error. This will also permit appropriate interpretation of results in the context of historical data where response has traditionally required confirmation in such trials. However, in all other circumstances, ie, in randomized trials (Phase 2 or 3) or trials where stable disease or progression are the primary endpoints, confirmation of response is not required since it will not add value to the interpretation of trial results. However, elimination of the requirement for response confirmation may increase the importance of central review to protect against bias, in particular in trials that are not blinded.

In the case of SD, measurements must have met the SD criteria at least once after trial entry at a minimum interval (in general not less than 6 weeks).

### Duration of Overall Response

The duration of overall response is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded on study).

The duration of overall complete response is measured from the time measurement criteria are first met for CR until the first date that recurrent disease is objectively documented.

### Duration of Stable Disease

Stable disease is measured from the start of the treatment (in randomized trials, from date of randomization) until the criteria for progression are met, taking as reference the smallest sum on study (if the baseline sum is the smallest, this is the reference for calculation of PD).

The clinical relevance of the duration of stable disease varies in different studies and diseases. If the proportion of patients achieving stable disease for a minimum period is an endpoint of importance in a particular trial, the protocol should specify the minimal time interval required between 2 measurements for determination of stable disease.

Note: The duration of response and stable disease as well as the progression-free survival are influenced by the frequency of follow-up after baseline evaluation. It is not in the scope of this guideline to define a standard follow-up frequency. The frequency should consider many parameters including disease types and stages, treatment periodicity, and standard practice. However, these

limitations of the precision of the measured endpoint should be considered if comparisons between trials are to be made.

#### APPENDIX 4. PRE-EXISTING IMMUNE DEFICIENCIES OR AUTOIMMUNE DISEASES

Prospective patients should be carefully questioned to determine whether they have any history of an acquired or congenital immune deficiency or autoimmune disease.

Please contact the medical monitor regarding any uncertainty about immune deficiency/autoimmune disease exclusions.

Acute disseminated encephalomyelitis	Addison's disease
Ankylosing spondylitis	Antiphospholipid antibody syndrome
Aplastic anemia	Autoimmune hemolytic anemia
Autoimmune hepatitis	Autoimmune hypoparathyroidism
Autoimmune hypophysitis	Autoimmune myocarditis
Autoimmune oophoritis	Autoimmune orchitis
Autoimmune thrombocytopenic purpura	Behcet's disease
Bullous pemphigoid	Chronic inflammatory demyelinating polyneuropathy
Chung-Strauss syndrome	Crohn's disease
Dermatomyositis	Dysautonomia
Epidermolysis bullosa acquisita	Gestational pemphigoid
Giant cell arteritis	Goodpasture's syndrome
Granulomatosis with polyangiitis	Graves' disease
Guillain-Barré syndrome	Hashimoto's disease
Immunoglobulin A (IgA) neuropathy	Inflammatory bowel disease
Interstitial cystitis	Kawasaki's disease
Lambert-Eaton myasthenia syndrome	Lupus erythematosus
Lyme disease (chronic)	Mooren's ulcer
Morphea	Multiple sclerosis
Myasthenia gravis	Neuromyotonia
Opsoclonus myoclonus syndrome	Optic neuritis
Ord's thyroiditis	Pemphigus
Pernicious anemia	Polyarteritis nodosa
Polyarthritis	Polyglandular autoimmune syndrome
Primary biliary cirrhosis	Psoriasis
Reiter's syndrome	Rheumatoid arthritis
Sarcoidosis	Sjögren's syndrome
Stiff person syndrome	Takayasu's arteritis
Ulcerative colitis	Vogt-Kovangai-Harada disease

---

## APPENDIX 5. NEW YORK HEART ASSOCIATION FUNCTIONAL CLASSIFICATION

Class	Symptoms
I	No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
II	Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
III	Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.
IV	Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Adapted from Dolgin M, Association NYH, Fox AC, Gorlin R, Levin RI, New York Heart Association. Criteria Committee. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston, MA: Lippincott Williams and Wilkins; March 1, 1994.

Original source: Criteria Committee, New York Heart Association, Inc. Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for diagnosis, 6th edition Boston, Little, Brown and Co. 1964, p 114.

## APPENDIX 6. IMMUNE-RELATED ADVERSE EVENT EVALUATION AND MANAGEMENT

The recommendations below for the diagnosis and management of any irAE are intended as guidance. This document should be used in conjunction with expert clinical judgment (by specialist physicians experienced in the treatment of cancer using immunological agents), and individual institutional guidelines or policies.

Criteria used to diagnose irAEs include blood tests, diagnostic imaging, histopathology, and microbiology assessments to exclude alternative causes such as infection, disease progression, and adverse effects of concomitant drugs. In addition to the results of these tests, the following factors should be considered when making an irAE diagnosis:

- What was the temporal relationship between initiation of tislelizumab and the adverse event?
- How did the patient respond to withdrawal of tislelizumab?
- Did the event recur when tislelizumab was reintroduced?
- Was there a clinical response to corticosteroids?
- Is the event an autoimmune endocrinopathy?
- Is disease progression or an alternative diagnosis a more likely explanation?

When alternative explanations to autoimmune toxicity have been excluded, the irAE field, associated with the AE in the eCRF should be checked.

### Recommended Diagnostic Tests in the Management of Possible Immune-related Adverse Events

Immune-related Toxicity	Diagnostic Evaluation Guideline
Thyroid Disorders	Scheduled and repeat thyroid function tests (TSH and T4).
Hypophysitis	Check visual fields and consider pituitary endocrine axis blood profile. Perform pituitary and whole-brain MRI in patients with headache, visual disturbance, unexplained fatigue, asthenia, weight loss, and unexplained constitutional symptoms. Consider consultation with an endocrinologist if an abnormality is detected.
Pneumonitis	All patients presenting with new or worsened pulmonary symptoms or signs, such as an upper respiratory infection, new cough, shortness of breath, or hypoxia should be assessed by high-resolution CT. Consider pulmonary function test including DLCO. Radiographic appearance is often nonspecific. Depending on the location of the abnormality, bronchoscopy and bronchoalveolar lavage or lung biopsy may be considered. Consult with a respiratory medicine physician for cases of uncertain cause.
Neurological Toxicity	Perform a comprehensive neurological examination and brain MRI for all CNS symptoms; review alcohol history and other medications. Conduct a diabetic screen, and assess blood B12/folate, HIV status, TFTs, and consider autoimmune serology. Consider the need for brain/spine MRI/MRA and nerve conduction study for peripheral neuropathy. Consult with a neurologist if there are abnormal findings.
Colitis	Review dietary intake and exclude steatorrhea. Consider comprehensive testing, including the following: FBC, UEC, LFTs, CRP, TFTs, stool microscopy and culture,

**Recommended Diagnostic Tests in the Management of  
 Possible Immune-related Adverse Events**

Immune-related Toxicity	Diagnostic Evaluation Guideline
	viral PCR, Clostridium difficile toxin, cryptosporidia (drug-resistant organism). In case of abdominal discomfort, consider imaging, eg, X-ray, CT scan. If a patient experiences bleeding, pain or distension, consider colonoscopy with biopsy and surgical intervention, as appropriate.
Eye Disorders	If patients experience acute, new onset, or worsening of eye inflammation, blurred vision, or other visual disturbances, refer the patient urgently to an ophthalmologist for evaluation and management.
Hepatitis	Check ALT/AST/total bilirubin, INR/albumin; the frequency will depend on severity of the AE (eg, daily if Grade 3-4; every 2-3 days if Grade 2, until recovering). Review medications (eg, statins, antibiotics) and alcohol history. Perform liver screen including Hepatitis A/B/C serology, Hepatitis E PCR and assess anti-ANA/SMA/LKM/SLA/LP/LCI, iron studies. Consider imaging, eg, ultrasound scan, for metastases or thromboembolism. Consult with a hepatologist and consider liver biopsy.
Renal Toxicity	Review hydration status and medication history. Test and culture urine. Consider renal ultrasound scan, protein assessment (dipstick/24-hour urine collection), or phase-contrast microscopy. Refer to nephrology for further management assistance.
Dermatology	Consider other causes by conducting a physical examination, consider dermatology referral for skin biopsy.
Rheumatology	Conduct musculoskeletal history and perform complete musculoskeletal examination. Consider joint X-ray and other imaging as required to exclude metastatic disease. Perform autoimmune serology and refer to rheumatology for further management assistance.

Abbreviations: AE, adverse event; ALT, alanine aminotransferase; ANA, antinuclear antibody; AST, aspartate aminotransferase; CNS, central nervous system; CRP, C-reactive protein; CT, computed tomography; DLCO, diffusing capacity for carbon monoxide; FBC, full blood count; HIV, human immunodeficiency virus; INR, international normalized ratio; LCI, liver cystolic antigen; LFT, liver function test; LKM, liver kidney microsomal antibody; LP, liver pancreas antigen; MRA, magnetic resonance angiogram; MRI, magnetic resonance imaging; PCR, polymerase chain reaction; SLA, soluble liver antigen; SMA, smooth muscle antibody; T4, thyroxine; TFT, thyroid function tests; TSH, thyroid-stimulating hormone; UEC, urea electrolytes and creatinine.

### Treatment of Immune-related Adverse Events

- Immune-related AEs can escalate quickly; study treatment interruption, close monitoring, timely diagnostic work-up and treatment intervention, as appropriate, with patients is required
- Immune-related AEs should improve promptly after introduction of immunosuppressive therapy. If this does not occur, review the diagnosis, seek further specialist advice and contact the study medical monitor
- For some Grade 3 toxicities that resolve quickly, rechallenge with study drug may be considered if there is evidence of a clinical response to study treatment, after consultation with the study medical monitor
- Steroid dosages in the table below are for oral or IV (methyl)prednisolone. Equivalent dosages of other corticosteroids can be substituted. For steroid-refractory irAEs, consider use of steroid-sparing agents (eg, mycophenolate mofetil [MMF])
- Consider prophylactic antibiotics for opportunistic infections if the patient is receiving long-term immunosuppressive therapy

Autoimmune Toxicity	Grade	Treatment Guidelines (Subject to Clinical Judgment)	Study Drug Management
Thyroid Disorders	1-2 Asymptomatic TFT abnormality or mild symptoms	Replace thyroxine if hypothyroid, until TSH/T4 levels return to normal range. Thyrotoxic patients should be referred to an endocrinologist. In cases with systemic symptoms: withhold study treatment, treat with a beta blocker and consider oral prednisolone 0.5 mg/kg/day for thyroid pain. Taper corticosteroids over 2-4 weeks. Monitor thyroid function regarding the need for hormone replacement.	Continue study treatment or withhold treatment in cases with systemic symptoms.
	3-4 Severe symptoms, hospitalization required	Refer patient to an endocrinologist. If hypothyroid, replace with thyroxine 0.5-1.6 µg/kg/day (for the elderly or those with comorbidities, the suggested starting dose is 0.5 µg/kg/day). Add oral prednisolone 0.5 mg/kg/day for thyroid pain. Thyrotoxic patients require treatment with a beta blocker and may require carbimazole until thyroiditis resolves.	Hold study treatment; resume when resolved/improved to grade 0-1.



<b>Autoimmune Toxicity</b>	<b>Grade</b>	<b>Treatment Guidelines (Subject to Clinical Judgment)</b>	<b>Study Drug Management</b>
<b>Hypophysitis</b>	<b>1-2</b> Mild symptoms	Refer patient to an endocrinologist for hormone replacement. Add oral prednisolone 0.5-1 mg/kg/day for patients with pituitary inflammation. Taper corticosteroids over at least 1 month. If there is no improvement in 48 hours, treat as Grade 3-4. Taper corticosteroids over at least 1 month.	Continue study treatment.
	<b>3-4</b> Moderate-severe symptoms	Refer patient to an endocrinologist for assessment and treatment. Initiate pulse IV methylprednisolone 1 mg/kg for patients with headache/visual disturbance due to pituitary inflammation. Convert to oral prednisolone and taper over at least 1 month. Maintain hormone replacement according to endocrinology advice. Maintain hormone replacement according to endocrinology advice.	Hold study treatment for patients with headache/visual disturbance due to pituitary inflammation until resolved/improved to Grade 2 or less. Discontinuation is usually not necessary.
<b>Pneumonitis</b>	<b>1</b> Radiographic changes only	Monitor symptoms every 2-3 days. If appearance worsens, treat as Grade 2.	Consider holding study treatment until appearance improves and cause is determined.
	<b>2</b> Symptomatic: exertional breathlessness	Commence antibiotics if infection suspected. Add oral prednisolone 1 mg/kg/day if symptoms/appearance persist for 48 hours or worsen. Consider Pneumocystis infection prophylaxis. Taper corticosteroids over at least 6 weeks. Consider prophylaxis for adverse steroid effects: eg, blood glucose monitoring, vitamin D/calcium supplement.	Hold study treatment. Retreatment is acceptable if symptoms resolve completely or are controlled on prednisolone ≤ 10 mg/day. Discontinue study treatment if symptoms persist with corticosteroid treatment.
	<b>3-4</b> Severe or life-threatening symptoms Breathless at rest	Admit to a hospital and initiate treatment with IV methylprednisolone 2-4 mg/kg/day. If there is no improvement, or worsening after 48 hours, add infliximab 5 mg/kg (if no hepatic involvement). Convert to oral prednisolone and taper over at least 2 months. Cover with empiric antibiotics and consider prophylaxis for Pneumocystis infection and other adverse steroid effects, eg, blood glucose monitoring, vitamin D/calcium supplement.	Discontinue study treatment.
<b>Neurological Toxicity</b>	<b>1</b> Mild symptoms		Continue study treatment.

Autoimmune Toxicity	Grade	Treatment Guidelines (Subject to Clinical Judgment)	Study Drug Management
	<b>2</b> Moderate symptoms	Treat with oral prednisolone 0.5-1 mg/kg/day. Taper over at least 4 weeks. Obtain neurology consultation.	Hold study treatment; resume when resolved/improved to grade 0-1.
	<b>3-4</b> Severe/life-threatening	Initiate treatment with oral prednisolone or IV methylprednisolone 1-2 mg/kg/day, depending on symptoms. Taper corticosteroids over at least 4 weeks. Consider azathioprine, MMF, cyclosporine if no response within 72-96 hours.	Discontinue study treatment.
<b>Colitis/Diarrhea</b>	<b>1</b> Mild symptoms: < 3 liquid stools per day over baseline and feeling well	Symptomatic management: fluids, loperamide, avoid high fiber/lactose diet. If Grade 1 persists for > 14 days manage as a Grade 2 event	Continue study treatment.
	<b>2</b> Moderate symptoms: 4 to 6 liquid stools per day over baseline, or abdominal pain, or blood in stool, or nausea, or nocturnal episodes	Oral prednisolone 0.5 mg/kg/day (non-enteric coated). Do not wait for any diagnostic tests to start treatment. Taper steroids over 2-4 weeks, consider endoscopy if symptoms are recurring.	Hold study treatment; resume when resolved/improved to baseline grade.
	<b>3</b> Severe symptoms: > 6 liquid stools per day over baseline, or if episodic within 1 hour of eating	Initiate IV methylprednisolone 1-2 mg/kg/day. Convert to oral prednisolone and taper over at least 4 weeks. Consider prophylaxis for adverse steroid effects, eg, blood glucose monitoring, vitamin D/calcium supplement.	Hold study treatment; retreatment may be considered when resolved/improved to baseline grade and after discussion with the study medical monitor.
	<b>4</b> Life-threatening symptoms	If no improvement in 72 hours or symptoms worsen, consider infliximab 5 mg/kg if no perforation, sepsis, TB, hepatitis, NYHA grade III/IV CHF or other immunosuppressive treatment: MMF or tacrolimus. Consult gastroenterologist to conduct colonoscopy/ sigmoidoscopy.	Discontinue study treatment.
<b>Skin reactions</b>	<b>1</b> Skin rash, with or without symptoms, < 10% BSA	Avoid skin irritants and sun exposure; topical emollients recommended.	Continue study treatment.

Autoimmune Toxicity	Grade	Treatment Guidelines (Subject to Clinical Judgment)	Study Drug Management
	<b>2</b> Rash covers 10%-30% of BSA	Avoid skin irritants and sun exposure; topical emollients recommended. Topical steroids (moderate strength cream once a day or potent cream twice a day) ± oral or topical antihistamines for itch. Consider a short course of oral steroids.	Continue study treatment.
	<b>3</b> Rash covers > 30% BSA or Grade 2 with substantial symptoms	Avoid skin irritants and sun exposure; topical emollients recommended. Initiate steroids as follows based on clinical judgment: For moderate symptoms: oral prednisolone 0.5-1 mg/kg/day for 3 days then taper over 2-4 weeks. For severe symptoms: IV methylprednisolone 0.5-1 mg/kg/day; convert to oral prednisolone and taper over at least 4 weeks.	Hold study treatment. Retreat when AE is resolved or improved to mild rash (Grade 1-2) after discussion with the study medical monitor.
	<b>4</b> Skin sloughing > 30% BSA with associated symptoms (eg, erythema, purpura, epidermal detachment)	Initiate IV methylprednisolone 1-2 mg/kg/day. Convert to oral prednisolone and taper over at least 4 weeks. Admit to a hospital and seek urgent dermatology consultation.	Discontinue study treatment.
<b>Hepatitis</b>	<b>1</b> ALT or AST > ULN to 3X ULN	Check LFTs within 1 week and before the next dose check LFTs to verify that there has been no worsening. If LFTs are worsening, recheck every 48-72 hours until improvement is seen.	Continue study treatment if LFTs are unchanged or improving. Hold study treatment if LFTs are worsening until improvement is seen.
	<b>2</b> ALT or AST 3-5X ULN	Recheck LFTs every 48-72 hours: For persistent ALT/AST elevation: consider oral prednisolone 0.5-1 mg/kg/day for 3 days then taper over 2-4 weeks. For rising ALT/AST: start oral prednisolone 1 mg/kg/day and taper over 2-4 weeks; reescalate dose if LFTs worsen, depending on clinical judgment.	Hold study treatment; treatment may be resumed when resolved/improved to baseline grade and prednisolone tapered to ≤ 10 mg.

Autoimmune Toxicity	Grade	Treatment Guidelines (Subject to Clinical Judgment)	Study Drug Management
	<b>3</b> ALT or AST 5-20X ULN	ALT/AST < 400 IU/L and normal bilirubin/INR/albumin: Initiate oral prednisolone 1 mg/kg and taper over at least 4 weeks. ALT/AST > 400 IU/L or raised bilirubin/INR/low albumin: Initiate IV (methyl)prednisolone 2 mg/kg/day. When LFTs improve to Grade 2 or lower, convert to oral prednisolone and taper over at least 4 weeks.	Hold study treatment until improved to baseline grade; reintroduce only after discussion with the study medical monitor.
	<b>4</b> ALT or AST > 20X ULN	Initiate IV methylprednisolone 2 mg/kg/day. Convert to oral prednisolone and taper over at least 6 weeks.	Discontinue study treatment.
	<b>Worsening LFTs despite steroids:</b> <ul style="list-style-type: none"> <li>• If on oral prednisolone change to pulsed IV methylprednisolone</li> <li>• If on IV add mycophenolate mofetil (MMF) 500-1000 mg twice a day</li> <li>• If worsens on MMF, consider addition of tacrolimus</li> </ul> Duration and dose of steroid required will depend on severity of event		
<b>Nephritis</b>	<b>1</b> Creatinine 1.5X baseline or > ULN to 1.5X ULN	Repeat creatinine weekly. If symptoms worsen, manage as per criteria below.	Continue study treatment.
	<b>2</b> Creatinine > 1.5-3X baseline or > 1.5-3X ULN	Ensure hydration and review creatinine in 48-72 hours; if not improving, consider creatinine clearance measurement by 24-hour urine collection. Discuss with nephrologist the need for kidney biopsy. If attributed to study drug, initiate oral prednisolone 0.5-1 mg/kg and taper over at least 2 weeks. Repeat creatinine/U&E every 48-72 hours.	Hold study treatment. If not attributed to drug toxicity, restart treatment. If attributed to study drug and resolved/improved to baseline grade: Restart study drug if tapered to < 10 mg prednisolone.
	<b>3</b> Creatinine > 3X baseline or > 3-6X ULN	Hospitalize patient for monitoring and fluid balance; repeat creatinine every 24 hours; refer to a nephrologist and discuss need for biopsy. If worsening, initiate IV (methyl)prednisolone 1-2 mg/kg. Taper corticosteroids over at least 4 weeks.	Hold study treatment until the cause is investigated. If study drug suspected: Discontinue study treatment.
	<b>4</b> Creatinine > 6X ULN	As per Grade 3, patient should be managed in a hospital where renal replacement therapy is available.	Discontinue study treatment.
<b>Diabetes/ Hyperglycemia</b>	<b>1</b> Fasting glucose value ULN to 160 mg/dL; ULN	Monitor closely and treat according to local guideline. Check for C-peptide and antibodies against glutamic acid	Continue study treatment.

Autoimmune Toxicity	Grade	Treatment Guidelines (Subject to Clinical Judgment)	Study Drug Management
	to 8.9 mmol/L	decarboxylase and islet cells are recommended	
	<b>2</b> Fasting glucose value 160-250 mg/dL; 8.9-13.9 mmol/L	Obtain a repeat blood glucose level at least every week. Manage according to local guideline.	Continue study treatment or hold treatment if hyperglycemia is worsening. Resume treatment when blood glucose is stabilized at baseline or grade 0-1.
	<b>3</b> Fasting glucose value 250-500 mg/dL; 13.9-27.8 mmol/L	Admit patient to hospital and refer to a diabetologist for hyperglycemia management. Corticosteroids may exacerbate hyperglycemia and should be avoided.	Hold study treatment until patient is hyperglycemia symptom-free, and blood glucose has been stabilized at baseline or grade 0-1.
	<b>4</b> Fasting glucose value > 500 mg/dL; > 27.8 mmol/L	Admit patient to hospital and institute local emergency diabetes management. Refer the patient to a diabetologist for insulin maintenance and monitoring.	
Ocular Toxicity	<b>1</b> Asymptomatic eye exam/test abnormality	Consider alternative causes and prescribe topical treatment as required.	Continue study treatment.
	<b>2</b> Anterior uveitis or mild symptoms	Refer patient to an ophthalmologist for assessment and topical corticosteroid treatment. Consider a course of oral steroids.	Continue study treatment or hold treatment if symptoms worsen or if there are symptoms of visual disturbance.
	<b>3</b> Posterior uveitis/panuveitis or significant symptoms	Refer patient urgently to an ophthalmologist. Initiate oral prednisolone 1-2 mg/kg and taper over at least 4 weeks.	Hold study treatment until improved to grade 0-1; reintroduce only after discussion with the study medical monitor.
	<b>4</b> Blindness (at least 20/200) in the affected eyes	Initiate IV (methyl)prednisolone 2 mg/kg/day. Convert to oral prednisolone and taper over at least 4 weeks.	Discontinue study treatment.
Pancreatitis	<b>2</b> Asymptomatic, blood test abnormalities	Monitor pancreatic enzymes.	Continue study treatment.
	<b>3</b> Abdominal pain, nausea and vomiting	Admit to hospital for urgent management. Initiate IV (methyl)prednisolone 1-2 mg/kg/day. Convert to oral prednisolone when amylase/lipase improved to Grade 2, and taper over at least 4 weeks	Hold study treatment; reintroduce only after discussion with the study medical monitor.

Autoimmune Toxicity	Grade	Treatment Guidelines (Subject to Clinical Judgment)	Study Drug Management
	<b>4</b> Acute abdominal pain, surgical emergency	Admit to hospital for emergency management and appropriate referral.	Discontinue study treatment.
Arthritis	<b>1</b> Mild pain with inflammation, swelling	Management per local guideline.	Continue study treatment.
	<b>2</b> Moderate pain with inflammation, swelling, limited instrumental (fine motor) activities	Management as per local guideline. Consider referring patient to a rheumatologist. If symptoms worsen on treatment manage as a Grade 3 event.	Continue treatment or, if symptoms continue worsens, hold study treatment until symptoms improve to baseline or grade 0-1.
	<b>3</b> Severe pain with inflammation or permanent joint damage, daily living activity limited	Refer patient urgently to a rheumatologist for assessment and management. Initiate oral prednisolone 0.5-1 mg/kg and taper over at least 4 weeks.	Hold study treatment unless improved to grade 0-1; reintroduce only after discussion with the study medical monitor.
Mucositis/stomatitis	<b>1</b> Test findings only or minimal symptoms	Consider topical treatment or analgesia as per local guideline.	Continue study treatment.
	<b>2</b> Moderate pain, reduced oral intake, limited instrumental activities	As per local guidelines, treat with analgesics, topical treatments, and oral hygiene care. Ensure adequate hydration. If symptoms worsen or there is sepsis or bleeding, manage as a Grade 3 event.	Continue study treatment.
	<b>3</b> Severe pain, limited food and fluid intake, daily living activity limited	Admit to hospital for appropriate management. Initiate IV (methyl)prednisolone 1-2 mg/kg/day. Convert to oral prednisolone when symptoms improved to Grade 2 and taper over at least 4 weeks.	Hold study treatment until improved to grade 0-1.
	<b>4</b> Life-threatening complications or dehydration	Admit to hospital for emergency care. Consider IV corticosteroids if not contraindicated by infection.	Discontinue study treatment.

Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body surface area; CHF, chronic heart failure; INR, international normalized ratio; IV, intravenous; LFT, liver function test; MMF, mycophenolate mofetil; NYHA, New York Heart Association; T4, thyroxine; TB, tuberculosis; TFT, thyroid function test; TSH, thyroid-stimulating hormone; U&E, urea and electrolytes; ULN, upper limit of normal.

---

## APPENDIX 7. CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION (CKD-EPI) EQUATION

In adults, the most widely used equations for estimating glomerular filtration rate (eGFR) from serum creatinine are the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and the Modification of Diet in Renal Disease (MDRD) Study equation. The National Kidney Disease Education Program (NKDEP) calculators rely on creatinine determinations which are isotope dilution mass spectrometry (IDMS) traceable. All laboratories should be using creatinine methods calibrated to be IDMS traceable. Read more about creatinine standardization.

This CKD-EPI equation calculator should be used when Scr reported in mg/dL. This equation is recommended when eGFR values above 60 mL/min/1.73 m<sup>2</sup> are desired.

$$\text{GFR} = 141 \times \min(\text{Scr} / \kappa, 1)^\alpha \times \max(\text{Scr} / \kappa, 1) - 1.209 \times 0.993^{\text{Age}} \times 1.018 [\text{if female}] \times 1.159 [\text{if black}]$$

where:

Scr is serum creatinine in mg/dL,

$\kappa$  is 0.7 for females and 0.9 for males,

$\alpha$  is -0.329 for females and -0.411 for males,

min indicates the minimum of Scr /  $\kappa$  or 1, and

max indicates the maximum of Scr /  $\kappa$  or 1.

The equation does not require weight because the results are reported normalized to 1.73 m<sup>2</sup> body surface area, which is an accepted average adult surface area.

The online calculator for CKD-EPI can be found here: <https://www.niddk.nih.gov/health-information/health-communication-programs/nkdep/lab-evaluation/gfr-calculators/Pages/gfr-calculators.aspx>

## APPENDIX 8. CONTRACEPTION GUIDELINES AND DEFINITIONS OF “WOMEN OF CHILDBEARING POTENTIAL,” “NO CHILDBEARING POTENTIAL”

### Contraception Guidelines

The Clinical Trials Facilitation Group’s recommendations related to contraception and pregnancy testing in clinical trials include the use of highly effective forms of birth control. These methods include the following:

- Combined (estrogen- and progestogen-containing) hormonal contraception associated with the inhibition of ovulation (oral, intravaginal, or transdermal)
- Progestogen-only hormonal contraception associated with the inhibition of ovulation (oral, injectable, or implantable)
- Intrauterine device (IUD)
- Intrauterine hormone-releasing system (IUS)
- Bilateral tubal occlusion
- Vasectomized male partner
- Sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of exposure associated with the study treatment).

NOTE: Total sexual abstinence should only be used as a contraceptive method if it is in line with the patient’s usual and preferred lifestyle. Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence for the duration of exposure to study drug, and withdrawal are not acceptable methods of contraception.

Of note, barrier contraception (including male and female condoms with or without spermicide) is not considered a highly effective method of contraception and if used, this method must be combined with another acceptable method listed above.

### Definitions of “Women of Childbearing Potential,” “Women of No Childbearing Potential”

As defined in this protocol, “women of childbearing potential” are female patients who are physiologically capable of becoming pregnant.

Conversely, “women of no childbearing potential” are defined as female patients meeting any of the following criteria:

- Surgically sterile (ie, through bilateral salpingectomy, bilateral oophorectomy, or hysterectomy)
- Postmenopausal, defined as:

≥ 55 years of age with no spontaneous menses for ≥ 12 months OR

< 55 years of age with no spontaneous menses for ≥ 12 months AND with postmenopausal follicle-stimulating hormone concentration > 30 IU/mL



Adapted from Clinical Trials Facilitation Group (CTFG). Recommendations related to contraception and pregnancy testing in clinical trials. September 15, 2014. [http://www.hma.eu/fileadmin/dateien/Human\\_Medicines/01-About\\_HMA/Working\\_Groups/CTFG/2014\\_09\\_HMA\\_CTFG\\_Contraception.pdf](http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf)

## APPENDIX 9. DOSE MODIFICATION GUIDELINES FOR CHEMOTHERAPY

Dose modification should be made in accordance to prescribing information and as per institutional guidelines.

- If considered in the best interest of the patient and consistent with local practice, investigators may decide to use supportive measures/treatment, and/or secondary prophylaxis instead of dose reductions for the next cycle.
- These provided triggers for dose modifications are recommendations only.
- Dose adjustments are based on nadir blood counts since the preceding chemotherapy administration. Dose level adjustments are relative to that of the preceding administration.
- All dose modifications should be made based on the worst grade toxicity.
- Carboplatin is only permitted to reduce to -25% doses once (from AUC 5 to AUC 4)

### Recommended Dose Modifications for Paclitaxel and carboplatin

Paclitaxel should not be repeated until the neutrophil count is at least 1500 cells/mm<sup>3</sup> and the platelet count is at least 100,000 cells/mm<sup>3</sup>. Patients who experience severe neutropenia (neutrophil < 500 cells/mm<sup>3</sup> for a week or longer) or severe peripheral neuropathy during paclitaxel therapy should have dosage reduced by 20% for subsequent courses of paclitaxel. Recommended dose modifications for hematologic and neurotoxicity are provided in [Table 10](#).

**Table 10. Dose Reduction for Paclitaxel and Carboplatin**

Adverse event	Every 3-week paclitaxel dose	Every 3-week Carboplatin Dose (AUC mg*min/mL)
Febrile neutropenia; documented infection	Dose reduction of 20% at first occurrence, discontinue treatment at second occurrence	Dose reduction of 25% at first occurrence, discontinue treatment at second occurrence
Grade 3 Neutropenia (0.5-0.99 x 10 <sup>9</sup> /L)	Delay until ≤ Grade 1 (≥1.5 x 10 <sup>9</sup> /L); restart with the full dose	Delay until ≤ Grade 1 (≥1.5 x 10 <sup>9</sup> /L); restart with the full dose
Grade 4 Neutropenia (< 0.5 x 10 <sup>9</sup> /L)	Delay until recovered to ≤ Grade 1; dose reduction by 20%	Dose reduction by 25%
Grade 2 Thrombocytopenia	Dose reduction of all further doses by 20%	No adjustment
≥ Grade 3 Thrombocytopenia	Discontinue treatment	Dose reduction by 25%
Grade 3 or 4 sensory neuropathy	Discontinue treatment	Dose reduction by 25%
Other organ toxicity, Grade 2	Delay chemotherapy until ≤ Grade 1 or baseline*	No adjustment
Other organ toxicity, Grade 3 to 4	Delay chemotherapy until recovered to Grade 1 or baseline*, dose reduction by 20%	Dose reduction by 25%

\*Skin reactions, paronychia, alopecia, fatigue, nausea/vomiting which may have resolved to Grade 2 or baseline.

### Recommended Dose Modifications for *Nab*-paclitaxel and Carboplatin

The dose adjustments of *nab*-paclitaxel and carboplatin are described in Table 11. Do not administer *nab*-paclitaxel on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm<sup>3</sup> and platelet count is at least 100,000 cells/mm<sup>3</sup>

- In patients who develop severe neutropenia or thrombocytopenia withhold treatment until counts recover to an absolute neutrophil count of at least 1500 cells/mm<sup>3</sup> and platelet count of at least 100,000 cells/mm<sup>3</sup> on Day 1 or to an absolute neutrophil count of at least 500 cells/mm<sup>3</sup> and platelet count of at least 50,000 cells/mm<sup>3</sup> on Days 8 or 15 of the cycle. Upon resumption of dosing, permanently reduce *nab*-paclitaxel and carboplatin doses as outlined in Table 11.
- Withhold *nab*-paclitaxel for Grade 3-4 peripheral neuropathy. Resume *nab*-paclitaxel and carboplatin at reduced doses (Table 11) when peripheral neuropathy improves to Grade 1 or completely resolves.

**Table 11. Dose Reductions for *Nab*-paclitaxel and Carboplatin**

Adverse events	Occurrence	Weekly <i>nab</i> -paclitaxel dose (mg/m <sup>2</sup> )	Every 3-week Carboplatin Dose (AUC mg*min/mL)
Neutropenic Fever (ANC < 500/mm <sup>3</sup> with fever > 38°C) OR	First	75	4
Delay of next cycle by >7 days for ANC < 1500/mm <sup>3</sup> OR	Second	50	Discontinue Treatment
ANC <500/mm <sup>3</sup> for more than 7 days	Third	Discontinue treatment	
Grade 3 thrombocytopenia (Platelet count less than 50000/mm <sup>3</sup> )	First	75	4
	second	Discontinue treatment	
Grade 3 or 4 sensory neuropathy	First	75	4
	Second	50	Discontinue treatment
	Third	Discontinue treatment	

Adapted from prescribing information of

1. Bobei<sup>®</sup> for carboplatin injection,
2. Abraxane<sup>®</sup> for injection suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), and
3. Taxol<sup>®</sup> (paclitaxel) injection.



**BeiGene**

## STATISTICAL ANALYSIS PLAN

**Study Protocol Number:** BGB-A317-307

**Study Protocol Title:** A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB-A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or *Nab*-Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-Small Cell Lung Cancer


**Date:** Jan 2, 2020

**Version:** 1.0

**SIGNATURE PAGE**

<p><b>Author:</b> Xiao Lin Sr. Statistician II, Biometrics</p>	
--	--

**Approval**

<p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	
---	---

**TABLE OF CONTENTS**

1	INTRODUCTION	6
2	STUDY OVERVIEW	6
3	STUDY OBJECTIVES	7
	3.1 Primary Objectives	7
	3.2 Secondary Objectives	8
	3.3 Exploratory Objectives	8
4	STUDY ENDPOINTS	9
	4.1 Primary Endpoints	9
	4.2 Secondary Endpoints	9
	4.3 Exploratory Endpoints	9
5	SAMPLE SIZE CONSIDERATIONS	10
6	TYPE-I-ERROR CONTROL WITH MULTIPLE ENDPOINTS	10
7	INTERIM ANALYSIS	11
8	STATISTICAL METHODS	12
	8.1 Analysis Sets	12
	8.2 Data Analysis General Considerations	12
	8.2.1 Definitions and Computations	12
	8.2.2 Conventions	13
	8.2.3 Handling of Missing Data	13
	8.2.4 Adjustment for Covariates	13
	8.2.5 Multiplicity Adjustment	13
	8.3 Subject Characteristics	13
	8.3.1 Subject Disposition	13
	8.3.2 Protocol Deviations	14
	8.3.3 Demographic and Other Baseline Characteristics	14
	8.3.4 Disease History	14
	8.3.5 Prior Anticancer Drug Therapies, Radiotherapy and Surgeries	14
	8.3.6 Prior and Concomitant Medications	14
	8.3.7 Medical History	15
	8.4 Efficacy Analysis	15
	8.4.1 Primary Efficacy Endpoints	15
	8.4.2 Secondary Efficacy Endpoints	16
	8.4.3 Subgroup Analyses	19
	8.4.4 Exploratory Analysis	19
	8.5 Safety Analyses	20
	8.5.1 Extent of Exposure	21
	8.5.2 Adverse Events	21
	8.5.3 Laboratory Values	23
	8.5.4 Vital Signs	23
	8.5.5 Electrocardiograms (ECG)	24
	8.5.6 Eastern Cooperative Oncology Group (ECOG)	24

BeiGene (Shanghai) Co, Ltd

BGB-A317-307  
(Statistical Analysis Plan)

---

8.6	Pharmacokinetic Analyses	24
8.7	immunogenicity Analysis	24
9	CHANGES IN THE PLANNED ANALYSIS	25
10	REFERENCES	25
10.1	PFS censoring rules	27
10.2	Health Related Quality of Life	28

**LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS**

<b>Abbreviation</b>	<b>Term</b>
ADA	Anti-drug antibody
ADI	Actual dose intensity
AE	Adverse event
AUC	Area under the concentration-time curve
BOR	Best overall response
CI	Confidence interval
CR	Complete response
CSR	Clinical study report
CTCAE	Common Terminology Criteria for Adverse Events
DOR	Duration of response
ECG	Electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eCRF	Electronic case report form
FDA	Food and Drug Administration
irAE	Immune-related adverse event
IRC	Independent Review Committee
MTD	Maximum tolerated dose
MedDRA	Medical Dictionary for Regulatory Activities
NCI	National Cancer Institute
ORR	Overall response rate
OS	Overall survival
PD	Progressive disease
PK	Pharmacokinetic
PFS	Progression-free survival
PR	Partial response
PS	Performance status
PT	Preferred term
RDI	Relative dose intensity
SAE	Serious adverse event
SAP	Statistical Analysis Plan
SOC	System Organ Class
TEAE	Treatment-emergent adverse event



## 1 INTRODUCTION

The purpose of this statistical analysis plan (SAP) is to describe the procedures and the statistical methods that will be used to analyze and report results for protocol BGB-A317-307: A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of tislelizumab (BGB-A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab-Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-Small Cell Lung Cancer. The focus of this SAP is for the planned primary, secondary and exploratory analysis specified in the study protocol.

The analysis details for exploratory biomarker analyses are not described within this SAP. Separate analysis plans will be completed for these analyses and will be attached to the clinical study report.

Reference materials for this statistical plan include the protocol amendment BGB-A317-307 (version 3.0, dated as 16Aug2019). If the protocol is amended or updated, then appropriate adjustments to the SAP may be made if they are related to the planned analyses.

The SAP described hereafter is an a priori plan. This is an open label study with a planned interim analysis, the SAP will be finalized and approved before interim analysis. Statistical programming may occur as study data accumulate in order to have analysis programs ready at the time the study finishes.

All statistical analyses will be conducted using SAS® (SAS Institute, Inc., Cary, NC, USA), Version 9.3 or higher.

## 2 STUDY OVERVIEW

This is an open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with carboplatin and either paclitaxel (Arm A) or *nab*-paclitaxel (Arm B) versus paclitaxel plus carboplatin alone (Arm C) as first-line treatment in approximately 342 patients with untreated Stage IIIB or IV squamous NSCLC.

Patients who have histologically confirmed and are untreated for their locally advanced (Stage IIIB) or metastatic (Stage IV) squamous NSCLC are eligible. Patients with tumors of mixed non-small cell histology (squamous and nonsquamous) are eligible if the major histological component is confirmed to be squamous. Histology of squamous NSCLC will be confirmed at the investigator's site. Patients with NSCLC tumors that have known EGFR-sensitizing mutation or ALK gene translocation are excluded but testing is not required if not known. Archival tumor specimens will be prospectively tested for PD-L1 expression by a central laboratory. If archived FFPE tissue is not sufficient for PD-L1 analysis, a fresh biopsy sample will be needed. PD-L1 status will be characterized as PD-L1 membrane staining on TC via the Ventana SP263 assay.

Patients will be stratified by disease stage (IIIB versus IV), and PD-L1 expression (3 levels: < 1% TC versus 1% to 49% TC versus  $\geq 50\%$  TC). Patients whose tissues are unevaluable for PD-L1 expression be included in the < 1% TC group. All patients will be randomized by a 1:1:1 ratio to receive one of the following treatment regimens:

- Arm A: Tislelizumab + paclitaxel + carboplatin
- Arm B: Tislelizumab + *nab*-paclitaxel + carboplatin
- Arm C: Paclitaxel + carboplatin

Patients who are randomized into the tislelizumab plus chemotherapy arms (Arms A and B) will be permitted to continue tislelizumab monotherapy at the discretion of investigator if they experience disease progressive per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 during chemotherapy combination phase or thereafter while receiving tislelizumab monotherapy, provided criteria stated in the protocol are met. Patients who are randomized into the chemotherapy arm (Arm C) will have the opportunity to cross over to receive tislelizumab if they experience radiographic disease progression on chemotherapy; that is, if disease progression per RECIST v1.1 has been confirmed by the independent review committee (IRC), provided criteria stated in the protocol are met and approval by the medical monitor has been obtained.

The study is composed of an initial screening phase (up to 28 days), a treatment phase (until disease progression, intolerable toxicity, or withdrawal for other reasons), safety follow-up phase (around 30 days), and survival follow-up phase.

During the study, tumor assessment will be performed at baseline, and approximately every 6 weeks ( $\pm 7$  days) for the first 6 months, every 9 weeks ( $\pm 7$  days) for the remainder of Year 1, every 12 weeks ( $\pm 7$  days) from Year 2 onwards. Tumor response will be assessed by the IRC and the investigator using RECIST v1.1. Patient who discontinues study treatment for reasons other than disease progression or death will continue to undergo tumor assessments following the original plan until the patient begins a subsequent anticancer treatment, experiences disease progression, withdraws consent, is lost to follow up, until death, or the study termination, whichever occurs first.

Patients will be evaluated for safety in this study through the monitoring of all adverse events (AEs) and lab results, defined and graded according to National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE v5.0). AEs and serious adverse events (SAEs) will be recorded during the study and for up to 30 days after the last dose of study drug or until the initiation of another anticancer therapy, whichever occurs first. Immune-related AEs will be recorded up to 90 days after the last dose of tislelizumab, regardless of whether the patient starts a new anticancer therapy.

### **3 STUDY OBJECTIVES**

#### **3.1 PRIMARY OBJECTIVES**

- To compare the PFS as assessed by the IRC per RECIST v1.1 in an Intent-to-Treat (ITT) analysis set between tislelizumab either combined with paclitaxel + carboplatin (Arm A)

or combined with *nab*-paclitaxel + carboplatin (Arm B) and paclitaxel + carboplatin alone (Arm C) in patients with untreated Stage IIIB or Stage IV squamous NSCLC.

### 3.2 SECONDARY OBJECTIVES

- To compare OS between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone in the ITT Analysis set.
- To compare ORR as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone.
- To compare duration of response (DOR) as assessed by the IRC and by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or carboplatin + *nab*-paclitaxel and paclitaxel + carboplatin alone.
- To compare PFS as assessed by the investigator per RECIST v1.1 between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone in an ITT Analysis set.
- To compare health-related quality of life (HRQoL) between tislelizumab combined with paclitaxel + carboplatin or carboplatin-*nab*-paclitaxel and paclitaxel + carboplatin alone.
- To evaluate the safety and tolerability of tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin compared with paclitaxel + carboplatin alone.
- To evaluate the correlation between programmed death-ligand1 (PD-L1) expression levels by IHC and antitumor activity of tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin.

### 3.3 EXPLORATORY OBJECTIVES

- To compare tumor assessment outcomes (eg, DCR, time to response [TTR]) between tislelizumab combined with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin and paclitaxel + carboplatin alone assessed by the investigator per RECIST v1.1.
- To assess tumor and blood-based biomarkers of tislelizumab response, resistance and patient prognosis.
- To characterize the PK of tislelizumab when given in combination with paclitaxel + carboplatin or *nab*-paclitaxel + carboplatin.
- To assess host immunogenicity to tislelizumab

## **4 STUDY ENDPOINTS**

### **4.1 PRIMARY ENDPOINTS**

- PFS as assessed by the IRC – the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the IRC per RECIST v1.1 in the ITT Analysis set

### **4.2 SECONDARY ENDPOINTS**

- OS – the time from the date of randomization to the date of death due to any cause in an ITT Analysis set.
- ORR as assessed by the IRC and investigator – the proportion of patients who had complete response (CR) or PR as assessed by the IRC and investigator per RECIST v1.1 in all randomized patients with measurable disease at baseline.
- DOR as assessed by the IRC and investigator – the time from the first occurrence of a documented objective response to the time of relapse, or death from any cause, whichever comes first, as assessed by the IRC and investigator per RECIST v1.1 in all randomized patients with documented objective responses.
- PFS as assessed by the investigator – the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1 in the ITT Analysis set.
- HRQoL – measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) and Core 30 (EORTC QLQ-C30) as presented in patient-reported outcomes.
- Incidence and severity of treatment-emergent AEs (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v5.0.
- PD-L1 expression by IHC as a predictive biomarker for response

### **4.3 EXPLORATORY ENDPOINTS**

- DCR – the proportion of patients who had CR, PR, Non-CR/Non-PD or SD as assessed by the investigator per RECIST v1.1.
- TTR – the time from randomization to the first occurrence of a documented objective response as assessed by the investigator per RECIST v1.1.
- Status of exploratory biomarkers including but not limited to: PD-L1, tumor mutation burden (TMB), and immune-related gene expression profiling (GEP) in archival and/or freshly obtained tumor tissues and blood (or blood derivatives) obtained before, during,

or after treatment with tislelizumab or at progression, and the association with disease status and/or response to tislelizumab in combination with chemotherapy.

- Summary of serum concentrations of tislelizumab.
- Assessments of immunogenicity of tislelizumab by determining the incidence of antidrug antibodies (ADAs).

## 5 SAMPLE SIZE CONSIDERATIONS

The sample size calculation is based on the number of PFS events required to demonstrate the PFS superiority of Arm A or Arm B to Arm C in the ITT analysis set, respectively. Exponential distribution is assumed for PFS. The estimates of the number of events required to demonstrate efficacy with regards to PFS are based on the following assumptions:


1. A one-sided  $\alpha$  of 0.025 and 80% power to detect a HR of 0.65, corresponding to an improvement in median PFS from 6 months to 9.2 months, in the PFS of A versus C comparison.
2. A one-sided  $\alpha$  of 0.025 and 80% power to detect a HR of 0.65, corresponding to an improvement in median PFS from 6 months to 9.2 months, in the PFS of B versus C comparison.
3. One planned interim analysis for both A versus C and B versus C comparisons when ~75% of targeted PFS events occurred, with Lan-DeMets O'Brien-Fleming approximation spending function.
4. Dropout rate of 5% per 12 months in PFS evaluation

With these assumptions, a total of approximately 173 PFS events are required for each primary comparison of Arm A versus Arm C or Arm B versus Arm C at final analysis for PFS.

Assuming 342 patients are to be enrolled and randomized at a 1:1:1 ratio over a 11.5-month period at a steady-state enrollment rate of 40 patients per month and enrollment ramp up duration of six month, ie, enrollment rate of 10 patients per month from study Month 0 to Month 2, 20 patients per month from Month 2 to Month 4, 30 patients per month from Month 4 to Month 6, and 40 patients per month afterwards.

## 6 TYPE-I-ERROR CONTROL WITH MULTIPLE ENDPOINTS

Type I error will be strongly controlled at an alpha of 0.025 by using sequential testing procedure. Hypothesis testing for the primary endpoint of PFS (Arm A vs C followed by Arm B vs C) will be carried out sequentially, each at a one-sided alpha of 0.025, until the first non-rejection. The alpha allocation algorithm is described in Figure 1 below.

**Figure 1. Type I error control schema**

## 7 INTERIM ANALYSIS

There will be one interim efficacy analysis of PFS in each comparison performed in the ITT Analysis Set. For PFS endpoint, the interim efficacy analysis will be performed after approximately 130 PFS events (75% of the target number of approximately 173 PFS events) have been observed in each comparison of A versus C or B versus C. It is estimated that it will take approximately 17 months to accumulate the required number of PFS events.

An independent statistical review will be conducted to determine if the required number of events have occurred in two arms of A vs C or B vs. C. If the time of observing the targeted number of events in each comparison is different from each other, the analysis could be separate.

The interim boundary is based on Lan DeMets O'Brien-Fleming approximation spending function. The interim and final analysis timing and stopping boundaries for PFS are summarized in Table 1 below. The times and boundaries for interim and final analysis are based on protocol-defined enrollment and PFS assumptions. They will be updated according to the actual PFS events included at interim and final analysis using Lan-DeMets spending function.

**Table 1 Analysis Timing and Stopping Boundaries for PFS in Each of the Primary Testing at One-Sided  $\alpha=0.025$**

Type of analysis	# Events	Expected Time (months)	Testing boundary	
			p-value boundary	Approx. hazard ratio threshold
Interim analysis	130	16.7	0.0097	0.6637
Final analysis	173	23.8	0.0221	0.7364

## 8 STATISTICAL METHODS

### 8.1 ANALYSIS SETS

Intent-to-Treat (ITT) Analysis Set: includes all patients randomized to the study, and patients will be grouped by assigned treatment at randomization. This will be the primary analysis set for efficacy analysis.

Per-Protocol analysis set (PP) includes patients in the ITT analysis set who had no important protocol deviations. Important protocol deviations are a subset of major protocol deviations impacting efficacy analysis. Criteria for exclusion from the PP will be determined and documented before the database lock for the primary analysis. This will be the secondary analysis set for efficacy analysis when there are over 10% ITT patients who had important protocol deviations.

Safety Analysis Set: includes all randomized patients who received at least 1 dose of any study treatment, and patients will be grouped by first actual treatment arm received. This will be used for all safety analyses. Patients who were randomized to Arm C (paclitaxel + carboplatin) but received any dose of tislelizumab as first-line treatment will be included in Arm A (tislelizumab + paclitaxel + carboplatin) in SAF. Patients who were randomized to Arm A (tislelizumab + paclitaxel + carboplatin) but did not received any dose of tislelizumab will be included in Arm C (paclitaxel + carboplatin) in SAF.

The HRQoL analysis set includes all randomized patients who received at least 1 dose of study drug and completed at least one HRQoL assessment. This will be the analysis set for HRQoL analysis.

PK Analysis Set: includes all patients who received at least 1 dose of tislelizumab per the protocol, for whom any post-baseline PK data are available.

ADA Analysis Set: includes all patients who received at least 1 dose of tislelizumab for whom both baseline ADA and at least 1 post-baseline ADA results are available.

### 8.2 DATA ANALYSIS GENERAL CONSIDERATIONS

All descriptive statistics for continuous variables will be reported using mean, standard deviation (SD), median, 25 percentile (Q1), 75 percentile (Q3), minimum (Min), maximum (Max) and n. Categorical variables will be summarized as number (percentage) of patients.

The study Table Listing Graph shells will be provided in a separate document, which will show the content and format of all tables, listings, and graphs in detail.

#### 8.2.1 Definitions and Computations

Baseline: Unless otherwise specified, a baseline value for ITT analysis set is defined as the last non-missing value collected before or at the time of randomization date, if not available, defines as last non-missing value collected before or at the time of first dose date. A baseline value for



safety analysis set is defined as the last non-missing value collected before or at the time of first dose date.

**Unscheduled Visits:** Unscheduled measurements will not be included in by-visit table summaries and graphs but will contribute to best/ worst case value where required (e.g. shift table). Listings will include scheduled and unscheduled data.

### 8.2.2 Conventions

Unless otherwise specified, the following conventions will be applied to all analyses:

- 1 year = 365.25 days. Number of years is calculated as (days/365.25) rounded up to 1 significant digit.
- 1 month = 30.4375 days. Number of months is calculated as (days/30.4375) rounded up to 1 significant digit.
- Age will be calculated as the integer part of (date of informed consent – date of birth + 1)/365.25
- P-values will be rounded to 4 decimal places. P-values that round to 0.0000 will be presented as '< 0.0001' and p-values that round to 1.000 will be presented as '> 0.9999'.

### 8.2.3 Handling of Missing Data

Missing data will not be imputed unless otherwise specified elsewhere in the SAP. Missing dates or partially missing dates will be imputed conservatively for adverse events and prior or concomitant medications/procedures.

By-visit endpoints will be analyzed using observed data, unless otherwise specified. For observed data analyses, missing data will not be imputed and only the observed records will be included.

### 8.2.4 Adjustment for Covariates

Not applicable.

### 8.2.5 Multiplicity Adjustment

Multiplicity adjustment for hypothesis testing of PFS has been described in [Section 6](#). No multiplicity adjustment for covariates.

## 8.3 SUBJECT CHARACTERISTICS

### 8.3.1 Subject Disposition

The number (percentage) of patients randomized, treated, permanently discontinued from study treatment, remained on treatment, discontinued from study, and remained on study will be summarized in the ITT Analysis Set. The primary reasons for study treatment discontinuation and study discontinuation will be summarized according to the categories in the CRF. Study follow-up time and primary reason for screen failure will be summarized.



### **8.3.2 Protocol Deviations**

Important protocol deviations are a subset of major protocol deviations impacting efficacy analysis. Criteria for major protocol deviation and important protocol deviation impacting efficacy will be established and patients with major and important protocol deviations will be identified and documented before the database lock.

Both major protocol deviations and important protocol deviations will be summarized and listed by category in the ITT analysis set.

### **8.3.3 Demographic and Other Baseline Characteristics**

Demographic and other baseline characteristics will be summarized using descriptive statistics in the ITT Analysis Set. Continuous variables include age, weight, BMI, baseline target lesions sum of diameters by investigator; categorical variables include sex, age group (<65 years, ≥65 years), ECOG performance status at baseline, smoking status, and stratification factors of disease stage and PD-L1 expression in tumor cell.

### **8.3.4 Disease History**

The number (percentage) of patients reporting a history of disease and characteristic, as recorded on the CRF, will be summarized in the ITT Analysis Set. Categorical disease characteristics variables include disease stage, histology, baseline target lesion location, and location of distant metastases. Continuous disease history variables include time from initial diagnosis to study entry and time from advanced/metastatic disease diagnosis to study entry.

Cancer associated symptoms at baseline will also be summarized by SOC, preferred term and CTCAE grade.

### **8.3.5 Prior Anticancer Drug Therapies, Radiotherapy and Surgeries**

The number and percentage of patients with prior anticancer drug therapies, time from end of last therapy to study entry, and type of prior anticancer drug therapy will be summarized in ITT Analysis Set.

The number and percentage of patients with prior anticancer radiotherapy, anatomical site and time from end of last radiotherapy to study entry will be summarized in ITT Analysis Set.

The number and percentage of patients with prior anticancer surgeries, curative intent (Yes, No), and time from last surgery to study entry will be summarized in ITT Analysis Set.

### **8.3.6 Prior and Concomitant Medications**

Prior and concomitant medications will be coded using the version of World Health Organization Drug Dictionary (WHO DD) drug codes currently in effect at Beigene at the time of database lock and will be further classified to the appropriate Anatomical Therapeutic Chemical (ATC) code.

The number (percentage) of patients reporting prior and concomitant medications will be summarized by ATC medication class and WHO DD preferred term (PT) in the Safety Analysis

Set. Prior medications are defined as medications that received within 30 days before randomization and stopped before the first dose date. Concomitant medications will be defined as medications that 1) started before the first dose of study drug and were continuing at the time of the first dose of study drug or 2) started on or after the date of the first dose of study drug up to 30 days after the patient's last dose (as of the Safety Follow-up Visit). In addition, telephone contacts with patients should be conducted to assess irAEs and concomitant medications (if appropriate, ie, associated with an irAE or is a new anticancer therapy) at 60 days, and 90 days ( $\pm 14$  days) after the last dose of study treatment, regardless of whether or not the patient starts a new anticancer therapy.

### 8.3.7 Medical History

Medical History will be coded using MedDRA of the version currently in effect at BeiGene at the time of database lock. The number (percentage) of patients reporting a history of any medical condition, as recorded on the CRF, will be summarized by system organ class (SOC) and PT in the ITT Analysis Set.

## 8.4 EFFICACY ANALYSIS

If not specified otherwise, efficacy analysis described in this section will be based on the ITT analysis set.

### 8.4.1 Primary Efficacy Endpoints

#### PFS per the IRC in ITT Analysis Set

PFS per the IRC is defined as the time from randomization to the first documented disease progression as assessed by the IRC with the use of RECIST v1.1, or death from any cause, whichever occurs first. The actual tumor assessment visit date will be used to calculate PFS. Patients who have a clinical determination of progression should undergo a CT/MRI, if possible, to correlate radiographic findings with the clinical findings. If a clinical determination of progression for a patient is confirmed, the date of the CT/MRI scan will be considered as the progression date for that patient.

The PFS censoring rules are specified in Appendix 11.1.

PFS per the IRC will be compared between tislelizumab in combination with paclitaxel + carboplatin (Arm A) and paclitaxel + carboplatin (Arm C), and between tislelizumab in combination with nab-paclitaxel + carboplatin (Arm B) and paclitaxel + carboplatin (Arm C). The two primary hypothesis tests are formed as follows:

#### One-sided testing of PFS superiority of Arm A to Arm C:

The null hypothesis to be tested is:

$$H_0: \text{PFS in Arm A} \leq \text{PFS in Arm C}$$

Against the alternative hypothesis:

$$H_a: \text{PFS in Arm A} > \text{PFS in Arm C}$$

#### One-sided testing of PFS superiority of Arm B to Arm C:

The null hypothesis to be tested is:

$$H_0: \text{PFS in Arm B} \leq \text{PFS in Arm C}$$

Against the alternative hypothesis:

$$H_a: \text{PFS in Arm B} > \text{PFS in Arm C}$$

The P value will be calculated from a stratified log-rank test at one-sided significance level  $\alpha=0.025$  based on the stratification factors defined in Section 2 using the actual values from EDC (disease stage) and from central lab (PD-L1 expression). Kaplan Meier methodology will be used to estimate median or other quartiles of PFS along with its 95% confidence interval (constructed using Brookmeyer and Crowley method). Kaplan Meier curves will be constructed to provide a visual description of the PFS distribution. Event free rate at selected timepoints will be estimated with 95% confidence interval using Greenwood formula. Follow-up time will be estimated by the reverse Kaplan-Meier method.

The HR for PFS for each comparison (ie, Arm A versus Arm C, Arm B versus Arm C) will be estimated using a stratified Cox proportional hazard model with Efron's method of tie handling, with treatment arm as a factor and stratified by the same stratification variables used for the stratified log-rank test. The 95% CI for the HR will be provided. Unstratified log-rank test and Cox regression model will also be performed to provide p-value, HR and corresponding 95% CI.

In order to evaluate the robustness of the PFS per IRC, we will perform possible sensitivity analyses with different censoring rules if the number of patients with censor reason (i.e. the specific situation in Appendix 11.1) is greater than or equal to 5% of patients in either of the comparison in the ITT analysis set. If the patient met multiple situations in Appendix 11.1, the censor reason will be the earliest situation. The PFS censoring rules is based on Appendix C and D from FDA guidance "Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics".

The sensitivity analysis 1 is the same as the primary analysis except that it progressed at date of documented progression with protocol specified continued follow-up in all treatment arms or died at date of death whichever is earlier when new anticancer therapy was started. Sensitivity analysis 1 will be performed when  $\geq 5\%$  of patients in either of the comparison in the ITT analysis set had started new anticancer therapy.

The sensitivity analysis 2 is the same as the primary analysis except that it progressed at date of documented progression or died at date of death whichever is earlier after  $\geq 2$  missed disease assessment. Sensitivity analysis 2 will be performed when  $\geq 5\%$  of patients in either of the comparison in the ITT analysis set had  $\geq 2$  missed disease assessment.

When there are over 10% ITT patients who had important protocol deviations, sensitivity analysis 3 in PP analysis set will be implemented using primary PFS censoring rule.

#### **8.4.2 Secondary Efficacy Endpoints**

##### **Overall Survival**

OS is defined as the time from randomization to death from any cause. Data for patients who are not reported as having died at the time of analysis will be censored at the date last known to be

alive. Data for patients who do not have postbaseline information will be censored at the date of randomization. Similar methodologies used to evaluate PFS per the IRC will be applied to OS analysis.

### **Progression-Free Survival per Investigator**

PFS per investigator is defined as the time from randomization to the first objectively documented disease progression assessed by investigator using RECIST v1.1, or death from any cause, whichever occurs first. PFS per the investigator will be analyzed similarly as PFS per the IRC. Concordance of PFS per the investigator and PFS per IRC in the ITT analysis set will also be assessed.

### **Objective Response Rate per the IRC**

ORR (confirmation not required according to RECIST v1.1) is the proportion of patients who had a CR or PR as assessed by the IRC per RECIST v1.1 in all randomized patients with measurable disease at baseline. Patients without any postbaseline assessment will be considered non-responders. Patients without measurable disease at baseline will also be considered as non-responders. The difference in ORR between Arm A versus Arm C and Arm B versus Arm C in the ITT Analysis Set will be evaluated using the Cochran-Mantel-Haenszel (CMH) chi-square test with the actual stratification factors as strata. The two-sided 95% CIs for the odds ratio and the difference in ORR will be calculated, as well as Clopper-Pearson 95% CIs for the ORR within each arm.

In addition, the number and percentage of patients for each of the BOR categories will be presented.

A waterfall plot of best percent change in sum of target lesion diameters from baseline will be provided for treatment arm (Arm A, Arm B and Arm C). The patients will be ordered by the percentage, patients with the largest percentage will be presented on the right.

### **Objective Response Rate per the Investigator**

ORR (confirmation not required according to RECIST v1.1) is the proportion of patients who had CR or PR as assessed by the investigator per RECIST v1.1 in all randomized patients with measurable disease at baseline. Patients without any postbaseline assessment will be considered non-responders. ORR per the investigator will be analyzed similarly as ORR per the IRC.

### **Duration of Response (DOR) per the IRC**

DOR per the IRC is defined for patients with an objective response as the time from the first documented objective response to documented disease progression as assessed by the IRC using RECIST v1.1, or death from any cause, whichever occurs first. Only the subset of patients who show a complete response or partial response will be included in the DOR analysis. Data for patients who are alive and who have not experienced disease progression at the time of analysis will be censored at the date of the last tumor assessment. If no tumor assessments were performed after the date of the first occurrence of the objective response (CR or PR), DOR will

be censored at the date of the first occurrence of the objective response. Median DOR and corresponding 95% CIs will be estimated using Kaplan-Meier methodology for each treatment arm. Comparisons of DOR per the IRC between treatment arms will be made using the log-rank test for descriptive purposes only.

### **Duration of Response (DOR) per the Investigator**

DOR per the investigator is defined for patients with an objective response as the time from the first documented objective response to documented disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. Similar censoring rules used for DOR per IRC will be applied for DOR per investigator. DOR per investigator will be analyzed similarly as DOR per IRC.

### **Health-Related Quality of Life**

#### Analysis Method

There is no multiplicity adjustment for the HRQoL analysis. Descriptive statistics will be used for all HRQoL analyses. All HRQoL analysis will be in HRQoL analysis set. Both EORTC QLQ-C30 and EORTC QLQ-LC13 instruments have been extensively tested for reliability and validity (Bergman et al, 1994; Osoba et al, 1994; Groenvold et al, 1997). Two items measuring overall health status and quality of life are graded on a 7-point Likert scale, while all remaining items are graded on a 4-point scale ranging from 1 (Not at all) to 4 (Very much).

#### Compliance

Compliance for the EORTC QLQ-C30 and EORTC QLQ-LC13 modules, defined as the proportion of questionnaires actual received out of the expected number (i.e, number of patients on treatment), in the HRQoL analysis set will be summarized for each assessment time point and treatment arm.

#### Change from Baseline by Visit

For each scale or item of EORTC QLQ-C30 and EORTC QLQ-LC13, summary statistics at each assessment time point and change from baseline will be presented by treatment arm in tables. Boxplot depicting the mean scores over time of global health status/quality of life will be provided for each treatment arm.

Details of HRQoL scoring are specified in Appendix 11.2 according to the algorithm described in the EORTC QLQ-C30 and EORTC QLQ-LC13 scoring manual (Fayers 2001).

#### Time to Deterioration (TTD) of HRQoL

Time to deterioration (TTD) is defined as the time from randomization to first onset time at which deterioration is clinically meaningful that is confirmed at a subsequent clinically meaningful deterioration. The minimum important clinically difference change in symptoms of QLQ-C30 and QLQ-LC13 is defined as  $\geq 10$  points increase from baseline (Osoba et al 1998; King, 1996; Maringwa et al 2011). The clinically meaningful deterioration in function and global health status/quality of life is defined as  $\geq 10$  points decrease from baseline. The median TTD of QLQ-C30 global health status/quality of life and composite of cough, chest pain, and dyspnea in

the QLQ-LC13 will be calculated using Kaplan-Meier estimates, and presented with 2-sided 95% CIs.

### **PD-L1 Expression as a Predictive Biomarker for Response**

Exploratory biomarker analyses will be performed to examine the relationship between tumor tissue PD-L1 expression and measures of efficacy. Additionally, predictive and prognostic exploratory biomarkers in tumor tissue and/or blood will be examined for their association with disease status and clinical outcomes. These exploratory analyses will not be included in the CSR for this study.

#### **8.4.3 Subgroup Analyses**

Subgroup analysis of primary endpoint of PFS per the IRC will be conducted to determine whether the treatment effect is consistent across various subgroups, and the HR estimates of PFS from an unstratified Cox model and its 95% CI will be estimated and plotted within each category of the following variables (a subgroup will not be analyzed if it includes <7% in one comparison of the ITT analysis set):

- PD-L1 expression in TC ( $\geq 50\%$  TC versus 1% to 49% TC versus  $< 1\%$  TC)
- Disease Stage (IIIB versus IV)
- age ( $\leq 65$  versus  $> 65$  years),
- sex (female versus male)
- ECOG PS (0 versus 1)
- smoking status (never versus former/current)
- Liver metastases at baseline (Yes versus no)
- Brain metastasis status at baseline (yes versus no)

Forest plot of subgroup analysis in PFS per the IRC will be provided. Additional subgroup analysis may also be conducted per additional prognosis factors as suggested. Subgroup analysis of secondary endpoint may also be conducted.

#### **8.4.4 Exploratory Analysis**

##### **Disease Control Rate per the IRC and per the Investigator**

DCR is defined as the proportion of patients with objective response (CR or PR), Non-CR/Non-PD, or stable disease maintained for  $\geq 6$  weeks using RECIST v1.1. Both DCR per the IRC and per the investigator will be analyzed. Similar methodologies for analysis of ORR will be applied

##### **Time to Response per the IRC and per the Investigator**

TTR per the investigator/IRC is defined for patients with an objective response as determined by the investigator/IRC as the time from randomization to the first occurrence of a CR or PR as assessed by the investigator/IRC using RECIST v1.1. Only the subset of patients who show a CR



or PR will be included in the TTR analysis. TTR will be summarized for descriptive purposes. The mean, standard error, median, and range of TTR will be provided.

#### **Time to first subsequent anticancer systemic therapy (TFST)**

TFST is defined for patients with the use of subsequent anticancer systemic therapy as the time from end of study treatment to first dose of subsequent anticancer systemic therapy. The mean, standard error, median, and range of TFST will be provided.

#### **Time to second progression-free survival per the investigator**

Analysis of progression-free survival after next line of treatment (PFS2) is defined as the time from randomization to second/subsequent disease progression, or death from any cause, whichever occurs first. Patients alive and for whom a second objective disease progression has not been observed will be censored at the last time known to be alive and without second objective disease progression. PFS2 analysis will be provided when data is mature. Similar methodology used to evaluate PFS per the IRC will be applied to analyze PFS2 per the investigator.

#### **Subsequent anticancer systemic therapy**

Subsequent anticancer systemic therapy will be summarized by category and PT in the ITT analysis set.

#### **Exploratory efficacy analysis of PFS/ORR in comparison of Arm B vs A**

After the success of hypothesis testing for the primary endpoint of PFS in both comparisons of A vs C and B vs C, hypothesis testing for B vs A will be carried out at a one-sided alpha of 0.025. For PFS endpoint, the P value from stratified log-rank test for descriptive purpose only, HR for PFS from a stratified Cox proportional hazard model and its 95% CI, median PFS along with its 95% CI using Kaplan Meier methodology, and event free rate at selected timepoints with 95% CI using Greenwood formula will be provided. For ORR endpoint, the difference in ORR between Arm B vs A and its 95% CI, odds ratio and its 95% CI, as well as Clopper-Pearson 95% CIs for the ORR within each arm will be provided.

### **8.5 SAFETY ANALYSES**

All safety analyses will be performed by treatment arm based on the safety analysis set. The incidence of treatment-emergent adverse events (TEAEs) and SAEs will be summarized. Laboratory test results, vital signs, ECG, ECOG and their changes from baseline will be summarized using descriptive statistics (e.g., n, mean, standard deviation, median, Q1, Q3, minimum, maximum for continuous variables; n [%] for categorical variables). Abnormal values will be flagged.

When crossover rate (the rate among the patients who crossed over to receive at least one dose of tislelizumab monotherapy) is equal to or larger than 10% among the patients who actually randomized into Arm C, additional analysis for patients who crossed over will be provided, including but not limited to tislelizumab extent of exposure, overall summary of TEAE, concomitant medication.

### 8.5.1 Extent of Exposure

The study treatment dose information of each patient will be assessed by the following variables:

- Number of treatment cycles equals to the count of cycles with tislelizumab and/or chemotherapy
- Duration of exposure (weeks) is defined as:

(date of last dose\* + 21 days – date of first dose)/7, with censored by death date and cutoff date, without censoring when calculating actual dose intensity.

\*For chemotherapy of *nab*-paclitaxel (dosing at Day 1,8,15), use the date of Day 1 in the last cycle.

- Cumulative dose (mg): the sum of all actual doses of tislelizumab/paclitaxel/*nab*-paclitaxel/carboplatin, given from first to last administration
- Actual dose intensity (ADI) in mg/cycle is defined as:

Cumulative dose (mg) / Duration of exposure (cycles)

- Relative dose intensity (RDI) in % is defined as:

$$100 \times \frac{\text{ADI (mg/cycle)}}{\text{Planned Dose Intensity (mg/cycle)}}$$

Where planned dose intensity for tislelizumab equals to 200 mg/cycle, for paclitaxel/*nab*-paclitaxel/carboplatin equal to the sum of all planned doses/total number of cycle started by the patient.

Number of cycles received by patient as a quantitative variable and by category (i.e., number (%) of patient receiving at least 1 cycle, at least 2 cycles etc.), duration of exposure, cumulative dose, ADI and RDI will be summarized by descriptive statistics.

### 8.5.2 Adverse Events

AEs will be graded by the investigators using CTCAE v5.0. The AE verbatim descriptions (investigator terms from the CRF) will be classified into standardized medical terminology using the Medical Dictionary for Regulatory Activities (MedDRA). Adverse events will be coded to the MedDRA (Version 20.0 or higher) lower level term closest to the verbatim term. The linked MedDRA preferred term (PT) and primary system organ class (SOC) are also captured in the database.

A TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pre-dose) on or after the date of first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever comes first. For the tislelizumab-containing arms, the TEAE classification also applies to immune-related AEs



(irAE) that are recorded up to 90 days after discontinuation from tislelizumab, regardless of whether the patient starts a new anticancer therapy. Only those AEs that were treatment emergent will be included in summary tables. All AEs, treatment emergent or otherwise, will be presented in subject data listings. AEs that were treatment emergent for patients who crossover to receive tislelizumab monotherapy may be separately summarized if data allows.

An overview of patients with at least one TEAE will be presented with the incidence of:

- patients with any TEAE
- patients with any TEAE with grade  $\geq 3$
- patients with any serious TEAEs
- patients with any TEAE leading to death
- patient with any TEAE leading to permanent discontinuation of any component of study treatment
- patients with any TEAE leading to treatment modification of tislelizumab and any component of chemotherapy
- patients with any TEAE related to any component of study drug
- patients with any TEAE related to tislelizumab
- patients with any TEAE related to tislelizumab and grade  $\geq 3$
- patients with any TEAE with grade  $\geq 3$  and related to any component of study treatment
- patients with any serious TEAEs related to any component of study treatment
- patients with any irTEAE

Treatment-related AEs include those events considered by the investigator to be related to study treatment or with missing assessment of the causal relationship. For patients with multiple occurrences of the same event will be counted only once, and the maximum grade per CTCAE v5.0 will be used if CTCAE grade is needed.

If the grade is missing for one of the treatment-emergent occurrences of an adverse event, the maximal severity on the remaining occurrences with the same preferred term of the same patient will be used. If the patient has no other TEAE with the same preferred term, then impute as the maximum severity on all TEAE with the same preferred term; If the severity is missing for all the occurrences, do not impute, a “missing” category will be added in the summary table.

The incidence of following TEAEs will be reported by SOC and PT, sorted by decreasing frequency of system organ class and preferred term:

- TEAE by maximum grade
- TEAE leading to permanent discontinuation of any component of study treatment
- TEAE leading to death
- TEAE with grade  $\geq 3$
- TEAE related to any component of study treatment
- Serious TEAE

All deaths and causes of death will be summarized by treatment arm, including those occurred during the study treatment period and those reported during the survival follow-up period after treatment completion/discontinuation.

### 8.5.3 Laboratory Values

Laboratory results will be evaluated for selected parameters described in Table 3.

Descriptive summary statistics (n, mean, standard deviation, median, minimum, maximum for continuous variables; n [%] for categorical variables) for laboratory parameters and their changes from baseline will be summarized by visit.

Laboratory parameters that are graded in NCI CTCAE (v.5.0) will be summarized by shifts from baseline CTCAE grades to maximum post-baseline grades. In the summary of laboratory parameters by CTCAE grade, parameters with CTCAE grading in both high and low directions will be summarized separately.

**Table 3. Serum Chemistry and Hematology Laboratory Tests**

Serum Chemistry	Hematology	Thyroid Function
Alanine aminotransferase (ALT)	Hemoglobin	Free Triiodothyronine (FT3)
Aspartate aminotransferase (AST)	White blood cell (WBC) count	Free Thyroxine (FT4)
Creatinine	Neutrophil (Absolute)	Thyroid Stimulating Hormone (TSH)
Potassium	Platelet count	
Sodium		
Creatine kinase (CK)		
Creatine kinase-cardiac muscle isoenzyme (CK-MB)		

### 8.5.4 Vital Signs

Descriptive statistics for vital sign parameters (i.e., systolic and diastolic blood pressure, pulse rate, temperature, and weight) and changes from baseline will be presented by visit.

### 8.5.5 Electrocardiograms (ECG)

ECG will be performed during screening, safety follow-up and as clinically indicated at other timepoints. Postbaseline abnormal QTc observations will be summarized.

### 8.5.6 Eastern Cooperative Oncology Group (ECOG)

A shift table from baseline to worst post-baseline in ECOG performance score will be summarized.

## 8.6 PHARMACOKINETIC ANALYSES

PK samples will be collected only in patients randomized to receive tislelizumab. Tislelizumab post-dose and Ctrough (pre-dose) will be tabulated and summarized for each cycle at which PK is to be measured. Descriptive statistics will include means, medians, ranges, (standard deviations), coefficient of variation (CV%), Geometric mean and geometric CV%, as appropriate.

Additional PK analyses, including population PK analyses and exposure-response (efficacy, safety endpoints) analyses may be conducted as appropriate and the results from these analyses will be reported separately from the CSR.

## 8.7 IMMUNOGENICITY ANALYSIS

Human anti-drug antibodies (ADA) to tislelizumab will be assessed during the study as defined in the protocol.

ADA attributes:

- Treatment boosted ADA is defined as ADA positive at baseline that was boosted to a 4-fold or higher level following drug administration.
- Treatment-induced ADA is defined as ADA negative at baseline and ADA positive post-baseline.
- Persistent ADA response is defined as Treatment-induced ADA detected at 2 or more time points during treatment or follow-up, where the first and last ADA positive samples are separated by 16 weeks or longer; or detected in the last time point.
- Transient ADA response is defined as Treatment-induced ADA detected only at 1 time point during treatment or follow-up, excluding last time point; or detected at 2 or more timepoints during treatment or follow-up, where the first and last positive samples (irrespective of any negative samples in between) are separated by less than 16 weeks and the last time point is negative. Transient ADA is a treatment-induced response that is not considered persistent.
- Neutralizing ADA is defined as ADA that inhibits or reduces the pharmacological activity.

ADA response endpoints:

- ADA incidence is defined as sum of treatment-emergent ADA, which include both treatment-induced and treatment-boosted ADA-positive patients, as a proportion of the ADA evaluable population.
- ADA prevalence is defined as proportion of all patients that are ADA positive, including pre-existing ADA, at any time point.

The immunogenicity results will be summarized using descriptive statistics by the number and percentage of patients who develop detectable ADA. The incidence of positive ADA and neutralizing ADA will be reported for evaluable patients. The effect of immunogenicity on PK, efficacy, and safety may be evaluated if data allow.

## 9 CHANGES IN THE PLANNED ANALYSIS

Not applicable so far.

## 10 REFERENCES

Brookmeyer R, Crowley J. A Confidence interval for the median survival time. *Biometrics*. 1982; 38: 29-41.

Clopper, C. and Pearson, ES. The use of confidence or fiducial limits illustrated in the case of the binomial, *Biometrika* 1934; 26: 404-413.

Collett D. *Modelling survival data in medical research*. New York: Chapman & Hall; 1994.

Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Washington, DC, USA, Nov 27, 2017.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009; 45:228-47.

Food and Drug Administration Center for Drug Evaluation Research CDER and Center for Biologics Evaluation and Research. *FDA Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics*, 2007.

Greenwood M. "The natural duration of cancer". *Reports on Public Health and Medical Patients* (London: Her Majesty's Stationery Office). 1926; 33:1-26.

Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958; 53:457-81.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. Brussels: EORTC, *EORTC QLQ-C30 Scoring Manual* (3rd edition). 2001. ISBN: 2-9300 64-22-6.

Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. *Eur J Cancer* 30A: 635-642.

Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J (1994) Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. *Qual Life Res* 3: 353-364.

Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. *J Clin Epidemiol* 50: 441–450.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 16: 139–144.

King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. *Qual Life Res* 1996; 5: 555–567.

Maringwa J, Quinten C, King M, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. *Annals of Oncology* 2011; 22: 2107–2112.

**APPENDIX****10.1 PFS CENSORING RULES**

Definition of Progression Date: Progression date is assigned to the first time when tumor progression was documented.

The PFS derivation rules in this SAP follow the Table C1 and C2 described in Appendix C of Food and Drug Administration (FDA) “Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics (2015)”.

Censoring rules for primary and sensitivity analyses are summarized in table 2.

**Table 4 Censoring Rules for Primary and Sensitivity Analysis of PFS Per RECIST version 1.1**

No.	Situation	Primary Analysis	Sensitivity Analysis
1	Incomplete or no baseline tumor assessments	Censored at randomization date	
2	No postbaseline tumor assessment and no death	Censored at randomization date	
3	No postbaseline tumor assessment and death	Died at date of death	
4	Progression documented between scheduled visits	Progressed at date of documented progression	
5	No progression	Censored at date of last adequate tumor assessment with no documented progression	
6	New anticancer treatment started	Censored at date of last adequate tumor assessment before date of new anticancer treatment	Progressed at Date of documented progression with protocol specified continued follow-up in all treatment arms or died at date of death whichever is earlier
7	Death between adequate assessment visits	Died at date of death	
8	Death or progression after $\geq 2$ missed visit	Censored at date of last adequate tumor assessment prior to the $\geq 2$ missed tumor assessments	Progressed at date of documented progression or Died at date of death whichever is earlier

## 10.2 HEALTH RELATED QUALITY OF LIFE

The QLQ-C30 consists of thirty questions that are associated with five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). QLQ-C30 and QLQ-LC13 scale scores will be calculated as described below.

### *Scoring Process*

The principle for scoring applies to all scales/scores: Raw scores are calculated as the average of the items that contribute to the scale.

A linear transformation to standardize the raw scores is utilized, so that the scores are ranged from 0 to 100. Increases in scores for functional domains (e.g., physical, role, social, emotional, etc.) are improvements while increases in scores for symptoms (e.g., fatigue, vomiting and nausea, diarrhea, pain, etc.) are deteriorations.

### *Missing Items*

If at least half of the items for a scale are answered, then all the completed items are used to calculate the score. Otherwise, the scale score is set to missing.

In practical terms, if items  $I_1, I_2, \dots, I_n$  are included in a scale, the procedure is as follows:

### *Raw Score*

For all scales, the raw score (RS), is the mean of the component items

$$RS = (I_1 + I_2 + \dots + I_n) / n$$

### *Derived Scale*

The derived scales are obtained from the raw scores as defined in the EORTC manual. The derived scales have a more intuitive interpretation: larger function scale or global health status / QoL are improvements while larger symptom scales (e.g., pain, nausea, etc.) are deteriorations.

The derivation formulas are as follows.

#### **Linear transformation**

Apply the linear transformation to 0-100 to obtain the score  $S$ ,

$$\text{Functional scales: } S = \left\{ 1 - \frac{(RS - 1)}{\text{range}} \right\} \times 100$$

$$\text{Symptom scales / items: } S = \left\{ \frac{(RS - 1)}{\text{range}} \right\} \times 100$$

$$\text{Global health status / QoL: } S = \left\{ \frac{(RS - 1)}{\text{range}} \right\} \times 100$$

**Table 5 Scoring of QLQ-C30**

	Scale	Number of items	Item range	Item Numbers
<b>Global health status/ QoL</b> Global health status/QOL	QL2	2	6	29,30
<b>Functional Scales</b>				
Physical functioning	PF2	5	3	1, 2, 3, 4, 5
Role functioning	RF2	2	3	6, 7
Emotional functioning	EF	4	3	21, 22, 23, 24
Cognitive functioning	CF	2	3	20, 25
Social functioning	SF	2	3	26, 27
<b>Symptom Scales/ items</b>				
Fatigue	FA	3	3	10, 12, 18
Nausea and vomiting	NV	2	3	14, 15
Pain	PA	2	3	9, 19
Dyspnoea	DY	1	3	8
Insomnia	SL	1	3	11
Appetite loss	AP	1	3	13
Constipation	CO	1	3	16
Diarrhoea	DI	1	3	17
Financial Difficulties	FI	1	3	28



**Table 6 Scoring of QLQ-LC13**

	Scale	Number of items	Item range	Item Numbers
<b>Symptom scales/items</b>				
Dyspnoea	LCDY	3	3	3,4,5
Coughing	LCCO	1	3	1
Haemoptysis	LCHA	1	3	2
Sore mouth	LCSM	1	3	6
Dysphagia	LCDS	1	3	7
Peripheral neuropathy	LCPN	1	3	8
Alopecia	LCHR	1	3	9
Pain in chest	LCPC	1	3	10
Pain in arm or shoulder	LCPA	1	3	11
Pain in other parts	LCPO	1	3	12

## PROTOCOL AMENDMENT, VERSION 1.0, RATIONALE

The main purpose of this protocol amendment is:

- To update the safety data and clinical PK data according to the latest tislelizumab IB 5.0 and protocol template
- To update statistical analysis parts by adjusting O'Brien-Fleming boundary per CDE comments
- To update myocarditis/myositis language and appendix (management of immune-related toxicity) according to FDA requirements
- To update the assessment procedure to make it more suitable for clinical practice

In addition, some contents (including administrative information, language, and format) are modified to improve the clarity and consistency throughout the document. Changes were made to the synopsis to match changes made in the protocol body. The version number of this protocol amendment is amendment 1.0.

### Substantial changes:

- Updated NCI-CTCAE version from v4.03 to v5.0 globally in the protocol
- In Section 1.5.2, Toxicology: added wording of 'cynomolgus' and 'toxicology' according to the latest IB to clarify the information in toxicology
- In Section 1.5.3, Clinical Pharmacology: updated clinical pharmacology results of tislelizumab per updated protocol template
- In Section 1.5.4 (including Section 1.5.4.1, 1.5.4.2 and 1.5.4.4), Prior Clinical Experience of tislelizumab: updated prior clinical experience of tislelizumab per updated protocol template
- In Section 1.5.4.3, BGB-A317-206: added clinical safety data from BGB-A317-206 study to support development of this study
- In Section 1.6.1, Rationale for the Chemotherapy Regimens Administered With Tislelizumab in the Treatment of Advanced Squamous NSCLC: added wording of rationale for tislelizumab in the treatment of advanced squamous NSCLC per latest protocol template
- In Section 1.6.2, Rationale for Selection of Tislelizumab Dose in Combination With Chemotherapy: added wording of rationale for selection of tislelizumab dose in combination with chemotherapy per latest protocol template and added reference to BGB-A317-206 study which tested the dose in combination with chemotherapy
- In Section 3.3, Treatment Period: updated the scope of Safety Follow-up Visit per latest protocol template
- In Section 3.3, Treatment Period; Section 7.6, Tumor and Response Evaluation; and the footnote of Appendix 1: updated the frequency for tumor assessments

- In Section 3.4, Safety Follow-up: updated the language per latest protocol template
- In Section 3.5, Survival Follow-up: updated the language
- In Section 3.6 (including Section 3.6.1 and 3.6.2), Patient, Treatment, Study, and Site Discontinuation from the Study Treatment or from the Study: updated the section title and contents per latest protocol template
- In Section 3.7, End of Study: updated the language per latest protocol template
- In Section 4.1, Inclusion Criteria #1, added ‘and the schedule of assessments’ per latest protocol template
- In Section 4.2, Exclusion Criteria #10, clarified the requirements on different scenario of severe infections of 2 weeks and 4 weeks
- In Section 4.2, Exclusion Criteria # 12, added ‘requiring general anesthesia’ per latest protocol template
- In Section 4.2, Exclusion Criteria #14, added ‘ $\leq 2$  years before randomization’ per latest protocol template
- In Section 4.2, removed Exclusion Criteria #19 to avoid duplicate with Exclusion Criteria #23
- In Section 4.2, Exclusion Criteria #23: clarified the requirements of underlying medical conditions or alcohol or drug abuse or dependence
- In Section 5.2, Dose, Administration, and Compliance, updated Table 3 per latest protocol template
- In Section 5.2.1, Tislelizumab, clarified the management on dose delay of tislelizumab for different scenarios:  $\leq 10$  days or  $> 10$  days
- In Section 5.2.2, Chemotherapy, removed ‘Q3W’ from administration of paclitaxel and carboplatin AUC 5
- In Section 5.5, Dose Delay, Interruption and Modification, updated the contents to make it fit the study
- In Section 5.5.1, General Guidance Regarding Dose Modifications, clarified the general management of dose modification both for chemotherapy and tislelizumab
- In Section 5.5.2, Dose Interruption or Delay for Tislelizumab, clarified the management of dose delay in tislelizumab
- In Section 5.5.3, Dose Modification of Chemotherapy Treatment, clarified the management of dose modification of chemotherapy
- In Section 5.6, Criteria for Discontinuing Chemotherapy Regimens, clarified the chemotherapy discontinuation criteria
- In Section 6.2.1, Permitted Concomitant Medications, clarified the activities before ruling out progression of disease

- In Section 7, Study Assessments and Procedures, removed “If the timing of a protocol-mandated study visit coincides with a holiday, weekend, or other event, the visit should be scheduled on the nearest feasible date (the visit window is provided in Appendix 1) with subsequent visits rescheduled according to the last treatment administration date” per latest protocol template
- In Section 7.1.1, Demographic Data and Medical History, removed “If appropriate, clinically significant disease should be graded according to NCI-CTCAE v4.03 and reported in the Medical History eCRF.” per latest protocol template
- In Section 7.2.1, Confirmation of Eligibility, updated the language per latest protocol template
- In Section 7.2.3, Randomization, updated the language to give flexibility on randomization
- In Section 7.5.4 and Appendix 1, Laboratory Safety Tests, added “total creatinine kinase and CK-MB” in laboratory assessments
- In Section 7.5.5, Electrocardiograms, clarified the assessments of ECG
- In Section 7.6, Tumor and Response Evaluations, clarified the criteria on patients with suspected pseudoprogression
- In Section 8.1, changed the section title to keep consistency with the latest protocol template
- In Section 8.6.2.2, Completion and Transmission of the Serious Adverse Event Report, removed “If the electronic data capture (EDC) system is nonoperational, the paper SAE form will be sent via either email or fax to the sponsor. After the EDC system becomes operational again, the investigator must enter the SAE information there.” to keep consistency with the latest protocol template
- In Section 8.6.5, Recording Deaths, updated the language per latest protocol template
- In Section 8.7.1, Infusion-Related Reactions, updated Table 6 per latest protocol template
- In Section 8.7.3, Immune-Related Adverse Events, updated the language of recommendation for diagnostic evaluation and management of irAEs per latest protocol template
- In Section 9.1.5, Prior and Concomitant Medications, clarified the visits and the frequency to assess irAEs and concomitant medications per latest protocol template
- In Section 9.3.2, Adverse Events, and Section 14.1.2, Data Management/Coding, changed version of MedDRA from version 20.1 to 20.0
- In Section 9.6, Sample Size Consideration; Section 9.7, Interim Analysis, updated contents of interim analysis and sample size consideration by adjusting O'Brien-Fleming boundary per CDE comments
- In Section 10.2, Independent Data Monitoring Committee, changed the frequency of IDMC from ‘every 4 months’ to ‘every 6 months’

- In Section 12.4, Drug Accountability, updated the language of drug disposal/destruction per latest protocol template
- In Section 13.1, Ethical Standard, added “by the principal investigator and the study center” per latest protocol template
- In Section 14.7, Information Disclosure and Inventions, updated the language per latest protocol template
- In Appendix 1, Schedule of Assessments, updated the window in treatment cycles per protocol template; updated the footnotes to keep consistency with contents in the protocol body
- In Appendix 6, Immune-related adverse event evaluation and management, updated the contents in table of “recommended diagnostic tests in the management of possible immune-related adverse events” and updated the contents in “Treatment of Immune-related Adverse Events” to keep consistency with the protocol template
- In Appendix 7, Cockcroft-Gault Formula and Calvert Formula, replaced the more commonly used formula
- In Appendix 9, Dose Modification Guidelines for Chemotherapy, clarified the definition of chemotherapy cycle

## PROTOCOL AMENDMENT, VERSION 2.0, RATIONALE

The main purpose of this protocol amendment is as follows:

- To clarify the operational details of serum creatinine kinase (CK) and creatinine kinase cardiac muscle isoenzyme (CK-MB) testing for close monitoring of myocarditis/myositis;
- To update myocarditis/myositis language (immune-related adverse event evaluation and management) according to FDA requirements;
- To revise the content for clarity and consistency to align with the latest updates to the tislelizumab protocol template, including updates to safety assessment;
- To update the procedures for select study assessments to allow for greater flexibility in keeping with clinical practice.

Further, administrative modifications were made to improve upon the clarity and consistency throughout the document. And the synopsis was updated to match changes made in the body of the protocol. The version number of this protocol amendment is 2.0.

Key changes made from the Protocol Amendment 1.0 (dated 27 April 2018) to Protocol Amendment 2.0 (dated 14 December 2018), are summarized by protocol section as below:

- Updated ‘population’ to ‘analysis set’ globally (where applicable) in the protocol as correction and for consistency with other BeiGene protocols;
- In cover page and Section 8.6.8, Expedited Reporting to Health Authorities, Investigators, Institutional Review Boards, and Independent Ethics Committees: added *nab*-paclitaxel as investigational product to reflect the information in recent clinical trial approval and replaced its label with Investigator’s Brochure as one of the reference safety information documents to treat *nab*-paclitaxel as an investigational product;
- In Section 2.1.1, Primary Objective: added ‘American Joint Committee Cancer 7<sup>th</sup> Edition of Cancer Staging Manual’ for clarification;
- In Section 2.2.3, Exploratory Endpoints: added the detail for consistency with the information in the exploratory objective related with pharmacokinetic;
- In Section 3.1 Summary of Study Design, Section 4.1 Inclusion Criteria, and Section 7.8 Biomarkers: allowed patients with unevaluable PD-L1 status to participate in this study with the purpose of expanding the scope of study population who are likely to benefit from the study treatment;
- In Section 3.1, Summary of Study Design and Section 5.2.2, Chemotherapy: updated the duration of administration for Carboplatin and Paclitaxel to be consistent with the information in their respective labels;
- In Section 3.3, Treatment Period: added the details of End of Treatment Visit for consistency with the information in Appendix 1 and removed the repeated information which is contained in Section 3.4 (Safety Follow-up);

- In Section 6.2.1, Permitted Concomitant Medications: added allowance for prophylactic use of antiviral therapy at the investigator’s discretion to align with local guidance;
- In Section 7.1, Screening and Section 7.1.4, Pulmonary Function Tests:
  - clarified the pulmonary function testing at Screening should, in addition to spirometry, include assessment of oxygenation, at a minimum pulse oximetry at rest and with exercise, or alternatively, assessment of diffusion capacity;
  - added the guidance on the assessment of pulmonary function in all patients during the Screening Period;
- In Section 7.4.2, Crossover Assessments and Procedures: clarified the safety assessment schedule for patients who cross over to tislelizumab monotherapy;
- In Section 7.5, Safety Assessments: modified frequency of select study assessments for patients who were randomized to Arms A and C to allow for greater flexibility in keeping with clinical practice;
- In Section 7.5.4, Laboratory Safety Test: clarified the assessment schedule of serum CK and CK-MB testing;
- Revised the following subsections in Section 8 for consistency with other BeiGene protocols:
  - In Section 8.3.3, Assessment of Causality;
  - In Section 8.3.5, Laboratory Test Abnormalities;
  - In Section 8.6.2.1, Prompt Reporting of Serious Adverse Events;
  - In Section 8.6.4, Disease Progression;
  - In Section 8.6.5, Deaths;
  - In Section 8.6.6, Pregnancies;
- In Section 9, Statistical Methods and Sample Size Determination: deleted the text of SAS<sup>®</sup> Version that is included in the statistical analysis plan;
- In Appendix 1, Schedule of Assessments: added details for consistency with the text in the protocol and other BeiGene protocols;
- In Appendix 3, The Response Evaluation Criteria in Solid Tumors Guidance, Version 1.1: added recommended CT scan slice thickness for clarification;
- In Appendix 6, Immune-related Adverse Event Evaluation and Management: added information on diagnostic tests and treatment for myocarditis/myositis;
- In Appendix 7, Cockcroft-Gault Formula and Calvert Formula: added the calculation details for the dose of carboplatin to avoid potential toxicity due to overdosing;
- In Appendix 9, Dose Modification Guidelines for Chemotherapy: following recommendations made by the steering committee, enhanced guidelines by increasing the

level of absolute neutrophil count upon which study treatment can resume, and clarified dose holds for *nab*-paclitaxel.



## PROTOCOL AMENDMENT, VERSION 3.0, RATIONALE

The main purpose of this protocol amendment is as follows:

- To update the statistical method to control overall Type I error for hypothesis tests of progression-free survival (PFS) in each comparison. Considering delayed treatment effect, to change hazard ratio assumption of PFS from 0.6 to 0.65, and increase the number of PFS events at both interim and final analyses. To update the statistical design to optimize the study to gain more power at both interim and final analyses.
- To change the analysis method for the secondary endpoint of Health-Related Quality of Life, from model-based method to descriptive method.
- To update the tumor assessment for treatment beyond progression and for crossover to provide the efficacy profile of tislelizumab monotherapy beyond progression and maximize data strength for future sensitivity analysis for publication purpose.
- To update sample collection for patients who crossover to receive tislelizumab.
- To clarify biomarker sample collection time and exploratory testing.
- To clarify recording of laboratory abnormality.

The synopsis was updated to match the changes made in the body of the protocol. The version number of this protocol amendment is 3.0.

Key changes made from Protocol Amendment 2.0 (dated 14 December 2018) to Protocol Amendment 3.0 (dated 16 August 2019), are summarized by protocol section as below:

- In Section **Error! Reference source not found.** Current First-Line Treatment of Advanced NSCLC: deleted **Error! Reference source not found.** Approved Anti-PD-1 or Anti-PD-L1 Inhibitors for the Treatment of Advanced or Metastatic NSCLC” as the information in the table was not up to date; added up-to-date clinical data on pembrolizumab.
- In Section **Error! Reference source not found.** Unmet Medical Needs for Advanced Squamous NSCLC: clarified that no immunotherapy was approved by National Medical Products Administration in the first line lung cancer treatment setting; deleted wording on pembrolizumab.
- In Section **Error! Reference source not found.** Exploratory Endpoints: added tumor-infiltrating immune cells in biomarker exploratory endpoints.
- In Section **Error! Reference source not found.** End of Study: updated the definition of study termination to further address study completion date and end of trial.
- In Section **Error! Reference source not found.** Tislelizumab: deleted the specific contents of the label and the specific storage conditions to allow much more flexibility to compliance to all local regulations and potential evolving changes.
- In Section **Error! Reference source not found.** Tumor and Response Evaluations: updated the tumor assessment for treatment beyond progression and for crossover.

- In Section **Error! Reference source not found.** Biomarkers: updated collection time for blood biomarker, tumor-infiltrating immune cells and sample collection for patients who crossover to receive tislelizumab.
- In Section **Error! Reference source not found.** Laboratory Test Abnormalities: added specific details with regard to recording laboratory abnormality so as to reduce the investigation system organ classes.
- In Section **Error! Reference source not found.** Primary Efficacy Analysis: moved the Type I error control method for primary endpoint PFS per Independent Review Committee from Section **Error! Reference source not found.** to Section **Error! Reference source not found.**
- In Section **Error! Reference source not found.** Secondary Efficacy Analysis: changed the analysis method for Health-Related Quality of Life, from model-based method to descriptive method.
- In Section **Error! Reference source not found.** Sample Size Consideration: updated PFS assumptions for sample size calculation and updated the timeline and number of PFS events at final analysis.
- In Section **Error! Reference source not found.**, Multiplicity: updated the statistical method to control overall Type I error for hypothesis tests of PFS in each comparison, and updated **Error! Reference source not found.** to describe alpha allocation scheme.
- In Section **Error! Reference source not found.**, Interim Analyses: updated the timeline and number of PFS events at both interim and final analyses, and updated **Error! Reference source not found.** to be consistent with the interim and final analyses for PFS.
- In [Appendix 1](#), Schedule of Assessments: updated sample collection for blood biomarker and for patients who crossover to receive tislelizumab to be consistent with Section **Error! Reference source not found.**